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Chapter 1 
CHAPTER 1: 
General Introduction 
1.1 TUlllor Necrosis Factor-a 
1.1.1 HistOlY ofTNF-a 
In the 19th century (1891) Coley observed that bacterial infections coincide with 
"spontaneous" regression of tumors and developed his so-called Coley's toxin, a 
mixture of Streptococcus pyogenes and Serratia marcescens and applied this toxin as 
an anticancer treatment l . The agent responsible for the anti-tumor effect has been 
identified in mice treated with Bacillus Cal mette-Guerin (BCG) in combination with 
lipopolysaccharide, as a soluble agent, later named tumor necrosis factor (TNF)-a '. 
Tumor-necrosis factor-a (TNF-a) belongs to the family of cytokines, which are small 
glycoproteins (molecular weight of less than 30 kDa), produced by both hematopoeitic 
and non-hematopoeitic cells. The protein was isolated and cDNA was cloned in 19843. 
In addition, it was characterized as the hormone cachectine, which suppressed the 
expression of lipoprotein lipase and other anabolic enzymes in fat'. Soon thereafter, its 
role as endogenous mediator in septic shock was revealed and its pro-inflammatory 
character was established"'. Recently, the anti-tumor capacity ofTNF-a has received 
renewed attention. Acute softening of the tumor, hemorrhagic necrosis and occlusion 
of the neo·vasculature leading to tumor necrosis revealed a possible object to 
anticancer therapy'·'. However, severe toxicity was encountered in phase IIII clinical 
trials, in which progressive heart failure was a prominent feature iO, which excludes 
systemic therapy. Nevertheless, local institution of TNF-a by isolated limb perfusion, 
shows encouraging results and may predict a new era of TNF'a as anti-tumor 
regimen8,9,ll, 
1.1.2 Production, working mechanisms and/imctiol1 ofTNF-a 
TNF -a, a pro-inflammatOlY cytokine, is predominantly produced by activated cells of 
the immune system: monocytes, macrophages, natural killer (NK) cells, B-cells and 
T-cells. TNF-« binds to receptors present on vil1ually all cells throughout the body, 
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except on red blood cells. Conditions, known to induce TNF-u production are 
inflammation, fever, acute phase reaction, and sepsis. Monocyte activation by 
endotoxins, like lipopolysaccharides (LPS), enterotoxins, toxic shock sydrome toxin, 
mycobacterial wall products (lipoarabinomannan), antibodies to monocytes (CD 14), 
and products of complement may result in a peak outburst of TNF_U12. Lymphocyte 
activation by antigenic or mitogenic stimuli also results in TNF-u production13•1 •. 
sepsis . 
inflammation enierotoxlnS 
I, \ 1 / complement Ipopoly-
saccharide............ / activated 
~C? monocytes I 
macrophages 
@ natural killer cells 
B-cells 
T-cells 
TNF- a (trl-meric) 
.---------- --------. 
55 kDa 
TNF-Rl 
1 
apoplosis \ J 
tumor cellysis (in vitro) 
hemorrhagic necrosis 1 bone resorption 
shock 
tissue damage 
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TNF-R2 
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TNF- a production after stimulation of target cells. 
TNF-u appeared to be a 
17kDa glycoprotein, which 
in its active form consists of 
3 molecules. This trimer is 
the biological active form 
of TNF -u and binds to the 
membrane-bound TNF re-
ceptor complex. 
The affinity of cytokines to 
their specific receptors is 
very strong. The 
dissociation constants (Kd) 
for TNF-u to its receptors 
are 2-5 x 10-10 and 3-7 x 
lO-IOM15 and result in 
biological activity at very 
low concentration levels·. 
For TNF-u two distinctive 
receptors have been des-
cribed: a 55 kDa TNF-R 
(TNF-Rl) and a 75 kDa 
TNF-R (TNF-R2) (see 
figure). TNF· a binds to its receptors present on virtually all cells 
throughout the body, causing a variety of reactions. 
Biological activity mediated 
by TNF-RI is distinct from activity mediated by TNF-R2. Cytotoxicity and apoptosis 
(programmed cell death) is predominantly mediated by TNF-RI, while cytotoxicity, 
and T- and B-ce1l proliferation induction are mainly conducted by TNF_R2 16-18• 
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However, as result of pleiomorfism, the function of RI can partially be inhibited by 
affecting R219. Rink reports the differentiation between the function of Rl and R2, 
however conflicting data are present concerning the clearness of the distinction 
between functions of R I and R2 as reported by others'o. After binding of TNF -u to its 
receptor, proteolytic cleavage of the extracellular domains result in the production of 
soluble receptors, sTNF-RI and sTNF-R2 (see figure). These soluble receptors can 
bind 1-3 circulating TNF molecules and act as a pool ofTNF-u4. 
TNF-a 
W 
~ internalizing 
1 
signaling 
After TNF- a binding to the receptor, the extracellular 
domain of the receptor is splitl off by proteolytic cleavage 
and soluble-TNF-R (sTNF) are formed, 
TNF -u, if released 
systemically in large 
amounts all at once, 
activates neutrophils, 
modifies anticoagulant 
properties of the 
endothelium, and 
induces the release of 
other inflammatory 
cytokines, such as IL-
l ~ and IL-6. These 
effects can culminate 
in card iovascular 
collaps and shock. On 
the contrary, chronic, 
low-level production 
of TNF -u may contribute to inflammatory responses in autoimmune diseases like 
rheumatoid aJ1hritis, morbus Crohn, but also attributes to bone resorption, fever, 
anemia and wasting4. Direct cytotoxic effects of TNF-u on endothelial cells result in 
upregulation of major histocompatibility complex (MHC) class I and II molecules, 
adhesion molecules, and chemoattraction of polymorphonuclear cells, which, after 
TNF-u activation release free radicals and thereby damage the endothelium'l. 
1,2 TNF-u and its role in the immune reponse 
1,2.1 Introduction of the immune system 
The immune system has evolved to protect us fi'om pathogens. Specific immune 
responses occur by different stimuli (antigens), e.g, microbiological agents, 
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alloantigens or auto-immune antigens. Antigens are processed by antigen presenting 
cells, e.g. monocytes, macrophages and polymorphonuclear neutrophils, which in turn 
present the antigens to specific lymphocytes that recognize the antigen, resulting in 
initiation of the immune response and elimination of the pathogen. [n this process 
lymphocytes have specific functions. Helper T-cells coordinate the immune response 
by direct cell-cell interactions and the release of cytokines, which help B-lymphocytes 
to secrete antibodies (humoral immune response), activate T-lymphocytes to 
proliferate, and to kill the target cell (cytotoxic T-cells). 
This specific immune response consists of 3 different distinct signals. Signal I refers to 
the antigen presentation, in which the APC process the antigen and presents it in its 
MHC class II molecule to the T-cell receptor (TCR), present on T-cells". Signal 2 is 
named the co-stimulatory pathway. Interaction of the T-cells with the APC needs this 
co-stimulation in order to become activated. There are different co-stimulatory 
pathways, in which each molecule on the T-cell interacts with its ligand on the APC. 
Well-known combinations are the CD281B7 1 and the CD40/CD40L interaction. Signal 
3 refers to the production of cytokines, like IL-I, IL-6 and TNF -a. 
After signal I to 3 the T-cell is activated and [L-2-production is started. This [L-2 
production results in proliferation and differentiation of helper T-cells and cytotoxic T-
cells. FUlthermore, [L-2 augments the cytolytic activity of NK cells, is involved in 
programmed cell death of activated T-cells, and promotes the synthesis of immune 
globulins by B-cells2l. 
1.2.2 TNF-fJ. and the imllllllle re;pollse 
In 1987 Waage first demonstrated high levels of circulating TNF -a in patients with 
severe meningococcal disease". Positive correlation between TNF-a levels and clinical 
outcome has been found". In an immune response the high levels of TNF-a are 
predominantly produced by monocytes, but also T-cells and natural killer cells produce 
TNF-a, upon stimulation. The production of TNF-a is strongly induced by 
Iipopolysaccharides. Cytokines, e.g. IL-15 and IFN-y, mediate TNF -a production by T-
cells and monocytes26.". Synchronous to the production ofTNF-a is the production of 
the soluble TNF receptors, sTNF-RI and sTNF-R2. 
Auto-immune inflammatory diseases, as well as bacterial induced inflammation is 
largely conducted by production ofTNF -a at the site of inflammation"'''. The levels of 
TNF -a reflect the disease activity in morbus CrohnJO•J1 • The central role of TNF -a in 
the immune response has been accepted, and has resulted in the development of anti-
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F h . b C I J2 33 .]4 d I 'd h" 35 36 B . fi . I TN t erapy. e.g. In mor us ro 111 • • sepsIs' an r leumatOl art rltlS . . elll ICla 
effects of blocking TNF-C( by antagonists is described in rheumatoid alihritis35 • but 
complete removal ofTNF-C( has deleterious effects in sepsis3'. 
1.3 TNF-C( in renal failure and dialysis 
TNF-C( is thought to play an important role in progressive renal fail ureJ7.J9. High 
expression levels ofTNF-a are found in kidneys of patients with glomerulonefritis, i.e. 
membranoproliferative or mesangial proliferative'o. In IgA glomerulopathies, high 
circulating levels of TNF -C( are found in presence of macroscopic hematuria41 • In non-
active or non-proliferative or non-hematuric glomerulopathies TNF -C( levels are within 
the normal range. TNF -C( is produced by cells of the affected kidney 42.43, but also by 
peripheral blood mononuclear cells (PBMC). For instance PBMC from patients with 
glomerulonefritis produced higher amounts of TNF-C( than PBMC from healthy 
controls"'''. Mechanisms leading to progressive renal failure involve actions of 
angiotensin-conveliing enzyme (ACE) and therefore ACE-inhibitors may be of benefit 
in those patients possibly by influencing TNF-C( production46,4'. Increased TNF-C( 
levels coincide with the malnourishment, which is often encountered in severe renal 
failure", and may be even the cause of uremia related cachexia. 
Another field in which TNF -C( is thought to playa key-role is in hemodialysis related 
disease. Hemodialysis procedures are frequently followed by fatique, fever, malaise 
and anorexia, while the hemodialysis-related hypotension can be a problem in some 
patients resulting in inadequate dialysis sessions49 • 
In 1983 the "interleukine hypothesis" was put forward: cytokines produced during 
hemodialysis are involved in the processes leading to hypotension, fever, and other 
acute phase responses observed in patients on dialysis49 • Due to continuous blood-
membrane contact in patients on dialysis, monocytes become activated, reflected by 
high levels of TNF-C( in patients on renal replacement therapy'°·51. TNF-C( protein, in 
contrast to the soluble receptors, sTNF-RI and sTNF-R2, is not detectable in plasma of 
healthy subjects'o. However, when chronic renal failure occurs, even in mild forms 
(creatinine clearance 40-80 mllmin), elevated TNF-C( plasma levels can be found'o. The 
plasma concentration ofTNF-a shows a positive relation with progressive renal failure. 
In patients on renal replacement therapy, peritoneal dialysis (CAPO) or hemodialysis 
(HO) higher plasma levels of TNF-a are found. The presence of free plasma TNF-C( 
however, is not constitutively observed by all investigators"'''. 
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Furthermore, TNF-a could playa role in the immune dysfunction seen in these 
patients. Increased susceptibility to infections, malignancy, and artherosclerosis are 
often found in patients on chronic hemodialysis. TNF-a, but also IL-l~, two pro-
. fl k' I'k I d' h d' I' I d 49,,·66 tn atnmatory cyto tnes, are 1 e y to me late t ese la YSls-re ate symptoms' . 
The activated state of the monocytes contrasts with the increased immune 
incompetence of patients on HD. The role the soluble TNF receptors as possible 
inhibitors of the biological activity of TNF -a 01' as pool of bioavailable TNF -a is still 
not completely clarified. The balance between TNF-a and its soluble receptors may be 
more impOliant than the exact levels of the proteins itself'·6'. Except TNF -a, many 
other cytokines have been studied in patients on HD. In vivo as well as in vitro 
production of IL-2, lL-6, IL-8, IL-I 0 and IL-12 by different cell types upon different 
stimuli have been described6l •69.JI • Overall, it seems that after in vitro stimulation, 
monocytes are capable of producing adequate amounts of mUltiple cytokines"·". 
Hemodialysis procedures are supposed to induce cytokine production, resulting in 
dialysis related morbidity. Moreover, HD patients show no adequate immune reponse 
on T-cell dependent antigens, i.e. hepatitis 8 vaccination in contrast to patients on 
peritoneal dialysisJJ.J4. The HD procedure, itself, seems to result in an inadequate 
immune response. Whether the defects in the immune response are at levels of APC, at 
T-cell levels 01' at the level of interaction between the APC and T-cells is not yet clear. 
The APC are activated and produce cytokines5o. The T-cell function in uremia and 
hemodialysis is extensively described by many authors. Normal, as well as intrinsic 
defects in T-cell are foundJ5·". However, initiation of hemodialysis treatment leads to 
improvement of T-cell and immune function, suggestive for an defective T-cell 
function"'·J8. TNF-a and T-cell function are also clearly related, as Taliaglia 
described l9. Therefore, TNF-a may playa central and pivotal role in the disturbed 
immune response in HD patients, but its role on the functions of the immune system in 
patients on renal replacement therapy is all but clear and can be described as pleiomorf 
as the cytokine itself. 
Illustrative is the appiclation of continuous alierio-venous 01' veno-venous hemodia-
lysis procedures (CA VHD, CVVH) in case of severe sepsis and hemodynamic 
instability as therapy of choice, in order to clear the overshoot of pro-inflammatory 
cytokines, like TNF -a, IL-I ~ and I L-6 J9.". 
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1.4 TNF-a and its role in heart failure 
Patients with chronic heart failure can suffer from cardiac cachexia that may be due to 
activation of the immune system", Increased circulating levels of TNF-a in patients 
with progressive heart failure are frequently described"-9I, Furthermore increased 
expression ofTNF-a has been found in cardiac tissue of explanted hemi from patients 
undergoing cardiac transplantation85, Besides the proinflammatory propeliies, TNF-a is 
known for its direct toxic effects on cardiomyocytes resulting in LV dysfunction, 
pulmonary edema, LV remodelling, and cardiomyopathy",93, These cardio-depressent 
propeliies of TNF -a were discovered afler the introduction of TNF-a as anti-tumor 
therapy, A high incidence of severe dilated cardiomyopathy was encountered in TNF-a 
treated patients 10, Animal studies have shown that transgenic mice that overexpress 
TNF-a in the cardiac compatiment develop progressive left ventricular (LV) dilatation 
and LV dysfunction9l , The origin of these high levels of TNF-a is a point of 
discussion, In failing hemis increased mRNA expression as well as cytosolic TNF-a is 
found, however, no correlation between intracardiac TNF-a and serum levels was 
established", On the other hand, heart failure may cause edema of the gut wall, which 
subsequently may result in altered gut permeability and fascilitate endotoxin release 
and TNF-a production by immune competent cells84, Also neuro-endoctine disorders, 
with stimulation of the sympatic nervous system, the renin-angiotensin-aldosteron axis 
and the natriuretic peptide system, which in tUI'll can stimulate TNF-a production, have 
been proposed94, High levels of TNF-a are associated with progressive heart failure, 
Recovering from severe heali failure by insertion of left ventricular device, coincides 
with a decrease ofTNF_a95, Also studies with TNF-a antagonists treatment in patients 
with severe heart failure improved the function of the failing heart, without serious 
side-effects", The favorable effects of continuous hemodialysis (CA VHD, CVVH) in 
patients undergoing cardiac surgery is thought to be the result of clearance of the pro-
inflammatory cytokine TNF_a97-99, High levels of TNF-a are associated with increased 
TNF-R expression on monocytes, endothelial cells, and on cardiomyocytes85,IOO, 
Shedding of the TNF-R results in production of soluble TNF-R in peripheral blood, 
These sTNF-R provide a pool for TNF-a by binding the active, trimeric TNF-a 
molecule and prevent dissociation of TNF-(X to inactive monomers87, As sTNF-R are 
metabolized by renal clearance it is obvious that sTNF-R show a positive correlation 
with serum creatinine1ol , Serum levels of sTNF-R predict outcome after cardiac 
surgery, Whether this reflects the better renal function 01' a larger pool of active TNF-a 
remains unclear lO2, The central role of TNF-a in hemi failure is well established, On 
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the longterm the effects of a continuously activated immune system with increased 
TNF-t( levels have to be evaluated, in relation to the overall immune competence of 
patients with heart failure. 
1.5 TNF-t( in organ transplantation 
1.5.1. TNF-a: il1l'ellailI'GIlSpianlalioll 
Much attention has been focused on the involvement of specific cytokines after renal 
transplantation 103. In particular, their involvement in graft rejection and tolerance has 
been evaluated in the clinical setting and in experimental models'04·109. TNF-t( plays a 
role in graft rejection. A significant increase of TNF-t( plasma levels was seen a few 
days before allograft rejection "0. Di:irge et al measured TNF-t( and the soluble 
receptors Rl and R2 before and daily after renal transplantation. These authors clearly 
showed an increase ofTNF-t( during acute allograft rejection'". Except measurements 
in peripheral blood, intragraft detection of specific cytokine patterns have shown to be 
correlated with rejection. Especially, increased mRNA expression of IL-2 and IL-2R 
was positively related to subsequent episodes of acute rejection "'. Messenger RNA 
expression of TNF-t(, IL-I P and IL-I 0 were also found during acute rejection, but were 
d · . 112113 C ki d" . II d . d d h not pre ,ct,ve . . yto ne pro uct,on 's genet,ca y etermme an some aut ors 
described the predictive value of TNF-t( gene polymorph isms and the occurrence of 
renal allograft rejection'I4·IIS. Especially the TNF-t( high-producer genotype of the 
recipient was positively correlated with multiple rejection episodes 115. As the role of 
TNF-t( in rejection is established, inhibition of the TNF-t( effects as anti-rejection 
therapy can be performed, using recombinant human TNF receptors (TNF-R). Eason et 
al desc,ibed encouraging results in delay of rejection when TNF-R was given alone, or 
in combination with CsA, in non-human primates ll6 , Sabatine et al performed a study 
with sTNF-R secreting tumor allografts which resulted in prolongation of the 
transplanted graft without rejection, suggestive for immunosuppressant properties of 
sTNF_R'I7. It is clear that TNF-t( and the receptors RI and R2 playa role in the 
immune response after renal transplantation. The production by activated macrophages 
and T-Iymphocytes in the allograft as result of allograft rejection may be the source of 
the increased TNF-a levels. The elevated levels of sTNF receptors may result from 
increased shedding and thereby reflect the activity of the TNF-t( system after renal 
transplantation. A strong cOlIeI.tion between these levels of the soluble receptors and 
16 
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serum creatinine has been described105, Therefore, measuring TNF-a and the soluble 
receptors after transplantation may provide a non-invasive diagnostic tool for rejection. 
1,5,2, TNF-11 ill heart transplantation 
After heart transplantation elevated levels of circulating TNF-a, and the receptors 
TNF-Rl and TNF-R2 may predict severe humoral and cellular rejections l18 , But, when 
the TNF-a levels were measured in coronary sinus serum, no relation with histological 
signs of rejection was found"9, These conflicting results are in part due to the different 
circumstances under which cytokine levels were measured, It appeared that elevated 
TNF-a levels, but also IL-6 levels, were found after anti thymocyt globulin (A TG)-
induction therapy 120, In contrast, Deng et al described a positive correlation between 
serum levels of IL-6, TNF-a and sIL-2R and hemodynamic (pulmonary wedge 
pressure, pulmonary arterial pressure, right atrial pressure and heart rate) and 
ultrasound (isovolumic relaxation, fractional shortening) parameters in cardiac allograft 
recipients '2l , When sequential blood samples were examined, TNF-a serum level 
correlated well with the findings in endomyocardial biopsies!", Cytokine 
measurements in peripheral blood may not entirely reflect the rejection process in the 
transplanted heart!22, Intragraft expression of cytokines at mRNA levels has been 
frequently described l2l,I24, But again, conflicting data are presented, Positive, weak and 
no relation between TNF-a and rejection are described 124. 126, However, mRNA 
expression is genetically regulated and gene polymorphisms are found fa!' multiple 
cytokines, including TNF-a, Again, in comparison to renal transplant recipients, the 
high TNF-a producer genotype of the recipient appeared to be more vulnerable to acute 
rejection 127, Furthermore, Baan et al found an everpresent TNF-a mRNA expression in 
endomyocardial biopsies, but the expression level was clearly related to rejection, since 
it significantly decreased after anti-rejection therapyl25, These data suggests that TNF-a 
is involved in rejection processes after clinical heart transplantation and may provide 
another diagnostic tool. However, the relation between TNF-a and cardiac allograft 
function has still to be evaluated, 
17 
Chapter 1 
1.6 Aim of this thesis 
We analyzed in detail the TNF-a system during organ failure and organ replacement 
therapy in an attempt to assess the role of TNF-a in the pathogenesis of the immune 
compromised status of patients with these conditions. 
In this respect we measured rnRNA expression, protein production, receptor 
expression, soluble receptor levels, serum buffer capacity and the TNF-a induced cell 
proliferation in patients with renal or heali failure, in patients on renal replacement 
therapy (peritoneal dialysis 01' hemodialysis), and in patients after kidney or cardiac 
transplantation. To determine whether the severity of renal failure or the mode of renal 
replacement therapy result in increasing abnormalities of cytokine systems, the TNF-a 
system was evaluated at various levels of renal insufficiency: pre-dialysis end-stage 
renal failure (ESRF), on peritoneal dialysis (CAPD) and hemodialysis (lID) (chapter 
2). 
TNF-recept01's are expressed by both pelipheral monocytes and T-Iymphocytes. 
Chapter 3 describes a quantitative flow cytometric analysis to assess the activation 
status of the TNF-a and IL-2 system at the single cell level in patients with ESRF, on 
CAPD andHD. 
To test whether an activated TNF-a system in patients on hemodialysis results in 
impaired T-cell response, variolls parameters of the TNF-a system (Antigen Presenting 
Cell) and IL-2 system (T-cells) were analyzed (chapter 4), while the cytokine-driven 
(TNF-a, lL-2) proliferation of T-cells was measured to find out whether the immune 
dysfunction was due to an intrinsic T-ceH defect (chapter 5). 
In chapter 6 the TNF -a system after renal transplantation is described. We performed 
selial measurements of selUm and urine samples, to study the clearance of the soluble 
receptors, directly after transplantation and at I year. These measurements were 
perfonmed after living (un-)related renal transplantation in order to prevent other 
factors, which may influence the TNF-a levels, e.g. delayed graft function. 
In chapter 7 the activity of the TNF-a system on mRNA level, plasma protein, and 
soluble TNF-receptors are described in patients with heart failure and after heart 
transplantation. 
18 
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Membrane receptor expression on target cells may reflect the activity of cytokine 
systems. In the immune response the cytokines TNF-a and IL-2 playa pivotal role. The 
impaired immune competence seen after transplantation might not only be the 
consequence of immunosuppressive therapy, but also be the result of unbalanced 
cytokine systems. To assess the activit ion status of the cytokine systems TNF-a and IL-
2, the receptor expression of these cytokine systems on peripheral monocytes and 
lymphocytes is measured, using the quatitative flow cytometry in chapter 8. 
19 
Chapter 1 
Reference List 
I. Coley N, Fowler G, Bogatko F. A review of the influence of bacterial infections and of 
bacterial products (Coley's toxin) on malignant tumors in man. Acta Med Scalld (suppl) 
1953; 274:24-97. 
2. Carswell E, Old L, Kassel R. An endotoxin-induced serum factol' that causes regression 
of tumors. Proc Nat! Acad Sci USA 1975; 72:3666-3670. 
3. Pcnnica D, Nedwin G, Hayflick J. Human tumor necrosis factor: precursor structure, 
expression and homology to lymphotoxin, Nature 1984; 312:724-728. 
4. Bazzoni F, Beutler B. How do tumor necrosis factor receptors work? J Inflamm 1995; 
45:221-238. 
5. Calandra T, Gerain J, Heumann D, Baumgartner ro, Glauser 1v1P. High circulating levels 
of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, 
and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. 
AmJMed 1991; 91:23-29. 
6. Beutler B, Grall GE. Tumor necrosis factor in the pathogenesis of infectious diseases. 
Crit Care Med 1993; 21:S423-S435 
7. Abraham E, 'Vunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy 
and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with 
sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-
alpha MAb Sepsis Study Group. JAMA 1995; 273:934-941. 
8. De Wilt J. Isolated limb perfusion as a treatment modality in cancel': from TNF to gene 
therapy. 2000; Erasmus University Rotterdam, Thesis 
9. Van del' Veen A. Tumor necrosis factor-a and tumor targeting:regiollal and systemic 
administration of TNF-a in the rat for treatment of solid tumors. 2000; Erasmus 
University Rotterdam, Thesis 
10. Hegewisch S, Weh H, Hossfeld D. TNF-induced cardiomyopathy. Lancet 1990; 21:171-
172. 
II. Eggennont AM, SchraffOl'dt KH, Klausner JM, Lienal'd D, Kroon BB, Schlag PM, et al. 
Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for 
advanced extremity soft tissue sarcomas. Semin Oncol 1997; 24:547-555. 
12. Tracey KJ, Cerami A. Tumor necrosis factor: an updated review of its biology. Cdt Care 
Med 1993; 21:S4IS-S422 
13. Bryl E, Mysliwska J, Debska-Slizien A, Rachon D, Bullo B, Lizakowski S , et al. The 
influence of recombinant human erythropoietin on tumor necrosis factor alpha and 
interleukin-lO production by whole blood cell cultures in hemodialysis patients. Artif 
Organs 1998; 22:177-181. 
20 
Chapter 1 
14. Hayakawa M, Hatana T, Sunabe T, Higa I, Osawa A, Cytokine production and 
cytotoxicity of lymphocytes in patients on maintenance short- or long-term 
haemodialysis. Nephrol Dial Transplant 1994; 9:655-661. 
15. Meager A, Bird C, Mire-Sluis A. Assays for measuring soluble cellular adhesion 
lIlolecules and soluble cytokine receptors. J IlIllllunol Methods 1996; 191 :97-112. 
16. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor 
(TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J BioI Chem 
1993; 268:18542-18548. 
17. Tartaglia LA, Rothe M, Hu YF, Goedde! DV . Tumor necrosis factor's cytotoxic activity 
is signaled by the p55 TNF receptor. Cell 1993; 73:213-216. 
18. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MAJ, Goeddel DV . The two 
different receptors for tumor necrosis factor mediate distinct cellular responses. Proc 
Nall Acad Sci USA 1991; 88:9292-9296. 
19. Tartaglia LA, Goeddel DV, Reynolds C, Figari IS, Weber RF, Fendly 8M, et al. 
Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor 
necrosis factor receptor, J Immunol 1993; 151 :4637 -4641. 
20, Rink L, Kirchner H, Recent progress in the tumor necrosis factor-a field, Int Arch 
Allergy Immunol1996; 111:199-209. 
21. MacKay F, Loetscher H, Strueber D, Tumor necrosis factor u (TNF-a) induced cell 
adhesionto human endothelial cells is under dominant control of one TNF-receptor type, 
TNF-R55. J Exp Med 1993; 177: 1277-1286. 
22, Male D, Raitt 1. Introduction to the immune system, In: Raitt, Brostoff, Male, editors, 
Immunology. fifth ed. 1998:1-11. 
23, Feldmann M. Cell cooperation in the antibody response, In: Raitt, Brastoff, Male, 
editors. Immunology. fifth ed. 1998:139-159. 
24. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in 
senlln and fatal outcome in patients with meningococcal disease. Lancet 1987; 1:355-
357. 
25. Debets JM, Kampmeijer R, van der Linden NIP, Buurman WA, van der Linden CJ, 
Plasllla tumor necrosis factor and mortality in critically ill septic patients, Cril Care Med 
1989; 17:489-494. 
26, McInnes lB, Liew FY. InterJeukin 15: a proinflanunatory role in rheumatoid arthritis 
synovitis. Immunol Today 1998; 19:75-79. 
27, Debets JM, van der Linden CJ, Spronken IE, Buurman 'VA. T cell-mediated production 
of tumour necrosis factor-alpha by monocytes, Scand J Immul1011988; 27:601-608. 
28, Van def Poll T, van Deventer SJ, Cytokines and anticytokines in the pathogenesis of 
sepsis. Infect Dis Clin North AIIl 1999; 13:413-26. 
21 
Chapter 1 
29. Juffermans NP, Verbon A, van Deventer SJ, van Deutekom H, Speelman P, van der Poll 
T. Tumor necrosis factor and interleukin-l inhibitors as markers of disease activity of 
tuberculosis. Am J Respir Crit Care Med 1998; 157:1328-133l. 
30. Simpson AJ, Smith MD, Weverling GJ, Suputtamongkol Y, Angus BJ, Chaowagul W, et 
al. Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-
6, and interleukill-10) and clinical parameters in severe melioidosis. J Infect Dis 2000; 
181:621-625. 
31. van Deventer S1. Tumour necrosis factor and Crohn's disease. Gut 1997; 40:443-448. 
32. Dekkers PE, Lauw FN, ten Hove T, te V A, Lumley P, Becherer D, et a!. The effect of a 
metalloproteinuse inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-aJpha) and 
TNF-alpha receptors during human endotoxemia. Blood 1999; 94:2252-2258. 
33. D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert P, et a1. 
Endoscopic and histological healing with infliximab anti-tumor necrosis factor 
antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999; 
116:1029-1034. 
34. Fisher Cll, Agosti JM, Opal SM, Lowry SF , Balk RA, Sadoff JC, et a!. Treatment of 
septic shock with the tumOr necrosis factor receptor:Fc fusion protein. The Soluble TNF 
Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-1702. 
35. Moreland LW, Schiff MR, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, 
et at. Etallercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann 
Intern Med 1999; 130:478-486. 
36. Moreland LW, Baumgartner SW, Schiff MR, Tindall EA, Fleischmann RM, Weaver AL, 
et a1. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor 
receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141-147. 
37. Baud L, Ardaillou R. Tumor necrosis factor in renal injury. Miner Electrolyte Metab 
1995; 21:336-34l. 
38. Ortiz A, Bustos C, Alonso J, Alcazar R, Lopez-Armada MJ, Plaza JJ, et al. Involvement 
of tumor necrosis factor-alpha in the pathogenesis of experimental and human 
glomerulonephritis. Adv Nephrol Necker Hosp 1995; 24:53-77. 
39. Cottone S, Vadala A, Vella MC, Mule G, Contonto A, Cerasola G. Comparison of 
tumour necrosis factor and endothelin-1 between essential and renal hypertensive 
patients. J Hum Hypertens 1998; 12:351-354. 
40. \Vu TH, Tsai CY, Yang WC. Excessive expression of the tumor necrosis factor-alpha 
gene in the kidneys of patients with membranous glomeruloneplu·itis. Chung Hua I 
Hsueh Tsa Chih (Taipei) abstract 1998; 61:524-530. 
41. Inaba S, Takahashi T, Ishihara S, Kurose K, Arai M, Sakai Y, et al. Serum tumor 
necrosis factor in mesangial IgA glomerulonephritis with macroscopic hematuria in 
children. Nephron 1996; 72:518-522. 
22 
Chapter 1 
42, Herrera-Esparza R, Barbosa-Cisneros 0, Villalobos-Hurtado R. Avalos-Diaz E, Renal 
expression of JL-6 and TNFalpha genes in lupus nephritis. Lupus 1998; 7:154-158. 
43, Ozen S, Saatci D, Tinaztepe K, Bakkaloglu A, Barut A. Urinary tumor necrosis factor 
levels in primary glomerulopathies. Nephron 1994; 66:291-294. 
44. Matsumoto K. Increased release of tumor necrosis factor-alpha by monocytes from 
patients with glomerulonephritis. Clin Nephro11993; 40:148-154. 
45. Cassidy MJ, De Jager C, Ebrahim 0, Camachio P, Robson S. Peripheral blood 
mononuclear cells from patients with chronic renal failure release factors which suppress 
erythropoietin secretion in vitro. Nephrol Dial Transplant 1994; 9:775-779. 
46. Klahr S. Mechanisms of progression of chronic renal damage. J Nephro11999; 12 Suppl 
2:S53-S62 
47. Stenvinkel P, Andersson P, Wang T, Lindholm B, Bergstrom J, Palmblad J, et al. Do 
ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic 
renal failure? J Intern Med 1999; 246:503-507. 
48. Abdullah MS, Wild G, Jacob V, Milford-Ward A, Ryad R, Zanaty M, et al. Cytokines 
and the malnutrition of chronic renal failure. Miner Electrolyte Metab 1997~ 23:237-242, 
49, Dinarello CA, Cytokines: agents provocateurs in hemodialysis? Kidney lnt 1992; 
41 :683-694. 
50. Descamps-Latscha B, Herbelin A, Nguyen AT, Raux-Lombard P, Zingraff J, Moynot A, 
et a1. Balance between IL-l beta, TNF-alpha, and their specific inhibitors in chronic 
renal failure and maintenance dialysis, Relationships with activation markers of T cells, 
B cells, and monocytes. J Immunol 1995; 154:882-892. 
51, Lonnemalln G, Haubitz M, Schindler R. Hemodialysis-associated induction of cytokines, 
Blood Purif 1990; 8:214-222. 
52. Powell AC, Bland LE, Oettinger CW, McAllister SK, Oliver JC, Arduino MJ , et al. 
Lack of plasma interleukin-l beta or tumor necrosis factor-alpha elevation during 
unfavorable hemodialysis conditions. J Am Soc Nephrol 1991; 2: 1007 -1013. 
53, McKenna RM, Macdonald C, Bernstein KN, Rush DN, Increased production of tumor 
necrosis factor activity by hemodialysis but not peritoneal dialysis patients, Nephron 
1994; 67:190-196. 
54. Zemel D, Imholz AL, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of 
tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of 
CAPD. Kidney Int 1994; 46:1422-1430. 
55. Sundaram S, Barrett TW, Meyer KB, Perrella C, Neto MC, King AJ, et al. 
Transmembrane passage of cytokille-inducing bacterial products across new and 
reprocessed polysulfone dialyzers. J Am Soc Nephrol 1996; 7:2183-2191. 
56. Pereira BJ. Cytokine production in patients on dialysis. Blood Purif 1995; 13:135-146. 
23 
Chapter 1 
57 .. Pereira BJ, Shapiro L, King AI, Falagas ME, Strom lA, Dinarello CA. Plasma levels of 
IL-I beta, TNF alpha and their specific inhibitors in undialyzed chronic rellal failure, 
CAPD and hemodialysis patients. Kidney Int 1994; 45:890-896. 
58. Pereira BI, Poutsiaka DD, King AJ, Strom lA, Narayan G, Levey AS, et al. In vitro 
production of interleukin-l receptor antagonist in chronic renal failure, CAPD and lID. 
Kidney Int 1992; 42:1419-1424. 
59. Schindler R, Lonnemann G, Shaldon S, Koch KM, Dinarello CA. Induction of 
interleukin-l and tumor necrosis factor during in vitro hemodialysis with different 
membranes. Contrib Nephro11989; 74:58-65. 
60. Dinarello CA. Interleukin-l--its multiple biological effects and its association with 
hemodialysis. Blood Purif 1988; 6:164-172. 
61. Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Meyer zBK, Fleischer B. 
Production of interleukin-6, tumor necrosis factor alpha and interieukin-lO in vitro 
correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 
1995; 47:559-565. 
62. Kaul H, Girndt M, Sester U, Sester M, Kohler H. Initiation of hemodialysis treatment 
leads to improvement of T-cell activation in patients with end-stage renal disease. Am J 
Kidney Dis 2000; 35:611-616. 
63. Girndt M, Heisel 0, Kohler H. Influence of dialysis with polyamide vs haemophan 
haemodialysers on monokines and complement activation during a 4-month long-term 
study. Nephrol Dial Transplant 1999; 14:676-682. 
64. Girndt M, Sester V, Kaul H, Kohler H. Production of proinfiammatory and regulatory 
monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 
1998; 9:1689-1696. 
65. Kohler H, Girndt M, Durnann H, Klingel R. The immune defect in kidney failure. II. The 
mechanisms of the "uremic" immune defect. Dtsch Med \Vochenschr 1993; 118:790-
795. 
66. Kohler H, Girndt M, Dumann H, Klingel R. The immune defect in kidney failure. I. The 
clinical manifestations. Dtsch Med Wochenschr 1993; 118:757-761. 
67. Pereira BJ. Balance between pro-inflammatory cytokines and their specific inhibitors in 
patients on dialysis. Nephrol Dial Transplant 1995; 10 SuppI7:27-32. 
68. Halwachs G, Tiran A, Reisinger EC, Zach R, Sabin K, Folsch B, et al. Serum levels of 
the soluble receptor for tumor necrosis factor in patients with renal disease. Clin Investig 
1994; 72:473-476. 
69. Engelberts I, Francot GI, Leunissen KiW, Haenen B, Ceska M, van der Linden eJ, et al. 
Effect of hemodialysis on peripheral blood monocyte tumor necrosis factor-alpha, 
interleuki;,-6, and interleukin-8 secretion in vitro. Nephron 1994; 66 :396-403. 
70. Zaoui P, Green \V, Hakim RM. Hemodialysis with cuprophane membrane modulates 
interleukin-2 receptor expression. Kidney Int 1991; 39: 1020-1026. 
24 
Chapter 1 
71. Yamaguchi T, Iwano M, Kubo A, Hirayama T • Akai Y, Horii Y, et al. IL-6 mRNA 
synthesis by peripheral blood mononuclear cells (PBMC) in patients with chronic renal 
failure. Clin Exp InmlUnol 1996; 103:279-284. 
72. Zamauskaite A, Perez-Cruz I, Yaqoob MM, Madrigal JA, Cohen SB. Effect of renal 
dialysis therapy modality all T cell cytokine production. Nephrol Dial Transplant 1999; 
14:49-55. 
73. Versluis DJ, Beyer WE, Masurel N, Diderich PP, Kramer P, Weimar \V. Intact humoral 
immune response in patients on continuous ambulatory peritoneal dialysis. Nephron 
1988; 49:16-19. 
74. Versluis DJ, Beyer \VE, Masurel N, \Veimar \V. Influenza vaccination in dialysis and 
transplant patients. Antiviral Res 1985; Suppll:289-292. 
75. Kelly CJ. T cell function in chronic renal failure and dialysis. Blood Purif 1994; 12:36-
41. 
76. Degiannis D, Czarnecki M, Donati D, Horner L, Eisinger RP, Raska KJ, et al. Normal T 
lymphocyte function in patients with end-stage renal disease hemodialyzed with 'high-
11ux' polysulfone membranes. Am J Nephrol 1990; 10:276-282. 
77. Donati D, Degiannis D, Raskova J, Raska KJ. Uremic serum effects on peripheral blood 
mononuclear cell and purified T lymphocyte responses. Kidney Int 1992; 42:681-689. 
78, Girndt M, Lengler S, Kaul H, Sesler U, Sesler M, Kohler H. Prospective crossover trial 
of the influence of vitamin E-coated dialyzer membranes on T-cell activation and 
cytokine induction. Am J Kidney Dis 2000; 35:95-104. 
79. Schindler R, Dinarello CA. Ultrafiltration to remove endotoxins and other cytokine-
inducing materials from tissue culture media and parenteral fluids. Biotechniques 1990; 
8:408-413. 
80. Lonnemann G, Bechstein M, Linnenweber S, Burg M, Koch KM. Tumor necrosis factor-
alpha during continuous high-tlux hemodialysis in sepsis with acute renal failure. Kidney 
Int Supp11999; 72:S84-S87 
81. Bagshaw ON, Anaes FR, Hutchinson A. Continuous arteriovenous haemofiltration and 
respiratory function in multiple organ systems failure. Intensive Care Med 1992; 18:334-
338. 
82. Van Bonullel EF, Hesse CJ, Jutle NH, Zietse R, Bruining HA, Weimar W. Impact of 
continuous hemofiltration on cytokines and cytokine inhibitors in oliguric patients 
suffering from systemic intlammatory response syndrome. Ren Fail 1997; 19 :443-454. 
83. Van Bonllllel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, \Veimar \V. Cytokine 
kinetics (TNF-alpha, IL-l beta, IL-6) during continuous hemofiltration: a laboratory and 
clinical study. Contrib Nephro11995; 116:62-75. 
84, Niebauer J, Yolk lID, Kemp M, Dominguez M , Schumann RR, Rauchhaus M, et al. 
Endotoxin and inunune activation in chronic heart failure: a prospective cohort study 
Lancet 1999; 353:1838-1842. 
25 
Chapter 1 
85. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young IB, et a1. Tumor 
necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. 
Circulation 1996; 93:704-711. 
86. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour 
necrosis factor in "cachectic" patients with severe chronic heart failure. Bf Heart J 1991; 
66:356-358. 
87. Ferrari R, Bachetti T, Confortini R, Opasich C, Peba 0, Corti A, et a!. Tumor necrosis 
factor soluble receptors in patients with various degrees of congestive heart failure. 
Circulation 1995; 92:1479-1486. 
88, Satah M, Nakamura M, Saitoh H, Satah H, Maesawa C, Segawa I, et al. Tumor necrosis 
factor-alpha-converting enzyme and tumor necrosis factor-alpha in human dilated 
cardiomyopathy. Circulation 1999; 99:3260-3265. 
89. Dutka DP, Elbom JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor alpha 
in severe congestive cardiac failure. Br Heart J 1993; 70:141-143. 
90. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor 
necrosis t;,ctor in severe chronic heart failure. N Engl J Med 1990; 323:236-241. 
91. Torre-Amione G, Bozkurt B, Deswal A, Mann DL. An overview of tumor necrosis factor 
alpha and the failing human heart. Curr Opin Cardiol1999; 14:206-210. 
92. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor 
necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad 
Sci USA 1989; 86:6753-6757. 
93. Yokoyama T, Vaca L, Rossen RD, Durante \V > Hazarika P, Mann DL. Cellular basis for 
the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian 
heart. J Clin Invest 1993; 92:2303-2312. 
94. Anker SD, Rauchhaus M. Insights into the pathogenesis of chronic heart failure: immune 
activation and cachexia. Curr Opin Cardiol1999; 14:211-216. 
95. Torre-Amione G, Vooletich MT, Farmer JA. Role of tumour necrosis factor-alpha in the 
progression of heart failure: therapeutic implications. Drugs 2000; 59:745-751. 
96. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, B10sch C, et a!. Safety and 
efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients 
with advanced heart failure. Circulation 1999; 99:3224-3226. 
97. Journois D, Israel-Biet D, Pouard P, Rolland B, Silvester W, Vouhe P, et a!. High-
volume, zero-balanced hemofiltration to reduce delayed inflammatory response to 
cardiopulmonary bypass in children. Anesthesiology 1996; 85:965-976. 
98. Journois D, Pouard P, Rolland B, Lagarde M. Ultrafiltration allows to reduce cytokine 
plasma concentrations during pediatric cardiopulmonary bypass. Contrib Nephrol 1995; 
116:86-88. 
26 
Chapter 1 
99. Iournois D, POllard p, Greeley \VI, Mauriat p, Vouhe P, Safran D. Hemofiltration during 
cardiopulmonary bypass in pediatric cardiac surgery. Effects on hemostasis, cytokines, 
and complement components. Anesthesiology 1994; 81: 1181-1189. 
100. Torre-Amione G, Kapadia S, Lee I, Bies RD, Lebovitz R, Mann DL. Expression and 
functional significance of tumor necrosis factor receptors in human myocardium. 
Circulation 1995; 92: 1487-1493. 
101. Koller-Strametz J, Pacher R, Frey B, Kos T, Woloszczuk W, Stanek B. Circulating 
tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor 
II, interleukin-6, and neurohumoral variables. J Heart Lung Transplant 1998; 17:356-
362. 
102. Pilz G, Fraunberger P, Appel R, Kreuzer E, Werdan K, Walli A, et al. Early prediction of 
outcome in score-identified, postcardiac surgical patients at high risk for sepsis. using 
soluble tumor necrosis factor receptor-p55 concentrations. Crit Care Med 1996; 24:596-
600. 
103. Strom TB, Tilney NL, Carpenter CB, Busch GJ. Identity and cytotoxic capacity of cells 
infiltrating renal allografts. N Engl J Med 1975; 292:1257-1263. 
104. Krams SM, Falco DA, Villanueva Je, Rabkin J, Tomlanovich SJ, Vincenti F, et at. 
Cytokine and T cell receptor gene expression at the site of allograft rejection. 
Transplantation 1992; 53: 151-156. 
105, Lambert C, Berthoux P, Vindimian M, Hacini J, Berthoux F. Natural serum TNF 
antagonists in end*stage renal failure and following renal transplantation. Nephrol Dial 
Transplant 1994; 9:1791-1796. 
106. Bemelman FJ, Jansen J, van der Poll T, van Deventer SJ, ten Berge RJ. Increase of sTNF 
receptor levels in acute cellal allograft rejection after treatment with OKT3. Nephrol Dial 
Transplant 1994; 9:1786-1790. 
107. Daniel Y, Pasker S, Wiesel M, Carl S, Pomer S, Staehler G, et al. Cytokine monitoring 
of infection and rejection in renal transplant recipients. Transplant Proc 1995; 27:884-
886. 
108. Blancho G, Moreau JF, Chabannes D, Chatenoud L, Soulillou JP. HILDNLIF, G.CSF, 
IL-l beta, IL-G, and TNF alpha production during acute rejection of human kidney 
allografts. Transplantation 1993; 56:597-602. 
109. Burlingham WJ, O'Connell PJ, Jacobson LM, Becker BN, Kirk AD, Pravica V , et al. 
Tumor necrosis factor-alpha and tumor growth factor-betal genotype: partial association 
with intragraft gene expression in two cases of long-tenn peripheral tolerance to a kidney 
transplant. Transplantation 2000; 69:1527-1530. 
110. Kutukculer N, Shenton BK, Clark K, Rigg KM, Forsythe JL, Kirby JA, et al. Renal 
allograft rejection: the temporal relationship and predictive value of plasma TNF (alpha 
and beta), lPN-gamma and soluble ICAM-I. Transpl Int 1995; 8:45-50. 
27 
Chapter 1 
11 L Dorge SE, Raux-Lombard P, Dayer JM, Koch KM, Frei V, Lonnemanll G. Plasma levels 
of tumor necrosis factor (TNF) and soluble TNF receptors in kidney transplant 
recipients. Transplantation 1994; 58:1000-1008. 
112. Kooijmans-Coutinho MF, Bruijn JA, Hermans J, Schindler R, Frei V, Schrama E, et at. 
Evaluation by histology, immunohistology and peR of protocolIized renal biopsies 1 
week posHranspiant in relation to subsequent rejection episodes. Nephrol Dial 
Transplant 1995; 10:847-854. 
113. Kirk AD, Bollinger RR, Finn OJ. Rapid, comprehensive analysis of human cytokine 
mRNA and its application to the study of acute renal allograft rejection. Hum Immunol 
1995; 43:113-128. 
114, Suthanthiran M. The importance of genetic polymorphisms in renal transplantation. CUff 
Opin Ural 2000; 10:71-75. 
115. Sankaran D, Asderakis A, Ashraf S, Roberts IS, Short CD, Dyer PA, et al. Cytokine gene 
polymorphisms predict acute graft rejection following renal transplantation. Kidney lnt 
1999; 56:281-288. 
116. Eason ro, Wee S, Kawai T, Hong HZ, Powelson JA, Widmer MB, et al. Inhibition of the 
effects of TNF in renal allograft recipients using recombinant human dimeric tumor 
necrosis factor receptors. Transpiant.1tion 1995; 59:300-305. 
117. Sabatine MS, Laufer T, Glimcher LH, \Vidmer M, Winn H, Auchincloss HJ. Delayed 
rejection of soluble tumor necrosis factor receptor-secreting tumor allografts. 
Transplantation 1998; 65:113-120. 
118. Jordan SC, Czer L, Toyoda M, Galfayan K, Doan D, Fishbein M, et al. Serum cytokine 
levels in heart allograft recipients: correlation with findings on endomyocardial biopsy. J 
Heart Lung Transplant 1993; 12:333-337. 
119. Fyfe A, Daly P, Galligan L, Pirc L, Feindel C, Cardella C. Coronary sinus sampling of 
cytokines after heart transplantation: evidence for macrophage activation and interleukin-
4 production within the graft. J Am Coli Cardiol 1993; 21:171-176. 
120. Grant SC, Lamb WR, Brooks NH, Brenchley PE, Hutchinson IV, Serum cytokines in 
human heart transplant recipients, Is there a relationship to rejection? Transplantation 
1996; 62 :480-491. 
121. Deng Me, Erren M, Kammerling L, Gunther F, Kerber S, Fahrenkamp A, et al. The 
relation of illterleukin-6, tumor necrosis factor-alpha, lL-2, and ll..-2 receptor levels to 
cellular rejection, allograft dysfunction, and clinical events early after cardiac 
transplantation. Transplantation 1995; 60: 1118-1124. 
122. Lagoo AS, George JF, Naftel DC, Griffin AK, Kirklin JK, Lagoo-Deenadayalan S, et al. 
Semiquantitative measurement of cytokine messenger RNA in endomyocardium and 
peripheral blood mononuclear cells from human heart transplant recipients. J Heart Lung 
Transplant 1996; 15:206-217. 
28 
Chapter 1 
123, Cunningham DA, Dunn MI, Yacoub "MH, Rose .ML, Local production of cytokines in 
the human cardiac allograft. A sequential stud y, Transplantation 1994; 57:1333-1337, 
124, Zhao XM, Yeah TK, Hiebert M, Frist WH, Miller GG, The expression of acidic 
fibroblast growth factor (heparin-binding growth factor-I) and cytokine genes in human 
cardiac allografts and T cells, Transplantation 1993; 56: 1177-1182, 
125. Baan ee, Niesters HG, Balk AH, Mochtar B, ZOl1dervan PE, \Veimar \V. The intragraft 
cytokine mRNA pattern reHeets the efficacy of steroid anti rejection therapy. J Heart 
Lung Transplant 1996; 15: 1184-1193, 
126, Van Hoffen E, Van Wichen D, Stuij I, De Jonge N, K\opping C, Lahpor J, et al. In situ 
expression of cytokines in human heart allografts, Am J Patho11996; 149:1991-2003, 
127, Turner D, Grant SC, Yonan N, Sheldon S, Dyer PA, Sinnott PJ, et al. Cytokine gene 
polymorphism and heart transplant rejection, Transplantation 1997; 64:776-779. 
29 
Chapter 1 
30 
Chapter 2 
CHAPTER 2 
TNF -u: mRNA, plasma protein levels and soluble receptors 
in patients on chronic hemodialysis, on CAPD and with end-
stage renal failure 
I.C. van Riemsdijk-van Overbeeke, C.C.Baan, C.J.Hesse, E.H.M.Loonen, 
H.G.M.Niesters, R. Zietse, W. Weimar. 
Department ofinternal Medicine 1 and Virology, 
University Hospital Rotterdam Dijkzigt, The Netherlands 
Clinical Nephrology 2000; 53:115-123 
31 
Chapter 2 
Abstract 
Patients on hemodialysis suffer from an impaired immunity against infectious agents, 
hyporesponsiveness to vaccination and are prone to develop malignancies. This clinical 
state of immunoincompetence may be due to a unbalance in their defense mechanisms 
in which TNF-o: and its soluble receptors I and 2 playa central role. We measured, 
with double-sandwich ELISA, the levels of TNF-a and the soluble TNF-receptors in 
pelipheral blood of patients on chronic intermittent hemodialysis (CIHD), on peritoneal 
dialysis (CAPD) and pre-dialysis end-stage renal failure (ESRF). Using Reverse 
Transcriptase Polymerase Chain Reaction (RT-PCR) analysis, we quantified the 
amount of TNF-a mRNA in peripheral blood mononuclear cells (PBMC) obtained 
from these patient groups. In none of the patient groups elevated levels of TNF -a were 
detected with ELISA, while high levels of soluble TNF'-receptors were present in 
ESRF, CAPD and CIHD patients. This may be the result of an activated TNF-a system 
or due to their impaired renal clearance. TNF-a mRNA level was elevated in CIHD 
patients compared to ESRF and CAPD patients or healthy controls. This suggests that 
only during chronic HD the TNF-o: system is activated. High levels of sTNFR, found 
in ESRF or CAPD patients do not reflect activation of TNF -a system, but are the result 
of impaired renal clearance of the receptors. Indeed, we found a strong linear 
correlation between the levels of sTNF receptors and renal function. Nevertheless, 
these high levels of sTNF-receptors are biological active, as they were able to bind 
active TNF-a up to 75% (range 46-83%) and thus inhibit the bioactivity and bioavaila-
bility of produced TNF-a. This may playa role in the immunoincompetence of these 
patients. 
Key words: TNF-a, ESRF, renal replacement therapy, immunoincompetence 
Introduction 
Patients on chronic hemodialysis are susceptible to infections and malignancies and 
show a decreased responsiveness in delayed hypersensitivity tests and defective 
antibody production to T-cell dependent antigens such as influenza and hepatitis B 
vaccine [Descamps-Latscha 1993, Girndt et al 1993, Girndt et aI1995]. This seems to 
contrast with the activation of the macrophage/monocyte system, as can be concluded 
from their increased cytokine production [Descamps-Latscha et al 1995, Descamps-
Latscha and Jungers 1996, Donati et al 1992]. Activation of the monocytes may be due 
to the blood-membrane interaction, as the production level of these inflammatory 
cytokines reflects the biocompatibility of the dialyser membrane [Lin et al 1996, Kino 
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et al 1995, Lonneman et al 1990, Niwa et al 1995). Cytokine production alone, 
however, can not predict the final outcome of an immune process, as both bioavailabi-
lity and bioactivity of these cytokines are highly dependent on the presence of their 
antagonists [Bazzoni and Beutler 1995, Bazzoni and Beutler 1996, Douvdedani et al 
1996]. For TNF-a the antagonists are the soluble TNF-receptors (sTNF), which are the 
split-products of the membrane-bound TNF-receptors Rl and R2. The sTNF-receptors 
are formed by proteolytic cleavage of the membrane-bound TNF-receptors after 
binding with TNF-a. In plasma the sTNF-receptors bind 1-3 TNF-a molecules with an 
affinity (K.,) of approximately 0.5 nM (sTNF-Rl) and 0.1 nM (sTNF-R2) [Meager et al 
1996). However, not all sTNF-receptor binding sites are occupied, leaving room for a 
certain buffer capacity for TNF-a [Bazzoni and Beutler 1996]. III vitro studies revealed 
that the cytotoxic and inflanunatory actions of TNF-a can be blocked by an excess of 
sTNF-Rl and sTNF-R2 [Terlizzese et al 1996]. It has been shown that the TNF-
alsTNFR-system is severely affected in patients with end-stage renal failure and in pa-
tients on renal replacement therapy [Pereira et al 1994, Noronha et al 1995). Although 
free TNF-a plasma levels are not consistently found in HD patients [Lin et al 1996, 
Lonneman et al 1996], high levels of several cytokines, including TNF-a, can be 
found. These cytokines are mainly produced by peripheral blood mononuclear cells 
upon stimulation [Roccatello et a11993, Engelberts et al 1994). The increased levels of 
sTNF-receptors may be the result of activation of the TNF-a system, but also impaired 
renal clearance [Floege and Grone 1995, Halwachs et al 1994, Lambert et al 1994]. 
Commercially available ELISA kits give variable results, due to differences in affinity 
for bound TNF-a to circulating antagonists or TNF-inhibiting proteins [Kreuzer et al 
1996). Measurements of mRNA expression by peripheral blood mononuclear cells 
(PBMC) for TNF-a, using RT-PCR is a semi-quantitative method detenning the level 
of activation of the TNF-a system. In the present study, we assessed the activity of the 
TNF-a system by measuring free TNF-a protein plasma levels, sTNF-receptors, R I 
and R2, and the TNF-a mRNA expression by PBMC. Moreover, we tried to determine 
the biological activity of soluble receptors by measuring the TNF-a binding capacity of 
patient plasma. Pre-dialysis ESRF patients were compared with patients on chronic 
intermittent hemodialysis (CIIID) and continuous ambulantory peritoneal dialysis 
(CAPD). Healthy laboratory personel served as controls. 
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Material and Methods 
Patients 
A total number of 48 subjects were analyzed. We studied 15 CIHD patients, who were 
on hemodialysis for a mean period of 35 months (range 12-59 months, median 38 
months). All patients were in stable hemodynamic condition during the dialysis 
procedure with no signs of infection or malignancy. They were dialysed 2 (n=8) or 3 
(n=7) times a week for 4-5 hours, in order to reach a KtN of approximately 1.35. The 
dialyser membranes used in this study were Polysulphone (F60 Fresenius, AG, Bad 
Homburg, Germany, n=9) and Hemophane (MA-12H, Kawasumi Laboratory Inc., 
Minamiohi Shinagawa, Tokyo, Japan, n=6). All patients were on bicarbonate dialysate. 
The dialysate was routinely cultered, no periods of contamination were encountered. 
Culture results were < 10 3 micro-organisms per ml. Stable CAPD patients (n=IO), 
using Baxter twinbag system (KtN=1.5), and patients with ESRF (n=ll) were used as 
control patient groups, while 12 healthy subjects served as controls. Causes of renal 
failure were hypeltension (n=9), membranous glomerulonephritis (n=II), Wegener's 
granulomatosis (n=I), focal segmental glomerulosclerosis (n=2), polycystic kidney 
disease (n=4), amyloidosis (n=I), reflux nephropathy (n=3) and IgA nephropathy (n=l) 
and unknown (n=3). Causes of renal failure were equally represented in the patient 
groups. Most patients were on anti-hypertensive drugs: Calcium-entry blockers, ACE-
inhibition and p-blockers, while all patients on renal replacement therapy (CAPD and 
CIHD) were on subcutaneous recombinant erythropoietin therapy. 
Sample preparation 
Blood samples were collected in pyrogen-free tubes containing EDTA in a final 
concentration of I mg/ml at the start of the hemodialysis-procedure. In patients with 
ESRF and CAPD the blood samples were collected during outdoor clinic control visits. 
The samples were immediately centrifugated, plasma and cell-fractions were separated 
and the plasma was stored at -80°C. For the isolation of PBMC the buffy coat was 
diluted in phosphate-buffered saline (PBS) solution and layered on a Ficoll-isopaque 
gradient (0 = 1.077). After centrifugation, the peripheral mononuclear cells (PBMC) 
were removed from the interface, and washed twice with ice-cold PBS. Immediately 
following procurement, 2 x 10' PBMC were snap-frozen in liquid nitrogen and stored 
at -80°C for RT-PCR analysis. 
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Isolation of mRNA and cDNA reaction 
Total mRNA was extracted from PBMC by a modification of the guanidinium method 
previous described by our group [Baan et al 1994]. Cells were homogenized in 500 J.lI 
4 molll guanidinium-isothiocyanate in the presence of 20 J.lg poly-A (Boehringer, 
Mannheim, Germany). The solution was extracted once with phenol, phenol-
chloroform-isoamylaIcohol (25:24:1) and chloroform-isoamylaIcohol (24: I), 
respectively. The total mRNA was precipitated with 600 J.lI 2-propanolol and 35 J.lI 3 
mollI sodium-acetate (pH 5.2) at -20°C for 18 hours. The precipitates were pelleted at 
1O.000xg at 4 °C and washed with 500 J.lI ice-cold 80% ethanol. Air-dried pellets were 
resuspended in 50 .11 diethylpyrocarbonate treated H20. mRNA was denaturated for 5 
minutes at 80°C and chilled on ice. First strand eDNA synthesis was pelformed from 
the isolated RNA with 0.5 J.lg hexanucleotides (promega Corporation, Madison, WI) 
and transcribed with 1000 U Moloney murine leukemia virus reverse transcriptase 
(Gibco-BRL, Gaithersburg, MD) at 42°C for 90 minutes in a total volume of 100 J.ll. 
Competitive template RT-PCR 
Sequence specific primers were used for amplification of the human TNF-a gene. 
TNF-a sense primer: 5' GAG TGA CAA GCC TGT AGC CCA TGT TGT AGC A 3', 
and TNF-a anti-sense primer: 5' GCA ATG ATC CCA AAG TAG ACC TGC CCA 
GAC T 3'. PCR primers detecting transcripts for the human house-keeping gene, 
keratin, were used as an internal control to monitor mRNA extraction and eDNA 
amplification [Baan et al 1994]. To estimate the relative initial amount of functional 
TNF-a mRNA in PBMC a competitive RT-PCR assay was used and comparison was 
made against the house-keeping keratin gene. The latter gene is assumed to be 
expressed at a constant level in PBMC. Five J.lI eDNA sample and 5 J.lI of gene specific 
competitive templates were added to 90 .11 PCR mixture containing 10 mM Tris-HCI 
pH 8.3, 50 mM KCI, 1.5 mM MgCI" 0.2 mM of each dATP, dCTP, dTTP, dGTP, 2 U 
Tag DNA polymerase (Promega) and 50 pmol of 5' and 3' sequence specific primers. 
To obtain a standard curve for TNF-a and keratin, known amounts of internal control 
fragment were added in different dilutions to constant amounts of sample cDNA for 
competitive co-amplification with specific primers. The internal control was designed 
to generate a PCR product of a different size to allow differentiation between the 
amplified target and internal standard (TNF-a: 444 bp. versus 326 bp., Fig.IA). For 
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keratin: the target 218 bp. and internal control 160 bp. Each reaction mixture was 
overlaid with 75 ).ll mineral oil (Sigma, St. Louis, MO) pdor to peR reaction in a DNA 
thermal cycler (Perkin Elmer-480, Branchburg, NI) under the following conditions. 
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After electrophoresis, the ethidium bromide stained agarose gel shows 2 peR 
products per lane representing target (444 bp) and internal standard (326 bp) 
Figure 1 B: (lower panel) 
The log of the ratio amplified TNF-a to competitor TNF-a is graphed as a 
function of the log of the known amount of competitor added to peR. At the 
point where target cDNA and internal control are in equivalence (ratio~1), the 
starting concentration of TNF-a cDNA prior to peR is equal to the known 
starting concentration of the competing internal control. 
After a 5 min. 94 °e denaturation step, samples were subjected to 40 cycles of 
denaturation at 94 °e for 1 min, annealing at 60 °e for 2 min, and extension at 72 °e 
for 3 min. The last cycle was extended with 7 min. at 72 °e. Positive control samples 
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were produced by stimulating 106 humau spleen cells with 1 % phytohemagglutinin 
(PHA)-M (Difco, Detroit, Ml) for 4 hours at 37°C. Negative controls consisted of 
omission of reverse transcriptase from the cDNA synthesis reaction for each sample 
followed by amplification in PCR with the TNF-Cl and keratin primers, and the use of 
diethylpyrocarbonate treated-H20 as no-template reaction. Following PCR, 16 III PCR 
product was analyzed by gel electrophoresis and the amount of products by the internal 
control and targets were determined for each individual reaction. The relative ethidium 
bromide intensity on gel was measured by luminescence with a DC-40 camera in 
combination with analysis software (Kodak, Rochester, NY). The logarithm of the ratio 
target/internal control is graphed as a function of the logarithm of the internal molar 
amount of the standard and at ratio I, the stalting concentration ofTNF-Cl and keratin 
eDNA prior to PCR is assumed to be equal to the known stmting concentration of the 
competing internal control (Fig. I B). The relative concentration of TNF-Cl transcripts 
were divided by the relative concentration of keratin. This represents the amount of 
TNF-a mRNA transcripts corrected for the amount of mRNA used for reverse 
transcription and the efficacy of each reaction. 
TNF-Cl alld soluble TNF-I'cccptol's by ELISA 
In a preliminary study we compared 4 commercially available ELISA kits. All kits are 
mostly based on mouse-antihuman TNF-o: and biotinylated mouse-antihuman TNF-o:. 
The Genzyme duo set uses biotinylated rabbit-antihuman TNF-o: in step 2 of the 
double sandwich ELISA, which is probably the reason for their lowest detection limits 
(1.4 pg/ml), compared to the 3 other ELISA tests (detection limits: 4.1-10.0 pg/rnl). 
Medgenix and Phanningen use specific clones of Mabs. In this study, we used the 
ELISA kit (Central Laboratory of Blood Bank, Amsterdam, The Netherlands), which 
was pelformed following the manufacturers instructions. The detection limit for TNF-o: 
was 10.0 pg/ml and the coefficient of variation was less than 10%. The standard curve 
is steep, especially in the measurement range. The sTNF-receptors R1 and R2 were 
measured by ELISA (R&D Systems Europe, Abington, United Kingdom). The 
detection Iilnit was 15 pg/ml for both sTNF-R1 and -R2. The coefficient of variation 
was <5% (sTNF-R1) and <10% (sTNF-R2). 
Biological activity (the ability to bind circulating TNF-o:, ill vitro) of the soluble TNF-
receptors was determined after 30 minutes incubation of patient plasma with 
recombinant human TNF-o: (final concentration: 300 pg/ml). After incubation, the 
concentration of free TNF-o: was measured using the above mentioned ELISA 
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technique. A standard curve was constlUcted using different concentrations of 
recombinant human TNF-o:. The TNF-o: concentration after incubation was calculated 
by extrapolation to the standard curve. The TNF-o: recovery is the residual TNF-o: 
concentration (after incubation) divided by the statt concentration (TNF-o: 
concentration in patients plasma) x 100%. 
Statistics 
The results are given as data and median with range or mean with standard deviation 
whenever appropriate. Mann Whitney U test was used to compare medians. The results 
of sTNF-receptors in plasma were evaluated and compared using the ANOV A. Results 
of the TNF-o: recovery are evaluated by the Dunn's multiple comparison test. P-values 
of < 0.05 were considered to be significant. 
Results 
All patients were in good clinical condition at time of blood sample collection. Patients 
on CIHD were stable dllling the dialysis procedure. There were no infections in the 
week before, at time of, or in the week after collection of the bloodsamples. Patients on 
CAPD did not suffer from peritonitis in the period of blood sample collection. Patients 
with ESRF were in stable clinical condition and did not start renal replacement therapy 
within several weeks after blood sample collection. Medication was continued in all 
patients. 
TNF-o: mRNA expression was detectable in all PBMC samples, including those of 
healthy controls. Therefore, we performed quantitative competitive template RT-PCR 
analysis in an attempt to detect differences in TNF-o: mRNA levels between these four 
groups. Using the competitive template RT-PCR, we found no statistical difference 
among the groups in expression of the positive control housekeeping gene, keratin. 
This indicates that the integrity of the mRNA for the three patient groups and the 
controls is the same (p>0.05, Kruskal-Wallis). 
Relative amounts of initial TNF-o: mRNA were individually normalized to the 
con'esponding keratin levels, which permitted more accurate comparison of TNF-o: 
gene transcript levels. Relative TNF-o: mRNA levels in PBMC from patients on CIHD 
were significantly higher than in healthy controls (median TNFlkeratin ratio: 47.541 vs 
528, P < .0001). These results show that chronic lID specifically activates the TNF-o: 
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system. Levels of mRNA-TNF-a in PBMC from patients on CAPD or with ESRF were 
in the same range as healthy controls (Fig 2). 
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Figure 2: 
Quantitative mRNA expression for TNF-a measured by RT-peR, denoted as 
TNF/keratin ratio, with keratin as housekeeping gene in different patients 
groups 
In spite of the high levels of mRNA expression of TNF-a, plasma levels of TNF-a 
were hardly detectable with ELISA in plasma obtained from both healthy controls and 
patients. To evaluate the influence of the dialysis procedure, we measured TNF-a 
concentrations at start of the dialysis period, after 30 minutes and at the end of the 
dialysis procedure. During the dialysis period no increase in TNF-a plasma protein 
concentrations was seen. Fm1hermore, no difference in TNF-a mRNA expression or 
TNF-a plasma protein concentrations were found in patients dialyzed with the 
polysulphone or hemophane membrane, indicating no difference in activation between 
the two membranes (data not shown). In contrast, sTNF-RI and -R2 levels were 
significantly higher in ESRF, CAPD and CllID-patients plasma compared to healthy 
controls (Table I). 
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Table 1: 
Patient characteristics and levels of TNF-a and the soluble TNF-receptors in 
patients with end-stage renal failure and on renal replacement therapy 
Controls 
(n=12) 
M1F 4/8 
Age[yrs] 30 
(26-54) 
Creat. [,lmolll] < 100 
TNF-a [pg/m!] <10 
sTNF-R I [ng/ml] 0.6 ± 0.2 
sTNF-R2 [ng/ml] 1.7 ± 0.5 
Age: median (range) 
Creatinine: mean (range) 
ESRF 
(n=l1) 
5/6 
46 
(21-82) 
552 
(340-735) 
<10 
8.2 ± 2.5' 
14.8 ± 6.6 a 
TNF-a and sTNF-Rl and sTNF-R2: mean ± s.d. 
CAPD 
(n=lO) 
8/2 
45 
(25-70) 
1031 
(586-1290) 
<10 
17.1 ±4.9' 
19.4 ± 5.0 a 
'p < 0.001 versus controls, b p < 0.001 versus ESRF; ANOVA 
TNF-a and sTNF-R: measured by ELISA 
CllID 
(n=15) 
6/9 
63 
(33-83) 
985 
(706-1325) 
<10 
15.9 ± 4.2 ,b 
21.3 ± 3.7 ab 
Again, no difference in sTNF-RI and -R2 levels between dialysis patients dialyzed 
with polysulphone versus hemophane membranes, nor could we detect a difference in 
sTNF-receptor plasma levels in the course of the dialysis procedure. Measurements of 
TNF-a and both sTNF-R at start, after 30 minutes and at the end of the dialysis 
procedure showed no significant increase (data not shown). All plasma concentrations 
of sTNF-R in patient groups were 15-30 times higher compared to healthy controls. In 
patients with ESRF plasma levels of sTNF-RI and sTNF-R2 were lower compared to 
levels of sTNF-RI and-R2 found in patients on renal replacement therapy, suggesting 
that some residual renal function is present. Positive correlation between sTNF-RI and 
sTNF-R2 with serum creatinine has already been rep0l1ed [Descamps-Latscha et al 
1995]. We confirmed this correlation (sTNF-RI:r=0.85; sTNF-R2:r=0.75, p<O.OOI, Fig 
3). 
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Correlation between serum creatinine and sTNF·R1 (left panel) and sTNF·R2 
(right panel) in patients with ESRF, on CAPO and on CIHD 
Incubation of control plasma with recombinant TNF·a solution (final 
concentration=300 pg/ml) had no effect on the immunoreactive TNF·a-Ievel, resulting 
in a recovery of 100% (range 92-104). In contrast, incubation of patients plasma 
resulted in a recovery of only 75% (CIHD), 72% (CAPD) and 90% (ESRF); p < 0.05: 
CAPD and CIHD versus controls (Fig 4). Thus, the high concentrations of TNF-a 
antagonists can act as a buffer for high, toxic concentrations of TNF-a, produced by 
activated PBMC of patients on chronic RD. 
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Figure 4: 
Recovery recombinant TNF-ex, after 30 minutes incubation, measured by 
ELISA in different patient groups. 
Discussion 
Many studies on the TNF-a system in HD patients have been reported during the last 
decade. Dinarello et al and Pereira et al are the founders of the cytokine paradigm in 
hemodialysis. Nevel1heless, in spite of many publications only Pereira [1994] was able 
to detect TNF-a in unstimulated, peripheral blood, using a sensitive RIA method. 
Descamps-Latscha used ELISA technique and detected TNF-a in sera of ESRF, 
patients on CAPD and hemodialysis. She and her co-workers did not perform mRNA 
measurements, but determined other parameters of monocyte and T-cell activation, like 
neopterin and soluble CD25. Others were only capable of detecting TNF-a after 
stimulation with mitogens or LPS. In the literature it is reported that the various 
available TNF-a ELISA kits show a wide range in outcome [Kreuzer et al 1994]. 
These different ELISA kits give non-comparable results, due to interference of TNF-a 
binding proteins or circulating antagonists [Terlizzese et al 1996]. The ELISA kit, used 
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in our study, was not able to detect free TNF-a protein in patients with ESRF, on 
CAPO and CIHD. To overcome this technical complication we measured mRNA-
expression for TNF-a by RT-PCR. Messenger RNA coding for TNF-a was present in 
all PBMC, including those of healthy controls. Significantly more TNF-a mRNA was 
detected in PBMC obtained from patients on CIHD versus all other groups (p < 
0.0001). However, despite the high levels ofmRNA-TNF-a, we were not able to detect 
significant levels of free TNF-a in peripheral blood. Besides, we found no increase in 
TNF-a concentrations during hemodialysis procedures. We did not find differences in 
concentrations of TNF-a or the soluble TNF-receptors between the two dialyzer 
membranes used, indicating that no difference in activation of the PBMC due to blood-
membrane contact could be detected. We, therefore. considered the patients on CIHD 
as one group. In contrast, high levels of soluble TNF -receptors were present in pre-
dialysis ESRF, and even higher soluble TNF-receptor levels were found in patients on 
renal replacement therapy, CAPO or CIHD, suggesting that renal function is requisite 
for clearance of the soluble receptors. This is supported by the linear correlation 
between the soluble receptors RI and R2 and serum-creatinine with r-values of 0.85 
(sTNF-RI) and 0.75 (sTNF-R2), p<O.OOI. 
In spite of the low molecular weight, clearance of the soluble receptors in any form of 
dialysis, CAPD or CIHD, is very poor. As sTNF-receptors are produced after binding 
ofTNF-a with the membrane receptors, the sTNF-receptors in peripheral blood reflect 
the presence ofTNF-a and reveal the overall activity of the TNF-a system when renal 
clearance is not impaired. High levels of sTNF-receptors in patients with progressive 
renal failure and on renal replacement therapy are the resultant of production of TNF-
a, together with the impaired renal clearance. The substantial difference between the 
patients on CIHD versus patients on CAPD in regard to the TNF-a mRNA indicates 
that the TNF-a system in CIHD is more activated. We assume that this activation is 
caused by repeated contact of mononuclear cells with the dialyzer membrane. This 
postulation is supported by our findings in PBMC of patients on CAPO. The levels of 
TNF-a mRNA in PBMC of patients on CAPO were in the range of healthy controls 
and ESRF patients, suggesting that no activation of the TNF -a system is present. Thus, 
monocyte activation by the blood-membrane interaction results in high levels ofTNF-
a mRNA expression by PBMC and high levels of sTNF-receptors in patients on 
chronic hemodialysis. Decreased recovery of TNF-a after incubation with CIHD and 
CAPO plasma reveals that the buffer capacity of the high levels of these sTNF-
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receptors is evident, resulting in partial blockade of the cytotoxic and inflammatory 
actions of TNF-a. Blocking the inflammatory actions of TNF-a can be effective in 
treatment of acute rheumatoid arthlitis by ameliorating the clinical symptoms 
[Baumgartner et al 1996]. However, an increased mortality is reported among patients 
in septic shock treated with anti-TNF-a antibodies. These unfavorable results are 
explained as possible toxic effects of the antibody, the deleterious effects of complete 
removing of TNF-a from the circulation or the prolonged presence of TNF-a in the 
circulation bound to the antibody, which acts as a buffer [Fischer et al 1996]. The 
cytokine paradigm makes TNF-a hold for the hemodialysis related morbidity, like 
hypotension, nausea, fever and amyloidosis. However, there is no clinical evidence that 
TNF-a alone is responsible for the lID related morbidity. Other cytokines, like IL-I~, 
IL-6 or IL-8, may be important mediators in this clinical situation as well. Unbalance 
between these cytokines and their antagonists may be of more impoltance than 
cytokine levels alone. The unbalance between TNF-a and its soluble receptors, found 
in our patients may contribute to the immunodeficiency and the higher susceptibility to 
infections and malignancies, due to the above mentioned reasons. A rational way to 
prevent this increased immunocompromised condition in these patients, is to increase 
the clearance of the soluble TNF-receptors and thus decrease the TNF-a buffercapacity 
to a level, which is seen in healthy controls. Successful kidney transplantation favors 
the renal clearance of the sTNF-receptors and may restore the unbalanced TNF-a 
system. However, in spite of a good renal function after renal transplantation, reaching 
creatinine clearance of 80 lnl/min, the unbalance is only in part restored, leading to a 
persistent immunocompromised state [Van Riemsdijk et a11998]. 
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Quantitative flow cytometry shows activation of the TNF-a 
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Abstract: 
Backgroulld: The immunological dysfunction in patients on hemodialysis may be 
related to imbalanced cytokine systems, like Tumor Necrosis Factor (TNF)-a and 
illterleukin (IL)-2. Despite activation of these systems, hemodialysis patients show 
high susceptibility for infections, malignancies and have a poor immunological 
reaction on T-cell dependent antigens, like hepatitis B vaccination. In this study we 
have determined the activation status of the two different cytokine systems, at a single 
cell level, using the quantitative flow cytometry. 
Methods: Using fluorescein-isothiocyanate (FITC) or phycoerythrin (PE) conjugated 
antibodies directed against the TNF-R2 (CDI20b), IL-2Ra (CD25) and IL-2Rp 
(CD122), we measured the expression of these receptors at a single cell level, in order 
to determine the level of activation of monocytes and T-Iymphocytes. 
Results: Significantly higher expression of the TNF-a receptor, TNF-R2, was present 
on both monocytes and T-Iymphocytes in patients on renal replacement therapy (RRT) 
compared to pre-dialysis end-stage renal failure (ESRF) and controls, indicating 
activation of the TNF-a system. In contrast to the IL-2R expression, which was 
comparable in all patient groups and healthy controls, is suggestive for a non-activated 
state of the IL-2 system. 
COllclusiolls: The present study illustrates the activated state of the TNF-a system in 
patients on renal replacement therapy, at a single cell level, while the JL-2 system 
seems not affected. These findings support the hypothesis that the interaction between 
the TNF-a and IL-2 cytokine systems is disturbed, leading to a increased susceptibility 
for infections and malignancy. 
Key words: activation; ESRF; IL-2; quantitative flow cytometry; RRT; TNF-a 
Introduction 
Patients with end-stage renal failure (ESRF) and on renal replacement therapy (RRT) 
suffer from a high susceptibility for infections and show a higher incidence of 
malignancies compared to healthy controls [1]. This immune incompetence may be due 
to imbalanced defence mechanisms in which cytokines derived from antigen presenting 
cells (APC) and T-cells play a central role. Kimmel et al reported that the 
immunological dysfunction in patients on hemodialysis (lID) is related to the overall 
survival [2]. In patients with ESRF, on peritoneal dialysis (CAPD) or hemodialysis 
(lID) various cytokine systems are affected [3-5]. TNF-a is a pro-inflammatory 
cytokine, that induces expression of MHC class I molecules, activates the production 
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of enzymes and adhesion molecules. It can induce programmed cell-death and is 
needed for T-cell proliferation. It is mainly produced by activated monocytes and 
macrophages and, to a lesser extent by lymphocytes (6). Therefore, it provides a 
pivotal role in the function of APC, whereas IL-2 is regarded as a central T-cell 
cytokine, that promotes expansion of T-cells, augments the cytolytic activity of NK 
cells, is involved in programmed cell death of activated T-cells and in the synthesis of 
immune globulins by B-cells [7). Measurements of free plasma TNF-a appeared to be 
difficult. Variable results of TNF protein measurements by commercially available 
ELISA kits complicated the compmlson between studies [8; 9). In addition, active 
TNF-a is unstable and inadequate collection of blood samples may result in 
undetectable circulating cytokines as also the IL-2 protein measurements are 
influenced by mode of collection [10). In contrast, measurements of the expression of 
membrane-bound activation markers by flow cytometry provide an elegant, 
reproducable and sensitive tool to determine the activated state of cytokine systems at 
the single ceilleve!. In this study, we used flow cytometry to quantitate the expression 
of activation markers of both the TNF-a and IL-2 system: the TNF-R2 (COI20b) on 
lymphocytes and monocytes and the IL-2Ra chain (C025) and the IL-2RP chain 
(COI22) on alp T-cell Receptor (TCR) positive T-cells. 
Patients and methods 
Patients 
In II patients (3 males, 8 females, mean age: 45.6 ± 19 years) with pre-dialysis ESRF, 
8 patients (7 males, I female, mean age: 44.5 ± 14 years) on CAPO and in 12 patients 
(6 males, 6 females, mean age: 57.8 ± 15 years) on HD the activation markers of the 
TNF-a and IL-2 system were determined on peripheral T-Iymphocytes and monocytes, 
using quantitative flow cytometry. Mean serum creatinine was 552 ~molll (ESRF), 
1031 /.lInolll (CAPO) and 995 /.Imol/l (HO). The patients with pre-dialysis ESRF had a 
mean creatinine clearance of 13 ± 2.5 mllnlin. In HD patients a KUV of 1.3 was 
obtained, while patients on CAPO were dialyzed and obtained a KUV of 1.5. Mean 
time on dialysis was for CAPO patients 27.4 ± 8.3 months and for HD patients 26.1 ± 
5.5 months. The dialyzer membranes used in the study were Polysulphone (F60 
Fresenius, AG, Bad Homburg, Germany) and Hemophane (MA-12H, Kawasumi 
Laboratory Inc., Minamiohi, Tokyo, Japan). Both dialyzers are known for their better 
bio-compatibility, compared to cuprophane membranes [11). Previously we have 
shown that patients dialyzed with either of the two membranes showed no differences 
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in activation parameters of the TNF-a system (12). The lID patients were on 
bicarbonate dialysate. The dialysate is routinely cultured and no periods of 
contamination were found (culture results: < lOJ micro organisms per mi.). The patients 
on CAPD used Baxter twinbag system 2 literlfour times daily. Before, during and at 
least 4 weeks after blood collection the patients on CAPD had no signs of peritonitis. 
Blood samples were collected during infection-free period. In lID patients blood 
samples were collected before stmt of the hemodialysis procedure. At time of blood 
sample collection no patients were known to have a malignancy. In ESRF and CAPO 
patients blood samples were collected during routinely outpatient control visits. Causes 
of renal failure were hypertension (n=lO), membranous glomerulonephritis (n=8), 
Wegener's granulomatosis (n=2), focal segmental glomemlosclerosis (n=2), polycystic 
kidney disease (n=4), IgA nephropathy (n=I), amyloidosis (n=I), unknown (n=3). 
Most patients used anti-hypeltensive drugs: calcium-entry blockers, ACE-inhibitors, p-
blockers. Subcutaneous recombinant erytropoietine treatment is installed in all patients 
with hemoglobin levels lower than 6 mm01l1 (=9.7 g/dl). None of the patients used 
corticosteroids. Amongst the patients and controls there were no diabetics. All data 
were compared to those of 9 healthy controls, who were not on medication (4 males, 5 
females, mean age: 35.6 years, mean creatinine < 100/.1010111). 
Methods 
Sample preparation alld Jlow cytometric analysis 
Blood samples were collected in pyrogen-free tubes, containing EDTA in a final 
concentration of I mglml. Whole blood EDTA samples were monitored for the 
presence of the immune competent cells: monoeytes (CDI4+) and lymphocytes (alp 
TCR positive). Surface activation markers were analyzed by two-colour flow 
cytometry after staining with monoclonal antibodies directed against CD 14 
(Immunotech, Marseille, France) as marker for the monocytes, and WT31 (Becton 
Dickinson, Mountain View, CA, USA) as a marker for the alp chain of the T cell 
receptor (TCR). In these subsets CD25 (lL-2Ra, Becton Dickinson), CD 122 (lL-2RP, 
Becton Dickinson) and CD120b (TNF-R2, Immunotech) were monitored. The 
antibodies, except CD 120b, were directly conjugated to fluorescein isothiocyanate 
(FITC) or phycoerythrin (PE). For CDI20b we used a two-step staining. After the first 
step with CD120b, cells were incubated with F(abh Goat-anti-Rat IgG PE. The 
staining procedure was performed by incubating 15 [11 III 00 diluted CD 120b antibody 
with 100 ~rl blood (30 min, at 4 DC). After washing in Hanks Balanced Salt Solution 
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(HBSS, Gibco BRL, Paisly, UK) with 0,1 % Bovine Semm Albumin (BSA, Sigma, St 
Louis, MO, USA) and 0.01% sodium azide (Merck, Darmstadt, Germany), the red 
blood cells were lysed by FACS Lysing Solution (Becton Dickinson). Samples were 
centrifugated and washed in Cell Pack (TOA, Hamburg, Gelmany). Flow cytometric 
analysis was performed on FACscan flow cytometer using Cell Quest software (Becton 
Dickinson). From each tube 10000 events ((/~ TCR positive, CDI4+) in the gate were 
measured. In order to compare the measurements in time the flowcytometer was 
calibrated using specific calibration beads (Calibration Beads Quantum 1000, Flow 
cytometry Standards Corp. San Jose, PR, USA). Each bead contains a known amount 
of fluorochrome. The intensity of the fluorescence is converted to a standard curve 
using Quick Cal program for Quantum Beads (Becton Dickinson). The mean 
fluorescence is denoted as molecular equivalents of t1uorochrome, MESF. Figurel . 
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Figure 1: 
Standard curve fluorescence intensity of calibration beads 
Upper panel: Flowcytometric analysis of calibration beads, each of which 
contains a specific amount of fluorescine. 
Lower panel: Standard curve of fluorescence intensity constructed after 
flowcytometric analysiS of calibration beads, using Quick Cal program for 
quantum beads software. The intensity of the fluorescence is depicted as 
molecular eqUivalents of soluble fluorochrome (ME SF) 
Relation between senlm creatinine and membrane receptor expression was analyzed 
for the whole group (patients and controls, n=40), using the Spearman Rank 
Coo·elation. Con-elation between time on dialysis (CAPD and HD) and membrane 
receptor expression lVas also evaluated by the Spearman Rank Con-elation test. 
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Statistics 
Data are recorded as mean ± SEM, or median and range. Absolute numbers of 
lymphocytes and monocytes in the patient groups were compared with the unpaired 
student's t test. Differences in receptor expression between patient groups were 
analyzed using one-way ANOYA test, while differences between groups, separately, 
were analyzed using Mann Whitney test. The Spearman I' correlation coefficients were 
used to determine the relationship between serum creatinine, time on dialysis and the 
membrane receptor expression (IL-2Ra (CD25), IL-2Rp (CDl22), TNF-R2 (CDI20b) 
on monocytes and lymphocytes). P-values :<:0.05 were considered as significant. 
Results 
Absolute number of alp TCR positive T-cells were significantly lower in HD patients 
than in healthy controls: 665±88 cells/ftl versus 979±99 cells/ftl, p=O.02. In patients on 
CAPD (673±116 celis/ill) and ESRF (738±172 celis/ill) the absolute number of alp 
TCR positive T-cells were lower than in the control group, p=0.07 and p=O.22, 
respectively, although not statistically significant. The absolute number of monocytes 
was comparable between all groups: 314±34 celis/ill (controls), 284±29 cells/ftl 
(ESRF), 374±59 ceJls/1l1 (CAPD) and 293±56 cells/fll (HD). 
Expression of the activation markers of the IL-2 system (i.e. CD25, CD122) was in the 
same range for patients and controls. The mean expression of the IL-2Ra (CD25) 
varied from 779±132 MESF (controls) to 992±163 MESF (CAPD), 762±49 MESF 
(ESRF) and 763±104 MESF (HD), p=0.51, ANOYA. The mean expression of the IL-
2Rp (CDI22) ranged from 365±14 MESF (controls), 409±19 ME SF (ESRF), 401±18 
MESF (CAPD) and 431±38 MESF (HD), p=0.40, ANOYA. Figure 2. 
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Figure 2: 
Expression of T-cell aclivalion markers: C025 (IL-2ra chain) and CO 122 (IL-
2RP chain) in palients with end-stage renal failure (ESRF), on peritoneal 
dialysis (CAPO) and hemodialysis (HO) measured with quanlitalive flow 
cytometry in peripheral blood. The quanlity of fluorescence is depicted as 
molecular equivalents of soluble fluorochrome (MESF). Tat error bars are 
SEM. 
In contrast to these comparable expression levels of the activation markers of the IL-2 
system on T-cells, the expression levels of the activation marker of the TNF-a system, 
TNF-R2 (CDI20b) were significantly higher in patients on renal replacement therapy, 
both on monocytes and on alp TCR positive lymphocytes, p=O.02 and p=O.03, 
respectively (ANOVA). The mean TNF-R2 (CD120b) expression on lymphocytes was 
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3153±508 MESF (controls) versus 3451±288 MESF (ESRF), p=O.65, in CAPD: 
5670±997 MESF, p=O.06, and in HD patients the expression: 5466±893 MESF, 
p=O.Ol. Mean TNF-R2 (CD 120b) expression on monocytes was also higher in patients 
on CAPD and HD, but not in ESRF compared to controls. MESF (CAPD): 7285±1516 
versus 2564±808 (controls), p=O.005. MESF (HD): l0233±3531, p=O.02, Mann-
Whitney Test. Figure 3. 
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Expression of the TNF-a activation marker: CD 120b (TNF-R2) on 
tymphocytes and monocytes in patients with end-stage renal failure (ESRF), 
on peritoneal dialysis (CAPO) and hemodialysis (HO) compared to healthy 
controls, measured by quantitative flow cytometry. The quantity of 
fluorescence is depicted as molecular equivalents of soluble fluorochrome 
(ME SF). Tat error bars are SEM. 
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Of the studied cytokine activation markers (CD25, CD122, CD120b on lymphocytes 
and monocytes) only CDI20b on monocytes showed a conelation with serum 
creatinine. R-coefficient for CD25 was 0.08 (p=0.62), for CD122: r=0.16 (p=0.31), 
CDI20b on lymphocytes: r=0.16 (p=0.31), and CD120b on monocytes: r=0.38 
(p=0.03), Spemman Rank Con·elation. Except for CD 120b expression on monocytes 
we found no correlation between age and cytokine receptor expression: CD25: r=-0.16 
(p=0.32), CD122: 1'=0.13 (p=0.42), CDI20b on lymphocytes: 1'=0.24 (p=0.16), and 
CDI20b on monocytes: r=0.43 (p=O.OI), Spearman Rank Correlation. Also time on 
dialysis was not con'elated with the expression of the membrane receptors: r=O.12, 
p=0.68, Spearman Rank Conelation. 
Discussion 
In the present study, we used quantitative flow cytometry to evaluate the expression of 
activation markers of the TNF-a and the IL-2 system in patients with ESRF and on 
renal replacement therapy. We determined the receptor expression for TNF-a and JL-2 
on immune competent cells, alp TCR positive lymphocytes and the CD14+ 
macrophages in order to differentiate which cells, T-cell or APC, are activated. To 
evaluate the activation of the IL-2 system we measured the expression of the IL-2Ra 
(CD25) and the IL-2Rp (CDI22). In this study we were predominantly interested in the 
expression of the TNF-R2, because TNF-a action directed by TNF-R2 results in 
proliferation of T-cells. We found reduced absolute numbers of lymphocytes in the 
presence of comparable absolute numbers of monocytes in patients on lID versus all 
other groups. It is known that activated lymphocytes are sequestered in the capillaries 
of the lung after blood dialyzer membrane contact [13]. Deenitchina et al reported that 
this lymphopenia was the consequence of low numbers of CD4+ T-cells [14]. We 
found an increased expression of the TNF-R2 on both monocytes and lymphocytes 
from patients on renal replacement therapy, which is suggestive for activation of the 
TNF-a system [15]. This coincides with the high levels of soluble receptors and the 
significantly higher levels of free plasma TNF-a in these patients [16]. In contrast, in 
patients with ESRF TNF-R2 expression was comparable to the expression measured on 
immune competent cells from healthy controls. This shows that the TNF-a system is 
not activated in ESRF patients. As the creatinine clearance in the patients with ESRF in 
this study was 13 mVmin, which is comparable to the creatinine clearance obtained in 
patients on renal replacement therapy, i.e. CAPD or lID, renal insufficiency alone, can 
not be responsible for the differences in expression of the TNF-a activation marker, 
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TNF-R2, found in these patients. Therefore, we think that the increased TNF-R2 
expression is not caused by renal insufficiency itself, but by renal replacement therapy, 
i.e. CAPD or lID. The expression of TNF-R2 on lymphocytes and monocytes is 
comparable between patients on CAPD and lID. The mode of renal replacement 
therapy is apparently not important for this TNF-R2 expression on lymphocytes or 
monocytes. After TNF-a binding to its membrane receptor, the extracellular domains 
are split off and can be identified as soluble TNF-R in peripheral blood. Other causes 
of shedding the membrane receptor are poorly understood. The sTNF-R are 
predominantly metabolized by renal clearance. Due to impaired renal clearance levels 
of sTNF-R show a strong positive conelation with serum creatinine and renal function 
[12; 17], In the present study we found no correlation between the expression ofCD25, 
CD122 and CDI20b on lymphocytes and monocytes and semm creatinine per patient 
group. Nor did we found a conelation between time on dialysis (CAPD or lID) and the 
expression of the membrane receptors. The expression of the TNF-R2 (CDI20b) on 
monocytes, seemed positively conelated with progressive renal insufficiency when the 
test was performed with all subjects, but not in the separate patient groups. Age may be 
another confounding factor in this study. In literature conflicting data are reported 
conceming cytokine levels and production in aged subjects. Higher [18-22] as well as 
lower [20; 23; 24] levels and production capacity of IL-2 and TNF-a in aged subjects 
are described. In the present study the mean age between the patient groups and 
controls is significantly different. However, the difference in mean age between the 
patient groups among themselves (ESRF versus CAPD and lID) is not significant, 
thereby showing that the increased expression of the TNF-R2 on cells of ESRF, CAPD 
and lID patients is the result of their renal insufficiency. Various dmgs are known to be 
of influence on TNF-a levels. Recombinant erytropoietine and Angiotensin-
Converting-Enzyme (ACE-) inhibitors may induce TNF-a [25; 26]. In this study all 
patients are on various medication. No differences in the use of ACE-i or 
erytropoietine between the various patient groups is present, and therefore the 
influence of the medication is not seen as a dominant factor influencing the results of 
the TNF-R2 expression. 
Despite the high expression of TNF-R2 on lymphocytes the T-cells seem not activated 
as shown by normal expression of the IL-2 activation markers on the cell membrane. 
The interaction between the TNF -a system and the T -cells appears to be inadequate, 
which may result in the high incidence of infection and malignancy found in lID 
patients. Previously, we found that the Phytohemagglutinin (PHA-) stimulated TNF-a 
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production by PBMC was significantly reduced in patients on HD, while PHA-
stimulated IL-2 production was comparable to the production by PBMC obtained from 
healthy controls [16]. Others reported differences between CAPO and HD patients in 
the production of specific T-cell cytokines. In CAPO the mitogen phorbol-12-myrisate-
13acetate (PMA-) stimulated T-cell production of TNF-a and IL-2 was lower 
compared to the production by T-cells obtained from HD patients [27]. We suggest this 
impaired TNF-« production results from "exhaustion" due to continuous activation of 
the TNF-« system. In HD patients this is explained by chronic blood-membrane 
contact, in CAPO patients by chronic, low-grade, subclinical intra-peritoneal 
int1anunation [28-30]. TNF-a activity, conducted by TNF-RI is responsible for 
signaling apoptosis, while TNF-a activity conducted by TNF-R2 is responsible for 
signaling proliferation of thymocytes and cytotoxic T-cells [15]. A distinct difference 
in action is, however, not ovet1. Monoclonal antibodies directed against TNF-R2 can 
partially antagonize the same TNF responses that are induced by TNF-Rl. Tm1aglia et 
al repOlted that specific activation of TNF-R2, in the presence of PHA, results in 
stimulation of human T-cells [30]. The increased expression of the TNF-R2 may thus 
result in T-cell activation and proliferation in the presence of TNF-a and mitogen. In 
summary, we found an activated TNF-« system shown by high expression of the TNF-
R2 on lymphocytes and monocytes. In previous studies we already found increased 
mRNA expression for TNF-a and elevated plasma TNF-a protein levels [12]. The IL-2 
system seems not activated, as shown by the comparable expression of the T-cell 
activation markers, IL-2Ra (CD25) and IL-2R~ (CDI22) in patients and controls. The 
immunoregulatory activity of TNF-«, which results in induction of the IL-2R 
expression and enhances T-cell responses directed by IL-2 [31], failed to induce T-cell 
activation in our studied patient groups. 
The present study shows that quantitati ve t10w cytometry provides additional 
information about the activated state of cytokine systems at a single cell level, and 
clarifies the nature of the immune competent cells involved in the immune responses in 
patients with ESRF and on renal replacement therapy. Our results show that interaction 
between APC (TNF-a) and T-cells (lL-2) is disturbed, which may contribute to the 
immune deficiency found in those patients. 
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CHAPTER 4 
Tachyphylaxis for TNF -a production by T -cells resulting 
from activation of the TNF-a system during hemodialysis 
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Abstract: 
Background: The inununosuppressive state of hemodialysis patients is accompanied by 
activation of antigen presenting cell-derived cytokines, e.g. TNF -a, which are required 
for T-cell activation. To test whether an activated TNF-a system results in impaired T-
cell response in these patients, we analyzed parameters of their APC function (e.g. 
TNF-a system) and T-cell function (e.g. IL-2 system). 
Methods: By quantitative flow cytometry the expression of the TNF-receptor2 (TNF-
R2 = CD120b) and the a- and p-chain of the IL-2R (CD25, CD122) were measured. 
Using RT-PCR the mRNA for TNF-a, IL-2 and IL-2R were determined. PHA- and IL-
2 stimulated proliferation and cytokine production were measured. Biological activity 
of soluble receptors was measured by adding recombinant cytokines to patient's 
plasma. 
Res/.tlts: CDI20b expression was significantly increased in lID patients. whereas CD25 
and CD 122 was comparable to controls. In contrast to mRNA for 1L-2 and IL-2R, 
mRNA for TNF-a was increased in HD. This resulted in significantly increased TNF-a 
levels in lID patients. In peripheral blood of lID patients high levels of soluble TNF-R 
(RI and R2) and IL-2R were found. These receptors were capable of binding 40% of 
added TNF-a and 55% of added IL-2. PH A-induced TNF-a production by T-cells from 
lID patients was significantly lower, While their PHA stimulated IL-2 production and 
proliferation capacity by T-cells were comparable to controls. 
Conc/usions: We conclude that although the TNF-a system is activated during 
hemodialysis the TNF-a production ofT-cells is impaired, suggesting tachyphylaxis of 
T-cells for TNF-a as their proliferation capacity and IL-2 production capacity do not 
impl y an intrinsic T-cell defect. 
Key words: tachyphylaxis, TNF-a, T-cells, hemodialysis 
Introdnction 
Patients on chronic hemodialysis suffer from general immunosuppression, leading to a 
high susceptibility for infection and cancer and show a deficient response on T-cell 
dependent antigens. like hepatitis B and influenza vaccination (1;2). 
This depression of T-cell activity might be the result of a defect in their antigen 
presenting cell (APC) function, in which the pro-inflammatOlY cytokine TNF-a plays a 
prominent role. However. the immunusuppressive state of lID patients seeIllB to be 
accompanied by activation rather than by impairment of the monocyte/macrophage 
system, resulting in an increased production of cytokines such as TNF-a, IL-Ip, IL-6 
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(3-6). Therefore, other factors than the TNF-a system might be involved in immune 
compromised state of HD patients, e.g. an intrinsic defect of T-cells to produce and to 
respond to IL-2. IL-2 promotes expansion of T-cells, augments the cytolytic activity of 
NK-cells, is involved in the synthesis of immunoglobulins by B-cells and protects 
activated T-cells from apoptosis (7-9). Immune reactivity, ill vivo, however, is not only 
determined by cytokine production, but also depends on the presence and activity of 
their antagonists, thus on the bioavailibility of cytokines. Biological activity of 
cytokines is regulated by membrane bound receptors. For TNF-a, 2 receptors have 
been identified, RI (p55) and R2 (p75), while IL-2 has its own IL-2R, consisting of 
three separate chains, IL-2Ra (CD25), IL-2Rp (CDl22), and IL-2Ry (CD132) chain. 
After binding, the extracellular domain of the receptor splits off and can be identified 
as soluble receptors: sTNF-Rl, sTNF-R2 and sIL-2R (9;10). These soluble receptors 
are mainly metabolized by renal clearance. However, their molecular weight prevents 
clearance by the dialyzer membrane. Recently, we found high levels of sTNF-Rl and 
sTNF-R2 in peripheral blood of patients on renal replacement therapy (11). These high 
levels appeared to be biological active and were able to buffer free, active TNF-a for 
40%. Previously, IL-2 buffer capacity by sIL-2R (sCD25) was also described (10). 
Thus, the immunosuppressive state of HD patients may be due to a deficient cytokine 
production capacity, an intrinsic T-cell defect, or a disturbed APCrr-cell interaction as 
result of biological active soluble cytokine receptors or deficiency in the costimulatory 
pathways. Data on T-cell function in HD patients are conflicting. Some authors have 
mentioned defective T-cell function, while others have repOlied nOlmal T-cell function 
or even activation, depending of the dialyzer membrane used (7;8;12-14). Previously, 
we already demonstrated no differences in mRNA expression for IL-2 in patients with 
pre-dialysis end-stage renal failure (ESRF), on peritoneal dialyisis (CAPD) or 
hemodialysis (HD) or in the expression of T-cell activation markers (CD25, CD122, 
HLA-DR) (15). To clarify the contribution of the cytokines, TNF-a and IL-2, on the 
immune compromised state of HD patients, we evaluated both cytokine systems in 
more detail. We measured cytokine plasma levels, mRNA expression (RT-PCR), 
cytokine production capacity of PBMC (ELISA), TNF-receptor (CD120b = TNF-R2) 
expression on monocytes and lymphocytes, and IL-2Ra, (CD25), IL-2RP (CD 122), and 
HLA-DR expression on alP positive T-cells. We performed IL-2 recovery studies to 
evaluate the biological activity of the sIL-2R (sCD25). In addition, we analyzed PHA-
and IL-2 induced T-cell proliferation in own uremic plasma, and in pooled healthy 
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serum, to determine the influence of the uremic environment on proliferation capacity 
of healthy and RD peripheral blood mononuclear cells (PBMC). 
Patients, Materials and Methods 
Patients 
15 patients on hemodialysis (RD, 8 males, mean age: 63 ± 15 yrs, semm creatinine: 
985 ± 169 Ilmolll) were evaluated. The patients were dialyzed 2-3 times/week, 4-6 
hours (645 ± 112 minutes/week). A mean KtiV of 1.3 was obtained in all patients. 
Time on dialysis varied from 8 till 91 months, mean 30 months. The dialyzer 
membranes used in the study were Polysulphone (F60 Fresenius, AG, Bad Hornburg, 
Germany, n=9) and Hemophane (MA-12H, Kawasurni Laboratory Inc., Minamiohi 
Shinagawa, Tokyo, Japan, n=6). Both dialyzer membranes belong to the 'high-flux' 
membranes and are known for their bio-compatibility. Previously, we have shown that 
no differences in the activation parameters of the TNF-a system were present between 
patients dialyzed with either of the membranes (11). All patients were on bicarbonate 
dialysate. The dialysate was routinely cultured, there were no periods of contamination, 
culture results were < 103 micro-organisms per m!. All patients were on subcutaneously 
erytropoeitin, depending on their hemoglobin levels. The controls were healthy 
laboratory personel (n=ll; 5 males, mean age: 35.6 ± 9.9 yrs, serum creatinine < 
100,tmolll). Non-detectable data are counted as zero. 
Smnple preparation 
Blood samples were collected in pyrogen-li'ee tubes containing EDT A in a final 
concentration of I mg/mJ at the start of the hemodialysis-procedure. Samples for flow 
cytometlic analysis were processed inmlediately after collection. For the isolation of 
peripheral blood mononuclear cells (PBMC) the buffy coat Was diluted in phosphate-
buffered saline (PBS) solution and layered over a Ficoll-Isopaque gradient (0 = 1.077). 
Immediately following procurement, 2 x 106 cells were snap-frozen in liquid nitrogen 
and stored at -80 °C for RT-PCR analysis. Plasma was stored at -80°C and the PBMC 
for ill vitro assays were kept in liquid nitrogen. 
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Messenger RNA (mRNA) isolation and copy DNA (cDNA) reaction and Reverse-
Transcriptase Polymerase Chain Reaction (RT -PCR) 
In PBMC we measured mRNA expression levels of TNF -a, IL-2 and IL-2R (CD25). 
Procedures for isolation of mRNA and reverse transcription into cDNA and RT-PCR 
were performed as previously described in detail (16). In brief, total RNA was 
extracted from snap-frozen PBMC (2.106) and subsequently cDNA was synthesized 
with random primers. Aliquots cDNA were directly used for PCR amplification using 
sequence-specific primers for TNF-a, IL-2, IL-2Ra (CD25) and the housekeeping gene 
keratin (16). 
Quantification of mRNA expression by competitive template RT-PCR 
To estimate the relative initial amount of functional TNF-a and IL-2R (CD25) mRNA 
in PBMC, a competitive template RT-PCR assay was used and comparison was made 
against the housekeeping gene keratin. The latter gene is assumed to be expressed at a 
constant level in PBMC. To obtain a standard curve for TNF -a, IL-2R (CD25) and 
keratin, known amounts of internal control fragment were added in different dilutions 
to constant amounts of sample cDNA for competitive co-amplification. The internal 
control was designed to generate a PCR product of a smaller size to allow 
differentiation between the amplified target and the internal control. The relative 
intensity of internal control and target products on gel was measured by luminescence 
with a DC-40 camera in combination with analysis software (Kodak, Rochester NY, 
USA). Subsequently, the relative concentrations of TNF-a and IL-2R (CD25) were 
divided by the relative concentration of keratin to estimate the initial cytokine mRNA 
expression level in PBMC. This represents the amount of TNF-a and IL-2R (CD25) 
mRNA transcripts corrected for the amount of mRNA used for reverse transcription 
and efficacy of each reaction. 
Flow cytometric analysis 
Whole blood EDTA samples were monitored for the presence of immune competent 
cells: monocytes (CDI4+) and lymphocytes (a/~ TCR positive). Surface activation 
markers were analyzed by two-color flow cytometry after staining with monoclonal 
antibodies directed to CDI4 (Immunotech, Marseille, France), as marker for 
monocytes, and WT31 (Becton Dickinson, Mountain View, CA, USA) as a marker for 
the a/~ chain of the T-cell receptor (TCR). In these subsets IL-2Ra (CD25), IL-2R~ 
(CDI22) and HLA-DR (Becton Dickinson) and TNF-R2 (CDI20b, Immunotech) were 
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monitored. The antibodies, except CD 120b, were directly conjugated to fluorescein 
isothiocyanate (mC) or phycoerythrin (PE). For CD 120b a two-step staining was 
used. After the first step with CD120b, cells were incubated with F(ab), Goat-anti-Rat 
IgG PE. The staining procedure was performed by incubating 15 ~1I 1/100 diluted 
CDI20b antibody with 100 ~ll blood (30 min, at 4°C). After washing in Hanks 
Balanced Salt Solution (HBSS, Gibco, BRL, Paisly, UK) with 0.1 % Bovine Se11lm 
Albumin (BSA, Sigma, St Louis, MO, USA) and 0.01% sodium azide (Merck, 
Darmstadt, Germany), the red blood cells were lysed by FACS Lysing Solution 
(Becton Dickinson). Samples were centrifugated and washed in Cell Pack (TOA, 
Hamburg, Germany). Flow cytometric analysis was perfOimed on a FACscan flow 
cytometer using Cell Quest software (Becton Dickinson). From each tube 10000 events 
in the gate were measured. In order to compare different flow cytometric assays in time 
we calibrated the llow cytometer using specific Calibration Beads (Calibration Beads 
Quantum 1000, Flow cytometer Standards Corp, San Jose, PR, USA). Each bead 
contains a known amount of fluorochrome. The intensity of the fluorescence is 
convelied to a standard curve by Quick Cal Program for Quantum Beads (Becton 
Dickinson). The mean lluorescence is denoted as molecular equivalents of soluble 
lluorochrome (MESF, Figure IA+IB). 
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Figure 1A: 
Quantitative flow cytometry: 
Construction of the standard curve using specific calibration beads, each 
containing a different, known amount of fluorochrome (upper panel). The 
amount of fluorochrome is converted by software into fluorescence intensity, 
denoted as molecular equivalents of fluorochrome (MESF) (lower panel). 
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Figure 18: 
Typical example of CD120b expression on alp TCR positive T-cells by 
quantitative flow cytometry. In the upper panel: the FITC labeled alP positive 
T-cells are gated. In the lower panel the fluorescence intensity of the CD120b 
positive T-cells is depicted. The mean fluorescence intensity can be 
extrapolated to the standard curve and denoted as MESF (fig. 1A). 
Enzyme Linked Inmll1no Sorbent Assay (ELISA) 
TNF-a, IL-2 and IL-2R (CD25) concentrations were measured by commercially 
available enzyme-linked immunosorbent assays (ELISA, BioSource International, Inc., 
Camarillo, CA and Inununotech, Diagnostic Product Corporation, Los Angeles, CA, 
respectively). The detection limit for TNF-a is <0.09 pg/ml and the coefficient of 
variation is 3.2-7.0%. The detection limit for IL-2 is 5 pg/ml, coefficient of variation 
5-10%. The detection limit for IL-2R is 16 U/mi with a coefficient of variation of 5%. 
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Soluble TNF-receptors RI and R2 were measured by ELISA (R&D Systems Europe, 
Abingdon, United Kingdom). The detection limit is IS pg/mJ for both sTNF-RI and -
R2. To evaluate the biological activity of the sIL-2R in HD, we pelformed a IL-2 
recovery assay. The test was peIformed with 2 concentrations recombinant human (rh) 
IL-2: 125 pg/ml and 500 pg/ml. After 30 minutes incubation of patients and control 
plasma with a known amount of rh IL-2, the residual IL-2 level was measured using 
the above mentioned ELISA. The recovery is: 
[measured IL-2] - [baseline + added rhIL-2] 
Recovery = x 100% 
added rh IL-2 
In vitro stimulation assays 
To test the proliferation response of PBMC from HD patients and controls, we 
stimulated PBMC, ill vilro, with phytohemagglutinin M (PHA-M), (1: 100, final 
dilution, Difco Laboratories, Detroit, MI, USA) and with rhIL-2 (10 ng/ml, Chiron, 
Amsterdam, The Netherlands), for 3 days at 37°C in a humidified atmosphere 
containing 5% CO2• Proliferation after 3H-thymidine (0.5~lCi/well) incubation for 8 
hours of culture, W(\S measured. Radioactivity was determined using a Betaplate 
counter (LKB, Bromma, Sweden) and expressed as mean counts per minute (CPM). 
All assays were performed in own plasma and in pooled serum. Both plasma and 
pooled serum is heat-inactivated. The pooled sera are obtained from healthy blood 
donors. Each individual sel11m, included in the pool, is tested for the presence of HLA-
specific antibodies and in a MLC using three different responder-stimulator 
combinations. The serum is excluded from the pool if antibodies or inhibitory, i.e. 
stimulatory effects on proliferation are present. To measure the influence of uremic 
environment on the proliferation capacity, PBMC obtained from healthy controls were 
stimulated with PHA or rhIL-2 in pooled healthy and uremic serum derived from HD 
patients. In the culture supernatants we analyzed the concentration ofTNF-a, sTNF-RI 
and R2, using the previously mentioned ELISA. 
73 
Chapter 4 
Statistics 
The results are given as mean ± SD or SEM, or median with range, whatever was 
appropriate. Comparison of normally distributed variables was addressed by analysis of 
variance (ANOV A). Qualitative RT-PCR (IL-2 mRNA) results were analyzed by the 
Fischer Exact test. Quantitative RT-PCR data (IL-2R mRNA,TNF-a mRNA) and 
concentrations of cytokines in peripheral blood were compared by Mann Whitney U 
test. P values" 0.05 were considered significant. 
Results 
Messenger RNA expression of TNF-a and IL-2 by RT -PCR 
In PBMC obtained li'om patients on HD and healthy controls we measured the mRNA 
expression for TNF-a, lL-2 and lL-2R (CD25). TNF-a mRNA expression levels were 
significantly higher in HD patients than in healthy controls: median TNFlkeratin ratio 
47541 versus 604, p<O.OOOI (Figure 2). In contrast, IL-2 mRNA expression was less 
often found in PBMC from HD patients compared to healthy controls, 6 out of 15 
(38%) in HD versus 9 out of II (88%) in controls, p=0.34. These results are in line 
with our previous study, in which we could not detect mRNA expression for IL-2 in 
patients with ESRF, on CAPD or on HD, neither in healthy controls (17). The mRNA 
expression levels of the IL-2Ra-chain (CD25) was also not different in patients and 
healthy controls: mean IL-2R1keratin ratio: 22.9 versus 14.2, n.s. (Figure 2). 
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Figure 2: 
Messenger RNA expression of TNF-a and IL-2R by peripheral blood 
mononuclear cells (PBMC) in patients on hemodialysis and healthy controls 
measured by RT-PCR. Results are denoted as cytokineikeratin ratio, in which 
keratin is the house-keeping gene. 
; 
TNF-a and IL-2 receptor expression on immunocompetent cells by quantitative 
flow cytometry 
The absolute numbers of a!~ positive T-cells were significantly lower in HD patients 
compared to healthy controls: mean 664 ± 87/111 versus 979 ± 99/111 (p=0.03). The 
absolute numbers of CDI4+ monocytes were not different in both groups. In patients 
on HD the expression of the TNF-R2 (CDI20b) was significantly enhanced on a/~ 
TCR positive lymphocytes: mean MESF 5466 ± 892 versus 315 J ± 507 as well as on 
monocytes: mean MESF 10233 ± 353 J versus 2563 ± 808, p=O.O J and p=0.02, 
respectively. In contrast, the expression of the activation markers on the T-cell surface, 
CD25 (IL-2Ra), cOIn (IL-2R~) and HLA-DR, were comparable between HD 
patients and healthy controls (Figure 3). 
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Figure 3: 
Expression of activation markers. 
IL-2Ra chain (CD25), IL-2RP chain (CD122) and HLA-DR on lymphocytes and 
TNF·R2 (CD120b) on lymphocytes and monocytes, measured by quantitative 
flow cytometry, denoted as MESF (Mean ± SEM). 
Soluble TNF and IL-2 receptor levels by ELISA 
TNF·o. system 
Plasma TNF·u protein levels were significantly higher HD patients compared to 
controls: 5.6 ± 0.9 pg/ml versus 0.9 ± 0.1 pg/ml, p<O.OOI. To test the TNF-u 
production capacity by T-cells we stimulated PBMC with the mitogen PHA. This 
resulted in significantly lower TNF-u concentrations in supernatants of PBMC from 
HD patients than in supernatants ofPBMC from healthy controls: mean TNF·u: 220.6 
± 92.9 pg/ml versus 1012.2 ± 341 pg/ml, respectively, p<O.OOl. Correction for the 
lymphopenia in HD patients results in a mean TNF-u production of 331 pg/ml, which 
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still is significantly lower compared to the production of the T-cells obtained from 
healthy controls, p=0.04. The levels of sTNF-Rl were significantly higher in culture 
supernatants of HD PBMC compared to control PBMC: mean sTNF-Rl (after PHA-
stimulation):115.0 ± 7.1 ng/ml (corrected for lymphopenia: 172 ng/mI) (HD) versus 
78.3 ± 9.0 ng/mI (controls), p=0.008 (p<O.OOOI, cOlTected). After IL-2 stimulation the 
sTNF-Rl levels were: 107.4 ± 11.0 ng/ml (corrected: 161 ng/ml) (HD) versus 74.8 ± 
6.7 ng/ml (controls), p=0.027 (conected: p<O.OOOI). The sTNF-R2 production after 
PHA stimulation was not significantly different between patients and controls. IL-2 
stimulation resulted in a higher production of sTNF-R2 in supernatants of HD patients: 
461.3 ± 51.4 ng/l111 (corrected: 692 ng/l111) versus 386.6 ±54.2 ng/ml (controls), 
p=0.0005 (after correction for lymphopenia). Table 1. 
Table 1: 
PHA and rhlL-2 (10 nglml) induced TNF·a, sTNF-R1 and sTNF-R2 production 
by PBMC obtained from hemodialysis patients and healthy controls, cultured 
in pooled serum, measured in supernatant after 3 days stimulation, by ELISA 
controls patients 
n=11 n=15 
TNF-a dayO 4.8 + 1.2 4.8 + 1.2 
[pg/l111] PHA 1012.2 ± 341' 220.6 ± 92.9' 
IL-2 31.2 ± 8.7 18.2 ± 3.4 
sTNF- day 0 79.0± 1.4 79.0 ± 1.4 
Rl 
[ ng/ml] PHA 78.3 ± 9.0 115.0 ± 7.1 
IL-2 74.8 ± 6.7 107.4 ± 11.0 
sTNF- clay 0 88.3 ± 1.0 88.3 ± 1.0 
R2 
[ng/mI] PHA 540.1 ± 94.9' 449.4 ± 94.7' 
IL-2 386.6 ± 54.2" 461.3 ± 51.4' 
Mean ±SEM 
* Student's t-test 
U p<O.OOl versus day 0 
b corrected for hemodialysis related lymphopenia 
n.s. ;::: not significant 
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patients p-value* 
conected dataO 
n.s. 
330.9 ± 92.9' 0.04 
27.3 + 3.4 n.s. 
n.s. 
172.5± 1.4 <0.0001 
161.1 + 11.0 <0.0001 
n.s. 
674.1 + 94.7" 0.34 
692.0 ± 51.4" 0.0005 
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IL-2 system 
In HD patients and controls baseline plasma IL-2 levels were within the detection limit 
of the used ELISA test. In contrast, IL-2R (CD25) levels were significantly higher in 
plasma of HD patients: mean 1467 ± 230 U/mJ versus 409 ± 13 U/ml, for healthy 
controls, p<O.OOI, table 2. After 3 days of PHA stimulation the IL-2 and sIL-2R 
(sCD2S) production capacity of PBMC, when measured in own plasma was 
comparable between PBMC from lID patients and controls. However, when the assay 
was performed in pooled serum, the PHA-induced IL-2 production by PBMC was 
significantly higher in lID patients, p=0.03. The PHA-induced sIL-2R production was 
comparable in both groups, table 2. 
To obtain an impression of the biological activity of the sIL-2R (sCD2S), we 
performed an IL-2 recovery study. In plasma, the IL-2 recovery after addition of 125 
pg/ml rhIL-2 was 55 ± 9.4% (lID) versus 43% (controls), p=0.02, and in the presence 
of surplus of rhIL-2 (500pg/ml) the recovery remained increased in 59.6 ± 9.4% versus 
49.9 ± 8.2%, respectively, p=0.05, Mann-Whitney. Table 2. 
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Table 2: 
Plasma levels at t=O (baseline) and the PHA-induced production of IL-2 and 
sIL-2R by PBMC obtained from healthy controls and HD patients, measured in 
supernatant after 3 days of stimulation using ELISA. Tests are performed in 
own plasma and pooled serum, 
controls ' patients 
n=l1 n=15 
Baseline 
1L-2 [pg/ml) 9.3 + 3,1 5.0 + 0.0 
slL-2R [U/ml) 409 ± I3 1467 + 230 
PHA -induced 
1L-2 [pg/ml) own 1440±217 1956 ± 944 
pooled 2823 + 558 2996 + 482 
slL-2R [U/ml) own 124 + 33 93 + 15 
pooled 99± 23 86± 31 
IL-2 recovery 
+ 125 pg rhlL-2 43.1 + 8.4% 55 ± 9.4% 
+ 500 pg rhlL-2 49.9 +8.2% 59 + 9.4% 
Mean ± SEM 
, corrected for dialysis related lymphopenia 
bStudent's t-test 
n.s, = not significant 
Proliferation tests 
I patients I p-value" 
corrected data' 
n.S. 
< 0.001 
2934 ± 944 0.19 
4494 ± 482 0.D3 
140 ± 15 n.s. 
129 ± 31 11.S. 
0.02 
0.05 
PHA and rhlL-2 stimulation resulted in a significantly increased proliferation of PBMC 
obtained from HD patients as well as from healthy controls. Proliferation assays 
performed in own plasma showed comparable proliferation capacity of PBMC from 
healthy controls and HD patients, when conected for the HD-related lymphopenia, 
p=0.07. When performed in pooled serum the PBMC from healthy controls, as well as 
from HD patients, had a higher proliferation capacity, without differences between the 
two groups. Figure 4A. Also 1L-2 induced proliferation capacity was, when results 
were corrected for the HD-related lymphopenia, comparable by PBMC obtained from 
healthy controls and HD patients, inespective whether the test was performed in own 
or pooled serum. Figure 4B. 
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Proliferation after PHA stimulation 
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Figure 4A: 
The PHA-stimulated proliferation capacity of PBMC obtained from patients on 
hemodialysis and controls in own plasma and pooled (healthy) serum. The 
right bar represents results alter correction for HD related lymphopenia. 
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Proliferation after IL-2 stimulation 
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Figure 48: 
The IL·2 slimulated proliferation capacity of PBMC obtained from patients on 
hemodialysis and controls in own plasma and pooled (healthy) serum. The 
right bar represents results after correction for HD related lymphopenia. 
Both the PHA· and IL·2 stimulated proliferation of PBMC from healthy controls lVas 
inhibited in uremic plasma. The mean relative stimulation index of the PHA·induced 
proliferation of healthy PBMC in normal plasma lVas 76 ± 9.0 versus 59.0 ± 8.0 in 
uremic plasma (p=0.16). The IL·2 induced proliferation resulted in a mean relative 
stimulation index of 93.5 ± 13.3 (normal plasma) and 68.0 ± 13.4 (uremic plasma), 
1'=0.08. 
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Discussion 
Inununologic function in hemodialysis patients is related to the overall survival in 
these patients (18). Cytokines, like TNF-Cl and IL-2, are impOliant in the regulation of 
the immune responses. Imbalanced cytokine systems may result in ineffective 
immunological responses and consequently lead to high susceptibility for infections, 
malignancies and decreased responses on T-cell dependent antigens (1;2). In the 
present study, we measured the activity of both the TNF-Cl and the IL-2 system in 
patients on chronic hemodialysis, on mRNA and protein level as well as on membrane 
bound and soluble receptor level. Both systems are of paramount importance in the 
APCrr cell interaction initiating specific immune responses. Moreover, we performed 
functional assays to find out whether, ill vitro, specific APCrr-cell defects were 
detectable in peripheral cells nfHD patients. 
The TNF-a; system 
In previous studies we detected significantly increased TNF-Cl mRNA expression by 
PBMC in patients on HD. FurhetTIlore, we found high levels of active, soluble TNF-R, 
sTNF-RI and sTNF-R2, which buffered recombinant TNF-Cl to a large extent (11). In 
the present study, we confirmed the activated state of PBMC by finding significantly 
increased receptor expression ofTNF-Cl, TNF-R2 (CDI20b) on both Iymphocyies and 
monocytes of patients on chronic HD. Moreover, we were able to detect significantly 
higher levels of free plasma TNF-Cl, by using the sensitive ELISA kit. To evaluate the 
TNF-Cl production capacity by T-cells we measured PHA- and IL-2 induced TNF-a 
production, ill vitro. In culture supernatants free TNF-Cl concentrations were 
significantly lower after PHA stimulation of PBMC from HD patients, in contrast to 
the IL-2 induced TNF-a. At the same time significantly higher concentrations sTNF-
Rl and sTNF-R2 were found in the supernatants after stimulation, reflecting shedding 
of their increased receptors. From these data, we conclude that, although PBMC from 
patients on HD are constantly activated, T-cells are not able to produce adequate 
amounts of TNF -a upon stimulation. 
Zamauskaite et al also described an impaired TNF-a production upon stimulation by T-
cells, using intracellular cytokine staining, but only in patients on petitoneal dialysis 
therapy (19). The overproduction ofTNF-a by PBMC of chronic HD patients reported 
by Girndt et ai, is not contradictive to our results as they induced mononuclear cells 
with LPS, which stimulates monocyte" rather than T-cells (12). 
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The JL-2 system 
Chatenoud et al (ZO) suggested that the immunosuppressive state of HD patients was 
due to a deficient IL-Z system. However. conflicting data concerning parameters of the 
IL-Z system in patients with ESRF, on CAPD or HD, are present. Weinstein et al and 
Caruana et al reported increased levels of IL-Z in patients with ESRF and HD, while in 
patients on CAPD increased, as well as normal levels of IL-Z are found, all compared 
to healthy controls (ZI ;2Z). Ha et al and Krisnamurthy et al demonstrated lower levels 
ofIL-Z and a decreased IL-Z production in ESRF and HD patients (23;Z4). Rostaing et 
al describes the intracytoplasmatic expression of various cytokines, i.e. IL-Z, IL-6, 
IFN-y and TNF -a, in relation to different dialyzer membranes and compared the results 
to patients with pre-dialysis ESRF and healthy controls. By measuring the cytokines 
intracytoplasmatic he prevents difficulties in assessment of plasma cytokine levels and 
provides more insight in the influence of the various dialyzer membranes. It appeared 
from this study that patients dialyzed with a polysulphone membrane (PS) have 
cytokine profiles highly comparable to healthy controls (25). Our, in vitro data are in 
line with these findings. At both mRNA and protein level we measured comparable 
production of IL-Z between HD patients (dialyzed with PS and Hemophane 
membranes) and healthy controls. Also expression of thea-chain (CDZ5) and p-chain 
(CDI22) of the IL-ZR complex was not increased on T-cells in these HD patients. In 
previous work we have demonstrated no differences in T-cell activation markers at the 
single cell level in patients with ESRF, on CAPD and HD, using the quantitative flow 
cytometric analysis (15). So, no overt indication for an intrinsic deficient IL-2 system 
was established. However, significantly higher levels of sIL-ZR (sCDZ5) were present 
in plasma from HD patients. These high levels of sIL-ZR did bind up to 55% of rhIL-Z, 
suggestive for an impaired biological availability of the produced IL-2. 
Proliferation tests 
In peripheral blood of patients on HD we found a significantly lower number of alp 
positive T-cells. To evaluate the functional capacity of these T-cells we measured the 
PHA-stimulated proliferation capacity. This proliferation capacity of T-cells from 
patients on HD appeared to be significantly decreased, compared to control T-cells. 
These results are in line with Krisnamurthy, Raskova and Severini et al (Z4;Z6;Z7). 
However, when we corrected the data for the overt lymphopenia, found in HD patients, 
no statistically differences were present in the proliferation capacity of T-cells. The 
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influence of uremic environment was determined by comparing the proliferation 
capacity of PBMC obtained from healthy controls in uremic and pooled plasma. This 
proliferation capacity significantly decreased in uremic plasma, thereby confirming the 
data of Donati and Severini et al who studied the effect of uremic serum on PHA 
stimulated proliferative responses of healthy PBMC and purified T-cell sub-
populations (27;28). The presence of a continiously activated TNF-a system and an 
inadequate TNF-a production upon stimulation suggest tachyphylaxis of T-cells. The 
IL-2 system seemed not intrinsically affected as T-cells were able to proliferate 
normally upon JL-2 stimulation. As in this present study, others have also attempted to 
link the TNF-a and IL-2 system (29). Owen-Schaub et al correlated the expression of 
TNF-R on lymphocytes to IL-2 production (30). According to these authors increased 
TNF-R expression indicated T-cell activation, whereas we assume that elevated TNF-R 
expression is independent ofT-ceil activation. Some publications described intIinsic T-
cell dysfunction (31), while others reported normal T-cell function (14;32). T-cell 
dysfunction may be induced by the hemodialysis procedure (33-36), or result from 
monocyte dysfunction (9). Our data are in line with Modai, Degiannis and Kelly 
(8;14;37): an intact T-cell function, but a disturbed APC function, e.g. TNF-a 
production. Additional dose-response studies on cytokine-induced proliferation of 
normal T-cells in uremic plasma in the presence of antibodies against various 
immunoreactants could provide further evidence for our hypothesis. The results of this 
study can be influenced by the significantly older age of the HD patients compared to 
the age of the healthy controls, p<O.OOl. Many authors have described the influence of 
aging on cytokine levels and production. However, data on cytokine levels and 
production are not consistent. Concerning the pro-inflammatory cytokines, IL-I p, IL-6 
and TNF-a, increased (38-40), as well as decreased (41;42) levels in the elderly are 
found. Bruunsgaard et al found lower levels ofIL-I p and TNF-a in healthy old people 
(age: 81 years) when he compared the results to young men (age: 19-31 years). 
However, these differences disappeared when he compared the results of the elderly to 
that of young women (41)! The same conflicting data are described for IL-2, !lA, IL-S 
and IFN-y (38;40;42-44). In our study the HD patients are significantly older compared 
to the healthy controls. However, in the the literature concerning about cytokine and 
aging, their mean age of 63 years is not regarded as old (in most studies old age is 80 
years and older). We do not think that the differences in the studied parameters of the 
TNF-a and IL-2 system are influenced by the older age of the HD patients. In 
conclusion, the present study shows that the TNF-a system of PBMC in HD patients is 
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activated on all levels studied. We found increased expression of mRNA, high levels of 
free protein and soluble receptors and an overexpression of membrane bound receptors. 
Nevertheless, despite increased expression of TNF -(! receptors, the TNF -(! production 
capacity ofT-celis is impaired, while other T-cell functions, e.g. their IL-2 production 
and proliferation capacity are intact. We hypothesize that this is due to tachyphylaxis 
resulting from continuous activation of the TNF-(! system, rather than to an intrinsic T-
cell defect. 
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Summary 
Patients on chronic hemodialysis suffer from general immune incompetence, resulting 
in high incidence of infectious complications, impaired response on vaccinations and a 
high incidence of malignancy. Multiple factors are involved in the defects of their 
immune system. Cytokines, which playa central role in the immune response are 
TNF-a and IL-2. Activated macrophages, shown by high expression of the membrane 
receptor, TNF-R2, and increased mRNA for TNF-a were found. A decreased PHA-
stimulated TNF-a production by T-cells, together with significantly higher levels of 
biologial, active soluble receptors, resulted in a impaired bioavailability of TNF-a. 
Furthermore, no indication was found of T-cell activation, shown by no increased 
expression of the IL-2R or IL-2 protein. In this study, in vitro, cytokine-induced T-cell 
proliferation assays of T-cells obtained from patients on chronic hemodialysis were 
performed. Interleukine-2 (IL-2), interleukine-IS (IL-IS) and TNF-a separately 
induced T-cell proliferation, however the combination TNF-a/IL-2 or TNF-a/IL-1S 
appeared to be synergistic in stimulation of the T-cell proliferation. The synergistic 
effects were more obvious in healthy controls compared to HD patients, but no 
differences were seen between both groups. Other macrophages-derived T-cell growth 
factors, like IL-1S, play an additional role in T-cell pl'Oliferation and may compensate 
the impaired TNF-a production. We conclude that T-cells fi'om HD patients show no 
intrinsic defects in proliferation capacity, in vilro. 
Key words: interleukine-2, interleukine-15, TNF-a, T-cell pl'Oliferation, hemodialysis 
Introduction 
Patients on chronic hemodialysis develop an immunosuppressive state, resulting in a 
high incidence of infectious complications, a low response on T-cell dependent 
antigens, like hepatitis B and influenza vaccinations and a high incidence of malignant 
diseases [Kimmel et ai, 1998; Maisonneuve et ai, 1999]. The cause of this dialysis-
related immune incompetence is not clarified. For initiating specific immune reponses 
three different signals are required [Male, Roitt, 1998]. The first signal is the antigen 
presentation by the antigen presenting cell (APC) in its MHC class II molecule to the 
T-cell receptor (TCR) on specific T-cells. Signal 2, the co-stimulation, is requisite for 
T-cells to become activated. Various co-stimulatory pathways have been identified: 
CD40ICD4L, CD28IBh2. The third signal refers to the production of specific 
cytokines by the activated APC (i.e. IL-I, IL-6, TNF -a) [Feldmann, 1998]. Cytokines 
playa pivotal role in the APC-T cell interaction. The macrophage-derived IL-IS is a 
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potent T-celi growth factor [Weiler et ai, 1998) and shares a number of bioiogicai 
functions with the T-cell derived IL-2 [Baan et ai, 1999; Kennedy, Park, 1996). TNF-Cl 
is mainly produced by monocytes, but T-cells can produce TNF-a as well, which can, 
in turn, be mediated by IL-15 [McInnes, Liew, 1998). The HD-reiated immune 
incompetence may be reiated to imbaianced cytokine production by antigen presenting 
cells, T-cells, or by impaired co-stimuiatory signaling pathways, or by intrinsic defects 
of APC and/or T-cells [Chatenoud et ai, 1986; Girndt et ai, 1995; Girndt et ai, 1993; 
Donati et ai, 1992). Many studies have been performed to clarify these different aspects 
of the immune response in patients on chronic hemodiaiysis [Gimdt et ai, 1999). 
Activated immunocompetent cells, unbaianced cytokine systems, i.e. TNF-a, IL-2, IL-
6, have been described in hemodialysis, CAPD and in chronic renai faiiure 
[Lonnemann et ai, 1990; Zaoui et ai, 1991; Roccatello et ai, 1993; Pereira et ai, 1994; 
Engeiberts et ai, 1994; Descamps-Latscha et ai, 1995; Pereira, 1995; Lin et ai, 1996). 
Both normai [Kelley, 1994] [Modai et ai, 1990) and deficient T-cell functions are 
described [Kurz et ai, 1986). In previous studies we found a significantiy iower PHA-
stimulated TNF-Cl production by T-cells despite an overall activated TNF-a system. We 
concluded that the T-cells were tachyphylactic concerning the TNF-a production, but 
could be otherwise intrinsically normal [Van Riemsdijk-van Overbeeke et ai, 2000a). 
To test this hypothesis we analyzed proliferation of T-cells, derived from chronic HD 
patients upon stimulation with recombinant IL-2, IL- J 5 and TNF-a, and various 
combinations of these cytokines. 
Patients and methods 
Patients 
From 9 patients (2 maies, 7 females; mean age: 58 ± 4.1 years; mean creatinine: 923 ± 
65 /-Imolll) on chronic hemodialysis (mean time on dialysis: 45 ± 7 months) for 3 
times/week, 4.5 hours/diaiysis procedure, we collected peripheral blood at the start of 
the dialysis procedure. None of the patients suffered from infection or malignancy at 
time of biood sample collection or 3 months thereafter. They were all dialyzed using 
Hemophane dialyser membranes (MA-12H, Kawasumi Laboratory Inc., Minamiohi 
Shinagawa, Tokyo, Japan). All patients were on bicarbonate dialysate, no infectious 
moments of the dialysate were encountered (routine culures: < 103 micro 
organisms/ml). All patients were on subcutaneously administered recombinant 
erytropoietin and all received heparin during dialysis procedure. Three patients had 
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detectable antibody titers against hepatitis B, while 6 patients did not develop 
protective antibody titers in spite of multiple vaccinations. No patients were on 
immunosuppressive drugs. Reasons for renal insufficiency were hypertension (n=4), 
glomerulonephritis (n=3), reflux nephropathy (n=l) and IgA nephropathy (n=I). Ten 
healthy laboratory personel served as controls (5 males, 5 females, mean age:33.6 ± 3.5 
years, creatinine < 100 ~lmoVI). 
Methods: 
Blood samples were collected in pyrogen-free tubes containing EDTA in a final 
concentration of I mg/ml at the statt of the dialysis procedure. For the isolation of 
petipheral blood mononuclear cells (PBMC) the buffy coat was diluted in phosphate-
buffered saline (PBS) solution and layered over a Ficoll-Isopaque gradient (Ii = 1.077). 
PBMC for the ill vitro assays were frozen and stored in liquid nitrogen. 
After defrosting, the blood samples were monitored for the presence of lymphocytes 
with FACscan flow cytometry, using the monoclonal antibody, WT31 (Becton 
Dickinson, Mountain View, CA, USA), dil'ected to the alp chain of the T-cell receptor 
(TCR). 
A dose-response curve of cytokine driven T-cell proliferation on rhTNF-a (S to 100 
ng/ml, Pepro Tech Inc, Rocky Hill, NJ, USA) was performed. Cytokine driven 
proliferation responses were tested by stimulating with rh~-2 (10 ng/ml, Chiron, 
Amsterdam, The Netherlands), rh~"15 (10 ng/ml, Serotec, Ltd, Oxford, UK) or a 
combination of 10 ng rhlL-2 plus SO ng rhTNF-a or 10 ng rhiL-IS plus 50 ng rhTNF-a 
for 7 days at 37 "C in a humidified atmosphere containing 5% CO2. Proliferation was 
measured after 3H-thymidine (0.5~lCilwelI) incubation for 8 hours of culture before 
harvesting. Radioactivity was determined using a Betaplate counter (LKB, Bromma, 
Sweden) and data are expressed as counts per minute (CPM). 
Statistics 
AlI data are mentioned as mean ± SO. Comparison between proliferative responses of 
patients and controls were analyzed using the unpaired Student's t test, while 
proliferative responses on rhIL-2, rhIL-IS, rhTNF-a and the combinations are analyzed 
in one group using the paired Student's t test. P-values ~ 0.05 are considered 
significant. 
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Results 
COlltrol experimellts: 
Seventy percent of the PBMC were TCR aI~ positive T-cells and 59% in samples from 
healthy controls, p>O.05. After stimulation with IOng/ml rhIL-2 the percentage TCR 
aI~ positive T-cells was 70% for HD patients and 67% for the controls, p>0.05. After 
incubation on 10 ng/ml rhIL-15: 75% (HD) and 69% (controls), p=0.34 and incubation 
on TNF-: 80% (HD) versus 77% (controls), p=0.55. After defrosting of PBMC the 
viability of the cells was tested by PHA stimulation. The mean CPM were 47,431 ± 
24,599 (HD) versus 51,463 ± 25,080 (controls), p>0.05. 
Cytokille proliferatioll assays: 
The lymphocyte proliferation on rhTNF-a was not influenced by concentrations lower 
than 20 ng/ml rhTNF-a. TNF-a induced stimulation resulted in significantly increased 
proliferation at concentrations above 50 ng/ml. Figure 1. Therefore, the 50 ng/ml 
concentration of TNF-a was llsed in the simultaneously induction of T-cell 
proliferation with T-cell growth factors (i.e. IL-2, IL-15). 
95 
Chapter 5 
E 
• u 
TNF-o dosis response 
7000 
6000 
5000 
4000 
3000 
2000 
1000 
0 
hom tnl5ng/ml tn! to nglml In! 20nWmi In! 50 ng/ml tn! 100 nglml 
Figure 1: 
T-cell proliferation on different doses of rhTNF-a (5 - 100 ng/ml) in 
hemodialysis patients (HO) and controls, depicted as counts per minute 
(CPM). Mean ± so 
The IL-2 induced proliferation capacity of T-cells, obtained from HD patients was 
comparable to the capacity of healthy T-cells: mean CPM: 23,781 ± 14,771 (lID) 
versus 22,578 ± 10,751 (controls). Also IL-15 induced proliferation was comparable in 
patients and controls: the mean proliferation capacity of T-cells was 3,334 ± 3,938 
CPM (lID) versus 4,105 ± 3,256 CPM (controls). All data are reported as mean ± SD. 
Simultaneous stimulation with TNF-a and IL-2 or ILlS showed a higher increase in 
proliferation capacity than the increase of both cytoldnes alone. The combination rhIL-
15 (10 ng/ml) and rhTNF-a (50 ng/ml) resulted in a mean ± SD CPM of7140 ± 7058 
(lID), increase of 19%, p=0.18. In controls the combination rhIL-15 (lOng/ml) and 
TNF-a (50 nglml) resulted in an increase of 57%, p~O.O I. Also the combination rhIL-2 
(10 ng/ml) and rhTNF-a (50 nglml) resulted in a proliferation capacity of 32,755 ± 
17,955 CPM, an increase in HD patients of 24%, p~0.26. While in controls the 
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combination 10ng/tnl rhIL-2 and 50 ng/ml rhTNF-a resulted in an increase of 55%, 
p=0.027. Figure 2. 
Cytokine-induced T-cell proliferation 
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Figure 2: 
T-cell proliferation after 7 days of stimulation with tumor necrosis factor-a (50 
ng/ml=TNF50), interleukin-2 (10 ng/ml=IL2) or simultaneously IL-2+ TNF-a 
(+TNF), interleukine-15 (10 ng/ml=IL 15) or simultaneol/sly IL-15+TNF-a 
(+ TNF) in controls and in patients on hemodialysis (HD), depicted as counts 
per minute (CPM). Mean ± SD 
III vitro, no significant differences were present in cytokine dliven T-cell proliferation 
between HD patients and controls. 
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Discussion 
Patients on chronic hemodialysis suffer from deficient immune competence resulting in 
multiple infectious complications, decreased response on T-cell dependent antigens, 
and even a pronounced increase in the incidence of malignant diseases [Kimmel et aI, 
1998; Maisonneuve et aI, 1999]. This seems in contrast to the activated state of the 
monocytes and macrophages in peripheral blood [Van Riemsdijk-van Overbeeke et aI, 
2000b] [Le Meur et aI, 1999]. T-cell functions, like mitogen induced IL-2 production 
[Chatenoud et aI, 1986], proliferation capacity [Donati et aI, 1992] were investigated in 
a number of studies. Some authors describe normal [Kelley, 1994; Modai et aI, 1990], 
while others describe impaired T-cell functions [Descamps-Latscha et aI, 1994; 
Deenitchina et aI, 1995]. Cytokine production capacity for TNF-a and IL-2 were 
described, showing a lower production of specific "Thtcytokines (IL-2, TNF-a, IFNy) 
in HD patients compared to patients on peritoneal dialysis [Zamauskaite et aI, 1999] 
[Girndt et aI, 1998]. In previous studies, we found a diminished TNF -a production by 
T-cells of patients on HD after mitogen (i.e. PHA) stimulation. In these patients the IL-
2 mRNA and PHA-stimulated IL-2 production were comparable to that of healthy 
controls. We postulated a tachyphylactic state of T-cells concerning the TNF-a 
production, probably as consequence of continuous stimulation by blood-membrane 
contact or subclinical infections without an intrinsic T cell defect [Van Riemsdijk-van 
Overbeeke et aI, 2000a]. Girndt et al [Girndt et aI, 1995] described a possible defect in 
the co-stimulatory pathways, as he exposed the uremic T-cells to Raji cells (human 
Burkitt's lymphoma) and concluded that defects in T-cell proliferation of HD patients 
were located in the costimulatory pathway: B7/CD28. In the complex cytokine network 
interactions between cytokines are important. 
In the present study we evaluated the proliferation capacity of T-cells, obtained from 
stable patients on long-term hemodialysis, after stimulation with rhIL-2, rhIL-15, and 
rhTNF-a in order to find out whether uremic T-cells are able to proliferate in the 
presence of adequate amounts of growth factors. We performed a TNF -a dose-response 
curve and found 50 ng/ml as optimal TNF -a concentration for our ill vitro stimulation 
assays. There were no statistically differences in proliferation capacity ofT-cells from 
HD patients or controls on TNF-a stimulation. Cytokine-induced T-cell proliferation 
on rhIL-2 (IOng/ml) and on rhIL-15 (IOng/ml) were comparable in HD and controls. 
IL-2 induction resulted in a stronger stimulation of the proliferation compared to 
induction with the macrophage-derived T-cell growth factor, IL-15. Simultaneous 
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stimulation of T-cells with the combination TNF-a/IL-2 or TNF-alIL-15 appeared to 
be stronger than stimulation with the cytokines alone. Again, no differences were 
found in proliferation capacity on cytokines between lymphocytes from lID patients 
and controls. From these data we conclude that in patients on chronic hemodialysis no 
int,insic T-cell defect, ill vitro, is present. The tachyphylactic state for TNF-a 
production by uremic T-cells results in a lower cytokine driven proliferation capacity, 
ill vitro. Another confounding factor is the uremic environment. This environment may 
strongly influence the function of T -cells. The results of our study confirm that 
lymphocytes from lID patients have no intrinsic defects and their proliferative capacity 
resembles that of "healthy" lymphocytes as long as adequate concentrations of growth 
factors are present. 
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Abstract 
The TNF-a system is thought to play a central role in the reduced immunity of 
hemodialysis patients. The imbalance between the high levels of soluble TNF-receptors 
Rl and R2 and the low levels of immunoactive TNF-a results in an increased TNF-a 
buffeting capacity leading to reduced immune responses. 
Apart from impaired renal clearance of the receptors, inefficient TNF-a production as a 
result of uraemia may also contribute to the imbalance between this cytokine and its 
receptors. In patients receiving a living-related kidney transplant, renal function is 
nearly normalized in a very short period. This restoration of renal function may result 
in a state of better immunocompetence, either as a result of improved clearance of the 
receptOl~ or as a result of reversal of the uraemic state. To differentiate between these 
two pOSSibilities, we measured TNF-a protein, mRNA and the soluble TNF-receptors 
RI and R2 before and after successful renal transplantation. TNF-a-mRNA was not 
affected by transplantation, indicating constant TNF-a production. The imbalance in 
the TNF-a system lVas markedly improved after transplantation, although normal 
values of the soluble receptors were not reached. One year after transplantation in 
stable kidney transplant recipients there lVas still an imbalance in the TNF-a system, 
caused by persistently elevated levels of the soluble TNF-receptors. These results 
suggest that even after successful kidney transplantation the TNF-a system remains 
activated. However, despite their inununosuppressive therapy, recipients of a living 
related kidney do have a better balanced TNF-a system compared to hemodialysis 
patients. 
Key words: TNFa, soluble TNF receptors, living related kidney transplantation 
Introduction 
Patients with renal insufficiency suffer from a high incidence of infections and 
malignancies [1,2]. This may be 11 result of generalized inununodeficiency owing to an 
imbalance of the defence mechanisms in which especially TNF-a and its soluble 
receptors are thought to play an important role [3-5]. 
Previously we have found increased levels of soluble TNF-receptors (sTNF-R) in 
peripheral blood in patients on haemodialysis, on petitoneal dialysis and in patients 
with preterminal end-stage renal failure [6]. Using Reverse Transcriptase Polymerase 
Chain Reaction (RT-PCR) analysis, high levels ofTNF-a mRNA have also been found 
in the peripheral blood mononuclear cells (PBMC) of such patients, reflecting a state of 
immunoactivation [7]. In spite of this activated state of the immunocompetent cells, an 
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impaired TNF-a system can still be detected owing to binding ofTNF-a protein to the 
abundant sTNF-R. As these receptors are metabolized and cleared by the kidney, one 
might expect a normalization of the TNF-a/sTNF-receptor balance after succesful 
kidney transplantation [8]. However, if factors other than clearance of the sTNF-R play 
a role, the imbalance of the TNF-a system would not improve after restoration of renal 
function [9]. In the present study we analyzed TNF-a-protein, the sTNF-RI and sTNF-
R2, and TNF-a mRNA before and after kidney transplantation. 
Patients, material and methods 
Patients 
In 16 patients (9 male, 7 female; age 22-55 years, mean 32 years) all receiving a living 
related kidney transplantation, we measured sTNF-R in peripheral blood and in urine 
before and during the first 6 days after transplantation. In PBMC TNF-a mRNA was 
measured. Before transplantation all, but two patients were on renal replacement 
therapy (eight patients on hemodialysis, six patients on CAPD). Donations were from 
parent to child in eight cases and between siblings in eight cases (five identical, four 
hap la-identical or better combinations). All grafts functioned immediately. No 
hyperacute, accelerated or acute rejections were observed. To evaluate the levels of 
sTNF-R over time, we measured serum and urine levels at one year after kidney 
transplantation in 20 other patients, with stable serum creatinine values, who used 
cyclospOline (n=1O) or azathioprine (n=1O) as maintenance immunosuppressive 
therapy. Healthy subjects (n=11) were used as controls. 
Sample preparation 
Blood samples were collected in pyrogen-free tubes containing EDTA in a final 
concentration of I mg/ml from all patients, before and after transplnntation daily until 
day 6. The samples were immediately centrifugated, plasma and cell fractions were 
separated and the plasma was stored at -80°C. After transplantation urine samples were 
collected until day 6. Urine was centtifugated and the supematant was stored at -80°C 
until analysis. For the isolation of PBMC the buffy coat was diluted in phosphate-
buffered saline (PBS) solution and layered over a Ficoll-Isopaque gradient (0 = 1.077). 
After centrifugation, the PBMC were removed from the interface, and washed twice 
with ice-cold PBS. Immediately following procurement, 2 x ]06 cells were snap-frozen 
in liquid nitrogen and stored at -80°C for RT-PCR analysis. 
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TNF-a protein and soluble TNF-receptors 
TNF-a in plasma was detected using four different commercially available ELISA kits 
(CLB, Amsterdam; Genzyme; Medgenix and Phanningen). All kits detected TNF-a, 
but they differed in their detection limits. Especially at the lower levels the kits of 
Genzyme and Pharmingen were more sensitive. The detection limits were 10 pg/ml 
(CLB), 4 pg/mJ (Genzyme), 12 pg/mJ (Medgenix) and 4 pg/mJ (Pharmingen). The 
sTNF-RI and -R2 in plasma and urine were measured using double sandwich ELISA 
(R&D Systems Europe, Abingdon, UK). The detection limit of this commercial kit was 
15 pg/m1 for sTNF-RI and -R2. All ELISA techniques were performed following the 
manufacturer's instlUctions. 
Isolation ofmRNA and eDNA reactioll 
Messenger RNA from the TNF-a gene and keratin gene, a housekeeping gene, was 
isolated, reverse transcribed and subjected to PCR analysis. Messenger RNA extraction 
and transcription were performed as described previously [9]. Sequence-specific 
primers were used for amplification of the human TNF-a and keratin genes. Briefly, 
total RNA was extracted from PBMC by a modification of the guanidinium method. 
Total RNA was precipitated, pelleted and washed, followed by denaturation for 5 min 
at 80 "C and chilled on ice. First strand eDNA synthesis was performed from the 
isolated RNA with 0.5 ~lg hexanucleotides (Promega Corporation, Madison, WI) and 
transcribed with 1000 U Moloney murine leukemia virus reverse transcriptase (Gibco-
BRL, Gaithersburg, MO) at 42 "C for 90 min in a total volume of 100 fI\. 
COlllpetitive template RT-PCR 
To estimate the initial relative amount of functional TNF-a mRNA in PBMC a 
competitive RT-PCR assay was used and comparison was made against the house-
keeping keratin gene. The latter gene is assumed to be expressed at a constant level in 
PBMC. A 5 ~tl aliquot of cDNA sample and 5 ~tl of gene specific competitive templates 
were added to 90 fIl PCR mixture containing 10 mM Tris-HCI, pH 8.3, 50 mM KCI, 
l.5 mM MgCI" 0.2 mM each of dATP, dCTP, dTTP, dGTP, 2 U Tag DNA 
polymerase (Promega) and 50 pmol of 5'- and 3'-sequence specific primers. 
To obtain a standard curve for TNF-a and keratin, known amounts of internal control 
fragment were added at different dilutions to constant amounts of sample eDNA for 
competitive coamplification with specific primers. The internal control was designed to 
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generate a PCR product of a different size to allow differentiation between the 
amplified target and internal standard. Dilutions of the competitor template, ranging 
from 5 ag to 50 pg were coamplified with constant amounts of sample cDNA. Each 
reaction mixture was overlaid with 75 ftlmineral oil (Sigma, st. Louis, MO) prior to 
PCR reaction in a DNA thermal cycler (Perkin Elmer-480, Branchburg, NJ) under the 
following conditions. After a 5 min 94 'c denaturation step, samples were subjected to 
40 cycles of denaturation at 94 'C for 1 min, annealing at 60 ·C for 2 min, and 
extension at 72 ·C for 3 min. The last cycle was extended with 7 min at 72 'C. Positive 
control samples were produced by stimulating 106 human spleen cells with 1 % 
phytohemagglutinin (PHA)-M (Difco, Detroit, MI) for 4 h at 37 'c. Negative controls 
consisted of omission of reverse transcriptase from the cDNA synthesis reaction for 
each sample followed by amplification in PCR with the TNF-a and keratin primers, 
and the use of diethylpyrocarbonate treated-H20 as a no-template reaction. 
Following PCR, 16 fti PCR product was analyzed by gel electrophoresis and the 
amount of products in relation to the internal control, and targets were determined for 
each individual reaction. The relative ethidium bromide intensity on the gel was 
measured by luminescence with a DC-40 camera in combination with analysis software 
(Kodak, Rochester, NY). The logarithm of the ratio target/internal control was plotted 
as a function of the logarithm of the internal molal' amount of the standard and at ratio 
I, the stal1ing concentration ofTNF-a and keratin cDNA prior to PCR was assumed to 
be equal to the known stal1ing concentration of the competing internal control. The 
relative concentrations of TNF-a transcripts were divided by the relative concentration 
of keratin. This represents the amount of TNF -a mRNA transcripts corrected for the 
amount of mRNA used for reverse transcription and the efficiency of each reaction. 
Results 
Serum creatinine and creatinine clearance 
Mean serum creatinine was 804 funol/I before operation (range 433-1334 pmol/I) and 
had decreased to 135 flmol/I (range 60-413 flmol/I, median 110 flmol/I) by day 6. The 
mean creatinine clearance was 60 mlImin on day 6 (range:20-117 ml/min). 
At 12 months after kidney transplantation, patients using cyclospotine had stable renal 
function with mean serum creatinine 171 flmol/I (range:76-265 flmol/I). The creatinine 
clearance was 59 ml/min. Patients using azathioprin had a mean semm creatinine of 
122 funol/I (range: 81-214 flmol/I) with a creatinine clearance of84 ml/min. 
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TNF-o. protein 
Using the four different sandwich ELISA techniques we were able to detect TNF-o: in 
plasma of all patients. However, levels were only just above the detection limits of the 
kits and no significantly higher levels were found in any of the patients. 
Soluble TNF-I'eceptol's ill serulil alld urille 
The concentrations of sTNF-RI and sTNF-R2 were high in the plasma from all patients 
before transplantation (sTNF-RI: 14.5 ± 6.5 ng/ml, sTNF-R2: 15.4 ± 5.7 ng/ml). Table 
1. 
Table 1: 
sTNF-receptors (Rl and R2) and mRNA TNF-a before and after kidney 
transplantation 
sTNF-RI [ng/ml] sTNF-R2 [ng/mll 
plasma 
controls 0.7±0.1 
pre-transpl 14.5 ± 6.5 * 
post -transplantation 
day 1 3.S ± 1.4 ** 
day 2 3.2 ± 1.2 
day 3 3.0 ± 1.1 
day 6 3.0± 1.4 
at 1 year after transplantation 
cyclosporine 
azathioprine 
mean ± s.d. 
n.d.: not done 
3.2 ± 1.3 
2.5 ± 0.7 
urine plasma 
n.d. 1.6 ± 0.5 
n.d. 15.4 ± 5.7 * 
10.9 ± 5.6 6.5 ± 2.5** 
12.4 ± 4.2 5.2 ± 2.3 
9.1 ± 3.5 4.9 ± 2.0 
6.7 ± 2.9 4.S ± 1.8 
1.8 ± 0.7 5.8 ± 1.8 
2.7 ± 1.1 4.0 ± 0.8 
, p < 0.001 versus controls and versus day 1; ANOVA 
"p < 0.001 versus pre-transplantation 
108 
urine 
n.d. 
n.d. 
7.2 ± 4.9 
7.S ± 3.6 
7.2 ± 3.7 
5.6 ± 0.9 
5.8 ± 1.1 
9.3 ± 1.8 
mRNA[fg] 
IS 
12 
10 
6 
66 
9 
n.d. 
n.d. 
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After transplantation sTNF-Rllevels decreased to 3.8 ± 1.4 ng/ml (p<O.OOI) on day I 
and 3.0 ± 1.4 ng/ml (p<O.OO I) on day 6 (Table I). In spite of the restoration of renal 
function sTNF-RI levels remained significantly higher than those of healthy controls 
(0.7 ± 0.1 ng/ml; p < 0.001). sTNF-R2 levels showed also a significant decrease after 
restoration of renal function: 15.4 ± 5.7 ng/ml (p<O.OOI) on day I to 4.8 ± 1.8 ng/ml 
(p<O.OO I) on day 6 (Table I). These levels were also significantly higher than those of 
healthy controls (1.6 ± 0.5 ng/ml; p < 0.001). 
Patients on cyclosporine, I year after kidney transplantation had sTNF-Rllevels (3.2 ± 
1.3 ng/ml) not significantly different from those in patients on azathioprine (2.5 ± 0.7 
ng/ml; N.S.). sTNF-R2 levels were also not significantly different in cyclosporine 
treated patients than in patients on azathioprine (5.8 ± 1.8 ng/ml versus 4.0 ± 0.8 
ng/ml). However, all receptor levels, both in patients on cyclosporine and in those on 
azathioprine were significantly higher than the levels in healthy controls (p<O.OOI). 
In the urine samples of patients shOlily after transplantation sTNF-Rllevels were 10.9 
± 2.5 nglml on day I and 6.7 ± 2.9 ng/ml on day 6 (N.S.). sTNF-R2 levels in urine 
were 7.2 ± 4.9 ng/ml on day I and 5.6 ± 0.9 ng/ml on day 6 (N.s). After I year sTNF-
RI levels in urine were 1.8 ± 0.7 ng/ml (cyclosporine group) and 2.7 ± 1.1 ng/ml 
(azathioprine group; N.S), while sTNF-R2 levels were 5.8 ± 1.1 ng/ml (cyclosporine) 
and 9.3 ± 1.8 ng/ml (azathioprine; N.S.). 
We evaluated the urinary excretion of sTNF-R by calculating the fractional clearance 
of the receptors in relation to that of the creatinine. Six days after renal transplantation 
the fractional clearance of sTNF-RI was 9% and of sTNF-R2 5%. The fractional 
clearances of the sTNF-R decreased to 2% for both receptors at one year after 
transplantation. After I year there was no significant difference in fractional clearances 
for both receptors between the patients on cyclosporine and those on azathioprine (1.9 
± 0.1 vs 2.3 ± 0.11; N.S.). 
TNF-a IIIRNA 
In the PBMC of the patients recelvlllg a living-related kidney transplantation we 
measured TNF-a mRNA using the RT-PCR method daily from the day before 
transplantation (day -\) through day 6 after transplantation. Levels of TNF -a mRNA 
are expressed as the TNF-a/keratin ratio in order to compensate for the total amount of 
mRNA produced by the cells and the methods of isolation and amplification. By using 
this method we were able to detect levels ofTNF-a mRNA in both patients and healthy 
controls. Levels of TNF -a mRNA as well as TNF -a/keratin ratio were not different in 
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patients compared to healthy controls (TNF-a mRNA: II fg vs. 18 fg.; TNF-alkeratin 
ratio: 284 vs. 528; N.S.). The levels of TNF-a and the TNF-a/keratin ratio did not 
change in the days following successful transplantation. 
Discussion 
After living related kidney transplantation renal function is normalized in a very short 
period of time. Creatinine clearance increases from < 10 mllmin to 60-90 mllmin. In 
the months after transplantation graft function may be compromised by nephrotoxic 
drugs such as cyciospOline, low grade rejection or urinary tract infections. In spite of 
this, renal function is stable in many patients. One year after kidney transplantation we 
found a creatinine clearance of 59 mlImin in the cyclosporine group compared to 84 
mllmin in the azathioprine group. In newly transplanted patients, restoration of renal 
function was accompanied by a rapid fall in plasma sTNF-R levels. However, the 
sTNF-R levels remained elevated in transplant recipients compared to healthy controls. 
In contrast plasma levels of TNF-a, measured by ELISA techniques, were comparable 
to those in healthy controls. The TNF-a mRNA expression of the PBMC was also 
comparable to that in the controls. We found no consistent decrease in TNF-a mRNA 
after succesful transplantation. However, there was still an imbalance in the TNF-a 
system, caused by elevated levels ofsTNF-R with normal levels ofTNF-a (protein and 
mRNA). TNF-a levels may be normal, because of impaired production by PBMC or a 
discrepancy between serum levels and locally produced TNF-a. Locally produced 
TNF-a binds to its membrane-bound receptor resulting in production of the split 
products, the sTNF-R. This shedding of the TNF-receptors is partly responsible for the 
increased serum levels and is an indication of the activation of the TNF-a system. 
As the fractional clearance of the sTNF-R was only 5 to 9%, the rapid fall in plasma 
levels of these receptors after transplantation can not be explained by increased renal 
function. 
Neveltheless, after succesful renal transplantation the imbalance in the TNF-a system 
in patients with renal failure is improved. However, compared to healthy controls the 
persisting imbalance suggests an ongoing immunocompromised state of these patients 
after transplantation. 
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Abstract 
The two soluble tumor necrosis factor (TNF) receptors (sTNF-Rl, sTNF-R2) can bind 
TNF-a, which is a cytokine with cardiodepressant propeliies. In heali failure and after 
heati tratlsplantation the TNF-a system is unbalanced, due to elevated levels of the sTNF-
receptors. 
Aim: To assess the activity of the TNF-a system in patients with heati failure and after 
heati transplantation. 
Methods: We measured TNF-a mRNA expression of peripheral blood mononuclear ceils, 
plasma levels ofTNF-a and sTNF-receptors, using RT-peR and ELISA and performed a 
TNF-a bindingcapacity analysis, quantitating the buffercapacity of patients plasma. 
Results: In II patients with heart failure and in IS cardiac allograft recipients, the TNF-a 
mRNA expression was comparable to controls. This level of mRNA was not accompanied 
by detectable TNF-a plasma levels. Significantly higher sTNF-receptors levels were found 
in patients: (p<O.OOI; ANOV A). The TNF-a binding capacity of patients plasma was 
significantly increased, which led to decreased TNF-a recovery (p<0.05). Both sTNF-
receptors showed a linear conelation with serum creatinine (sTNF-RI: 1'=0.92; sTNF-R2: 
1'=0.82, p<O.OOI). 
Conclusions: the TNF -a mRNA expression and plasma levels show that the "peripheral" 
TNF-a system is not activated. The high sTNF-receptors levels and their elevated TNF-a 
bindingcapacity resulting in a decreased TNF-a bioavailability may contribute to an 
immunosuppressed state in these patients. 
Key words: TNF-a, soluble TNF-receptors, heart failure, heart transplantation 
Introduction 
Tumor necrosis factor-a (TNF-a) is a pro-inflammatory cy10kine with cardiodepressant 
propeliies [1]. In dilated cardiomyopathy, in end-stage ischemic heart disease and after 
heati transplantation elevated plasma levels ofTNF-a may be found [2-5]. In addition, we 
and others repolied significant expression ofTNF-a mRNA within the allograft after heati 
transplantation and we also showed that this level of TNF-a gene expression correlated 
with the efficacy of steroid anti-rejection therapy [6,7). In general, activated peripheral 
blood mononuclear cells are the main source of TNF-a. In patients with heart failure a 
positive correlation is found between the severity ofheati failure and the TNF-a levels [8]. 
Excessive catecholamine production and generalized endothelial dysfunction in these 
patients may contribute to the activation of TNF-a, both at peripheral and central cardiac 
level [9]. In heart transplant patients, TNF-a can be produced not only by activated 
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recipient derived, graft infiltrating cells, but also by donor cells, e.g myocytes and 
endothelium [2,11-13]. In spite of local TNF-a production in the allograft, no clear 
relationship between sTNF-receptors and rejection has been established [14]. All cells, 
except erytrocytes and resting T-cells, have membrane-bound TNF-receptors Rl and R2, 
which regulate the biological activity of TNF-a. After binding with the receptor, 
proteolytic cleavage results in splitproducts, the soluble TNF-receptors Rl and R2. High 
levels of sTNF-receptors are found in patients with heart failure and after successful heart 
transplantation, indicating that produced TNF-a is bound to its receptors, resulting in the 
production of these splitproducts. The circulating sTNF-receptors can bind 1 to 3 free 
TNF-a molecules, thereby acting as a buffer for locally produced TNF-a [15]. Under 
physiological circumstances free TNF-a is in balance with its sTNF-receptors. However, 
under a variety of clinical conditions the TNF-a/sTNF-receptor ratio may be distl11'bed 
[16]. Apart from hemt faill11'e, conditions in which the TNF-a system is out of balance are 
sepsis [17] and compromised renal function (renal failure, haemodialysis) [18]. In sepsis 
the TNF-a production overcomes the buffercapacity of the sTNF-receptors and fi'ee 
TNF-a can be detected in the plasma. In renal failure, the impaired clearance of the sTNF-
receptors is the reason for the unbalanced TNF system, while during haemodialysis both 
TNF-a production by activated peripheral blood mononuclear' cells, and impaired 
clearance of the receptors disturbs the balance between TNF-a and its receptors. 
Moreover, generalized m1eriosclerosis and nephrotoxic immunosuppressive dmgs cause 
impaired renal function and lead to a decreased clearance of the sTNF-receptors in both 
hemt failure and cardiac allograft recipients. This results in a disturbed TNF-a/sTNF-
receptor ratio. 
In the present study, we evaluated the netto balance of the factors: production and 
clearance. Therefore, we analyzed the potential TNF-a production by measl11'ing its 
mRNA expression in peripheral blood mononuclear cells, free plasma protein levels 
and sTNF-receptors, RI and R2. In order to evaluate the bioactivity of the sTNF-
receptors, we measl11'ed the plasma bindingcapacity for recombinant TNF-a in patients 
and control plasma, after incubation with free, active, recombinant human TNF-a. 
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Patients and Methods 
In 11 patients with hemt failure (eight males and three females, mean age 66 years, range 
22-76, mean selUm creatinine 107 ~l1noVl, range 53-390), we measured TNF-u mRNA 
expression of peripheral blood mononuclear cells, free plasma TNF-u and soluble TNF-
receptors (sTNF-RI and sTNF-R2). The patients suffered from heart failure, due to 
ischemic heart disease (multiple myocardial infarctions, n=6), dilated cardiomyopathy 
after alcohol abuse (n=2), mitral valve stenosis (n=2) and congenital hemt disease (n=I). 
These patients had been admitted to the hospital, because of progression of heatt failure. 
They were classified according to the New Yark Hemt Association Class ill (n=9) or IV 
(n=2). Four patients underwent hemt catheterization. During this procedure the left 
venliicular ejection fraction, and right and left sided pressures were measured (mean 
pulmonary mterial pressures ranged from 21-45 mmHg). In 7 patients the left ventricular 
ejection fmction was determined by radionucleotide angiography. Mean left ventricular 
ejection fraction was 18% (range:15-20%) in 9 patients. The 2 patients with mitral valve 
stenosis, however had a left ventricular ejection fraction of 65-70%. Medication consisted 
of digoxin (n=5), nitrates (n=5), Ca-entlY blockers (n=5), B-blockers (n=2), diuretics (n=6) 
and ACE-inhibitors (n=9). Two patients used amiodarone. 
TNF-u measurements were also performed in 15 cardiac allograft recipients (11 males, 4 
females; mean age 56 years, range 21-67) with stable renal function (mean semm 
creatinine: 113 ~lmoVl; range 63-140 J.lmoVl, creatinine clearance: 90 ± 27 mVmin). 
Echocardiography, at the time of blood sampling, revealed nonnal systolic left ventricular 
function. There were no signs of rejection or infection. Time after transplantation ranged 
from 4 till 127 months (median 59 months). All heart transplant patients received 
cyclosporine and steroids as maintenance immunosuppressive therapy. The mean whole 
blood trough cyclosporine level was 158 ng/mi (range 85-320 ng/mi, median 145). 
Twelve healthy subjects served as controls (4 males, mean age 30 years, range 24-52, 
creatinine <100 ~lmolll). 
Sample preparation 
Blood samples were collected in pyrogen-free tubes, containing EDTA in a final 
concentration of 1 mg/ml. The samples were immediately centrifugated, plasma and cell 
fraction were separated and plasma was stored at -80 'c until analysis. For the isolation of 
peripheral blood mononuclear cells the buffy coat was diluted in phosphate-buffered 
saline and layered on a Ficoll-Isopaque gradient. After centrifugation, the mononuclear 
116 
Chapter 7 
cells were removed from the interface, and washed twice with ice-cold phosphate-buffered 
saline. Immediately after procurement, 2x 106 cells were snap-frozen in liquid nitrogen 
and stored at -so °C for Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). 
Isolation of mRNA and copy-DNA reaction 
Total RNA was extracted from snap-frozen samples by a modification of the guanidinium 
method (Chomczynski [19]), described by Baan [20]. Cells were homogenized in 500 ~114 
mollL guanidinium-isothiocyanate in the presence of 20 Ilg poly A (Boehringer, 
Mannheim, Germany). The solution was extracted once with phenol, phenol-chloroform-
isoamylalcohol [25:24:1] and chloroform-isoamylalcohol [24:1], respectively. Total RNA 
was precipitated with 600 III 2-propanol and 35 ~II 3 mollL sodium acetate (pH 5.2) at -
20°C for IS hours. Precipitates were pelleted at 10.000xg at 4 °C and washed once with 
500 ~II ice-cold SO% ethanol. Air-dried pellets were resuspended in 50 III 
diethylpyrocarbonate treated-H20. Total RNA was denaturated for 5 min at SO °C and 
then chilled on ice. First strand cDNA synthesis was pelfOimed from the isolated RNA 
with 0.5 ~Ig hexanucleotides (Promega Corporation, Madison, WI) and transctibed with 
1000 U Moloney mUline leukemia virus reverse transcriptase (Gibco-BRL, Gaithersburg, 
MD) at 42°C for 90 minutes in a total volume of 100 fll. The reaction mixture consisted 
of20 fll 5x MMLV-RT buffer (250 mmollL Tris-HCI pH S.3, 15 ruM MgCh, 375 ruM 
KCI), 5 ttl (10 mM) dNTP, 400 U of RNA sin (Promega) and 10 [II O.IM DTT. 
Competitive template Reverse Transcrip!ase Polymerase Chain Reaction (RT-PCR) 
Sequence specific primers were used for amplification of the human TNF-(.( gene (sense 
primer:5' GAG TGA CAA GCC TGT AGC CCA TGT TGT AGC A 3' and anti-sense 
ptimer:5' GCA ATG ATC CCA AAG TAG ACC TGC CCA GAC l' 3'). PCR primers 
detecting transcripts for the human housekeeping gene, keratin, were used as an internal 
control to monitor mRNA extraction and cDNA amplification [22]. To estimate the 
relative initial amount of functional TNF-(.( mRNA in peripheral blood mononuclear cells 
a competitive template RT -PCR assay was used and comparison was made against the 
housekeeping keratin gene. The latter gene is assumed to be expressed at a constant level 
in hematopoeitic cells [21]. Five ftl cDNA sample and 5 ftl of gene specific competitive 
templates were added to 90 ftl PCR mixture containing 10 mM Tris-HCI pH S.3, 50 mM 
KCI, 1.5 mM MgCI" 0.2 ruM of each dATP, dCTP, dTTP, dGTP, 2 U Taq DNA 
polymerase (Promega) and 50 pmol of 5' and 3' sequence specific ptimers. To obtain a 
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standard curve for TNF-C! and keratin, known amounts of internal control fragment were 
added in different dilutions to constant amounts of sample cDNA for competitive co-
amplification with specitlc primers. (Figure lA). 
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Typical example of quantitative RT-PCR analysis of TNF-a. After 
electrophoresis, the ethidium bromide stained agarose gel shows two PCR 
products of TNF-a per lane, representing the amplified target (444 bp) and 
internal control (326 bp) 
Figure 1 B: (lower panel) 
The log of the amplified TNF-a to competitor TNF-a is graphed as a function 
of the log of the known amount of competitor added to PCR. At the point 
where target cDNA and internal control are in equivalence (ratio=1), the 
starting concentration of TNF-a cDNA prior to PCR is equal to the known 
starting concentration of the competing internal control 
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The internal control was designed to generate a PCR prodnct of a different size to allow 
differentiation between the amplified target and internal standard (1NF-a: 444 and 326 
bp) and keratin (target = 218 bp, internal control = 160 bp). Each reaction mixture was 
overlaid with 75 ~tl mineral oil (Sigma, St. Louis, MO) prior to PCR reaction in a DNA 
thermal cycler (Perkin Elmer- 480, Branchburg, NJ) under the following conditions. After 
a 5 min 94°C denaturation step, samples were subjected to 40 cycles of denaturation at 
94 °c for 1 min, annealing at 60°C for 2 min, and extension at 72 °c for 3 min. The last 
cycle was extended with 7 min at 72 0c. Positive control samples were produced by 
stimulating 10' human spleen cells with 1% phytohemagglutinin (PHA)-M (Difco, 
Detroit, Ml) for 4 h at 37°C. Negative controls consisted of omission of reverse 
transcriptase from the eDNA synthesis reaction for each sample followed by amplification 
in PCR with the TNF-a and keratin primers, and the use of diethylpyrocarbonate treated-
H20 as no-template reaction. Following PCR, 16 ~I PCR product was analyzed by gel 
electrophoresis and the amount of products by the internal control and targets were 
determined for each individual reaction. The relative ethidium bromide intensity on gel 
was measured by luminescence with a DC-40 camera in combination with analysis 
software (Kodak, Rochester, NY). The logarithm of the ratio target/internal control is 
graphed as a function of the logarithm of the internal molar amount of the standard and at 
ratio I, the starting concentration ofTNF-a and keratin eDNA prior to PCR is assumed to 
be equal to the known statting concentration of the competing intemal control (Fig. lB). 
The relative concentration of1NF-a transcripts were divided by the relative concentration 
of keratin. This represents the amount of 1NF-a mRNA transcripts corrected for the 
amount of mRNA used for reverse transcription and the emcacy of each reaction. 
TNF-a and soluble receptors Rl and R2 by ELISA 
1NF-a in plasma was measured by a commercially available Enzyme Linked Immuno 
Sorbent Assay (Genzyme, Brussels, Belgium). The detection limit is 4 pg/ml, the 
coemcient of variation is 5-10%. 
The plasma soluble TNF-receptors Rl and R2 are detected in the same blood sample, 
using double sandwich ELISA technique (R&D Systems Europe, Abingdon, United 
Kingdom). The detection limit for both receptors is 15 pglmJ, the coefficient of variation is 
less than 5% (s1NF-Rl) and less than 10% (sTNF-R2). 
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Plasma TNF-(( bindingcapacity aftcr incubation 
Plasma sTNF-receptors can bind 1-3 free TNF-a molecules. TNF-a binding assays can be 
performed, using various bio-assays [IS]. We performed the TNF-a binding assay 
measuring the remaining TNF-a after incubation with patient or conh'ol plasma using a 
commercially available ELISA. A standard curve was constmcted using different 
concentrations of the recombinant TNF-a (final concentration 300 pg/ml). The plasma 
TNF-a bindingcapacity can be expressed as the TNF-a recovery. The TNF-a recovery is 
the residual TNF-a concentration (after incubation of recombinant TNF-a with sTNF-
receptor containing plasma) divided by the initial concentration of TNF-a x 100%. After 
incubation of O.S ml plasma with recombinant human TNF-a at room temperature, the 
ELISA test was performed following the manufacturer's instl1lctions. Calculation of the 
residual TNF-a concentration was completed by extrapolation to the standard curve. 
Statistics 
The results are denoted as mean ± standard deviation, or median with range, whenever 
appropriate. The Mann Whitney U test was used for non-parametric analysis, p-values 
< O.OS were considered significant. The data of the soluble TNF-receptors were 
compared using the ANOYA. The TNF-a recovery is evaluated by the Dunn's multiple 
comparison test. 
Results 
TNF-a mRNA expression was detectable in all blood samples, including those 
obtained from healthy controls. Therefore, we performed a quantitative competitive 
template RT-PCR analysis to determine the level of TNF-a mRNA expression. Using 
the RT-PCR, we found no statistical difference among groups in expression of the 
positive control housekeeping gene, keratin. This indicates that the integrity of the 
mRNA in the analyzed patient groups and in controls was the same (p>0.05, Kl1Iskal-
Wallis). Relative amounts of initial TNF-a mRNA were individually normalized to the 
corresponding keratin levels, which permitted more accmate comparison of TNF-a 
gene transcript levels. Relative TNF-a mRNA levels in peripheral blood mononuclear 
cells were not different in patients with heart failure or after heart transplantation 
compared to controls (mean TNF-a/keratin ratio: 129 (heart failure) vs 186 (heart 
transplantation) p=0.57; 129 (heart failure) vs 598 (controls), p=0.56; 186 (heart 
transplantation) vs S98 (controls), p=0.45; Mann Whitney U, Figure 2). 
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Figure 2: 
TNF-a mRNA production by peripheral blood mononuclear cells obtained from 
patients with heart failure (HF), after heart transplantation (HTX). compared to 
healthy controls, denoted as the relative TNF-a/Keratin ratio, measured by 
competitive template RT-peR. 
This level of TNF-a mRNA-expression did not result in detectable TNF-a levels in 
plasma in either the patient groups or the healthy controls (all samples: TNF-a < 4.0 
pg/ml, which is the lowest detection limit of the ELISA). However, significantly higher 
levels of sTNF-receptor Rl and R2 were found in plasma, obtained from patients with 
heart failure and after heart transplantation compared to control plasma. In patients 
with heart failure the mean plasma level of sTNF-Rl was 2.6 ± 1.7 and of sTNF-R2: 
5.6 ± 2.7 ng/ml. In plasma obtained from heart transplant recipients the mean level of 
sTNF-Rl was 2.9 ± 1.3 and of sTNF-R2: 4.9 ± 2.1. In controls the mean plasma level 
of sTNF-Rl is 0.7 ± 0.1 ng/ml, and of sTNF-R2: 1.6 ± 0.5 ng/ml, p<O.OOOl; ANOYA. 
(Figure 3). 
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Figure 3: 
Plasma levels of soluble TNF-receptors R1 and R2 [ng/mll in patients with 
heart failure (HF) and after heart transplantation (HTX), compared to controls, 
measured by ELISA 
Both sTNF-receptors showed a linear correlation with serum creatinine levels (sTNF-
RI: r=O.92, sTNF-R2: r=0.82, p<O.OOI, Figure 4A + 4B). 
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(ng/ml) [AJ and R2 (ng/ml) [BJ in patients with heart failure and after heart 
transplantation 
Our results suggest that the absence of free, detectable plasma TNF-(( is the 
consequence of the surplus of circulating sTNF-receptors. We, therefore, speculate that 
produced TNF-(( is bound to the surplus of the circulating sTNF-receptors. To evaluate 
the biological activity of this surplus of sTNF-receptors we performed a TNF-(( 
recovery test. A fixed amount of recombinant TNF-(( was incubated with both patient 
plasma (healt failure and after heatt transplantation) and control plasma. The TNF-(( 
recovery was significantly reduced after incubation with patient plasma compared to 
incubation with plasma obtained from healthy controls (79 ±16% (heart failure), 75 
±S% (after heart transplantation) vs 100 ±7%; p < 0.05; ANOYA). Figure 5. 
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Figure 5: 
TNF-a recovery, measured after incubation of 30 minutes of recombinant 
TNF-a in plasma of patients with heart failure (HF) and after heart 
transplantation (HTX) and control plasma, by ELISA, denoted as percentage 
of remaining TNF-a 
Discussion 
The TNF-a system has been repOlied to be out of balance, both in heati failure and renal 
insufficiency, and after organ transplantation [4,5,8,9,14,18,22]. Activation of the system 
may result in fliliher pl'Ogression of heati failure [1-3], while impairment of the TNF-a 
system may be the cause of higher susceptibility for infections and development of 
malignancies. In an attempt to asses the biological significance of the disturbed TNF-a 
system, we studied various components of the TNF-a system in patients with heati failure 
and after heart transplantation. We found an unbalanced TNF/sTNF-receptor ratio in both 
patient groups. This disturbance lVas mainly caused by high levels of biological active 
soluble TNF-receptors. These sTNF-receptors are splitproducts of the TNF-membrane 
receptor, which are shed after TNF-a binding. Virtually all cells cany TNF-membrane 
receptors. Cell-activation or TNF-binding results in increased expression of the TNF-
receptors [23,24]. Binding to the membrane-bound TNF-receptor RI or R2 result in a 
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cascade of events. Depending on interaction with RI or R2, TNF-u binding leads to 
apoptosis, tumor cell lysis, hemorrhagic necrosis, T-cell proliferation or insulin resistence 
[24]. 
High amounts of TNF -u have been found in plasma of patients with chronic heatt failure, 
depending on the severity of heatt failure [S]. However, a wide ratlge between individuals 
can be found, known as genetically low or high TNF -u producers [2S]. 
The lower detection limit of 4 pglml of our ELISA kit led us to anticipate finding TNF-u 
in the plasma from patients with heatt failure. However, we detected no free plasma 
TNF-a. Commercially available ELISA kits show a wide range in measurement results, 
whieh make comparison between studies hardly possible [IS]. Besides that, the high levels 
of sTNF -receptors were able to bind 2S-30% of free, active TNF -u, in vitro, and thus 
could prevent measurement of free TNF-a. In previous studies we described the TNF-a 
system in end-stage renal failure and after kidney tranSplatltation [18-22]. In patients on 
cill'onie haemodialysis, as well as patients on peritoneal dialysis and with end-stage renal 
failure the TNF/sTNF balance was disturbed, due to high levels of mRNA-TNF-a 
expression (only in patients on haemodialysis) and high levels ofsTNF-receptors. Uremia 
itself is known to be a potent initiator of TNF -a production, but in cill'onie haemodialysis, 
the blood-membrane interaction is seen as the main TNF-a production inductor. Impaired 
renal clearance has been found to give a positive correlation with the sTNF-receptor levels 
[23]. After successful kidney transplantation, the TNF-alsTNF-receptor balance was only 
in patt restored, mainly because of persistent elevation of the plasma levels of soluble 
TNF-receptors. The reason for these high levels remains unclear. In renal transplant 
recipients TNF-a production may be provided by graft-infiltrating cells in the tratlsplanted 
kidney. After binding to local receptors production of sTNF-receptors occurs. In addition, 
impaired renal clearance, due to nephrotoxic dlUgs, results in high plasma levels ofsTNF-
receptors. This "central" cytokine concept parallels the situation in heatt transplant 
recipients, in which TNF-a production by graft infiltrating cells leads to high production 
of sTNF -receptors [9]. However, a normal renal function seems a prerequisite for 
maintaining the physiological balance between TNF -a and its receptors. In this study the 
sTNF-receptors levels showed a positive correlation with the serum creatinine both in 
patients with heart failure and after heart transplantation (figAA+4B). Healthy controls 
reside below the regression line, suggesting that besides renal clearance, other factors, e.g. 
production, playa significant role. We found an unbalanced TNF-a system in patients 
with heat1 failure and after hem transplantation, caused by high levels of the soluble TNF-
receptors, rather than high levels of TNF -a. The normal expression of mRNA -TNF -a by 
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peripheral blood mononuclear cells in both patient groups suggest a non-activated 
"peripheral" TNF -a system. This finding seems in contradiction with the "peripheral" 
cytokine concept for the role of TNF -a in heali failure [7]. Speculation remains about the 
source of the high levels of the soluble TNF-receptors. Production, as well as decreased 
renal clearance, may have contributed to the high sTNF-receptor levels in our patient 
groups. Heart failure itself, may lead to cytokine synthesis and release by inducing 
production of excessive catecholamines, production of angiotensin II and endothelial 
dysfunction, provoked by myocardial injury. After heart transplantation, TNF-a mRNA in 
the graft is constitutively expressed. Before, during and even after successful anti-rejection 
therapy with c0l1icosteroids intragraft TNF-a mRNA expression is present [6]. This 
everpresent, smoldering TNF-a mRNA expression by graft infiltrating mononuclear cells, 
endothelium or cardiac myocytes may be the result of ongoing allogeneic reactions in the 
graft. Binding to the membrane-bound TNF-receptors can lead to elevated levels of 
soluble TNF-receptors, found in peripheral blood. Nephrotoxic agents, such as 
cyclosporine, can diminish the renal clearance of these receptors, resulting in even higher 
levels. These biological active receptors can bind immunoactive TNF-a and result in 
decreased bioavailability of TNF-a. Complete removal of circulating TNF-a can have 
deleterious effects in patients, leading to a high m0l1ality from sepsis related side-effects, 
as described by Fischer et al [27]. In contrast, benificial results are described in patients 
treated for acute rheumatoid at1hritis with anti TNF -a antibodies [28]. As TNF -a is known 
for its cardiodepressent propeliies, blocking of the TNF -a seems to favour prevention of 
ful1her cardiac failure. A balance between TNF -a and its receptors is necessary to 
maintain adequate immuno reactivity. Imbalance between TNF-a and receptors can lead 
to increased immunosuppression, contributing to the high incidence of infections and 
malignancies in these patients. In conclusion, patients with end-stage heart or renal failure 
and after transplantation suffer from generalized immunosuppression, in which the TNF-a 
system may playa central role. To overcome this decreased immunoreactivity, due to the 
imbalanced TNF -a system we have to increase clearance of the sTNF-receptors and thus 
decrease TNF-a buffercapacity of the plasma to a level, which is encountered in healthy 
controls. 
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Letter to the editor: 
TNF -a system in chronic heart failure 
We appreciate the comments of Drs. Doehner and Anker regarding our paper about the 
TNF-a system in heart failure and after heart transplantation (Eur Heart J 1999; 20: 
833-840). Their main concern is that we drew our conclusions from non-detectable 
TNF-a levels. In order to overcome this problem elegantly, we measured mRNA 
expression levels, which proVide indirectly information about TNF-a production, and 
soluble TNF-receptors (sTNF-R), which are produced after TNF-a binding to their 
specific membrane receptor. Levels of sTNF-R can serve as reflection of this binding 
process and thus activity of the pro-inflammatory cytokine TNF-a. In the study we 
measured oedematous, as well as non-oedematous patients with chronic heat1 failure 
(NYHC ill or IV, mean left ventricular ejection fraction 18%). Statistically there were 
no differences between patients with or without oedema in TNF-a mRNA expression 
levels or sTNF-R levels. In none of the patients (with hemt failure or after heart 
transplantation) or controls free TNF-a was detectable. After reading the manuscript of 
Niebauer et al [1], we performed another TNF-a study in patients with severe heart 
failure and oedema. In this study we used the Quantikine high sensitivity ELISA kit for 
TNF-a (R&D Systems), with detection limit of 0.5 pg/ml. This ELISA kit was also 
used by Niebauer et al [I]. As positive controls we measured TNF-a plasma levels in 
renal transplant recipients, who received rabbit-Anti-Thymocyte-Globulin (r-ATG) as 
rejection treatment. Healthy volunteers served as controls. TNF-a levels were 349 
pg/ml after r-ATG treatment, 1.2 pg/ml for healthy controls and 4.0 pg/ml in patients 
with heart fai lure, which did not significantly decrease after treatment. These data, 
especially the results of the patients suffeling from heatt failure, are in line with our 
previous study. We are not able to reproduce the data on TNF-a levels, found in 
healthy controls and in heart failure, as described by Niebauer [1]. Their levels of 
sTNF-R are comparable to our data. Moreover, it is known that due to various aspects, 
TNF-a measurements are hard to compare [2]. The sensitivity of the ELISA kit used in 
the previous study was low (detection limit 4 pg/ml). The TNF-a results, measured by 
the high sensitivity R&D ELISA kit, do not force us to change our conclusions. The 
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approximately IOOO-fold excess of sTNF-R may interfere with the function of low free, 
bioactive TNF-o: concentrations. Therefore, we think that measuring TNF-o: mRNA by 
RT-PCR is a more reliable method of analyzing cytokine systems of chronic heart 
failure patients. Data of the TNF-o: system in end-stage renal failure are reported in our 
article, which will be published soon [3]. 
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Abstract 
After heart transplantation a high incidence of infections and malignancies is found. 
Not only immunosuppression, but also intrinsic unbalanced cytokine systems, e.g. 
TNF -(l and IL-2, can result in impaired immune competence and may have a role in 
these complications. 
The aim of this study was to assess the activity of the TNF-(l and IL-2 systems after 
heati transplantation. In peripheral blood we measured expression of activation 
markers of TNF-(l (TNF-R2) and IL-2 (IL-2R(l, IL-2Rp-chain) on monocytes and 
lymphocytes using quantitative flow cytometric analysis. TNF-R2 expression was 
significantly enhanced on monocytes and lymphocytes in patients after heali 
transplantation, while the expression of IL-2R(l and lL-2Rp was not elevated. 
Increased TNF-R2 expression in peripheral blood after heart transplantation reflects an 
activated TNF-a system, leading to high levels of active sTNF-R, which impairs 
TNF-(l bioavailability and consequently leads to immune incompetence. 
Key words: TNF-(l receptor, IL-2R, heart transplantation, immune incompetence 
Introduction 
After heart transplantation (HTx) infections and malignancies are frequently 
encountered. At the UniverSity Hospital Rotterdam 333 cardiac allografts were 
transplanted between 1984 and 1997. Approximately 10% (n=35) of these patients died 
within 12 months after transplantation. In 9 of the 35 the cause of death was infection 
(n=4) or Iymphoproliferative disease (PTLD, n=5). At 5 years post transplant another 
24 patients had died, fOUlieen of them of infection (n=3) 01' malignancy (n= II). 
Infection and cancel' were the reason for mortality in the follow-up after 5 years post-
transplant in 2 and 8 out of 52 deceased, respectively [2,4]. Our data are in line with 
the ISHLT registry data [9]. The cause of death was infection, including 
cytomegalovirus (CMV), 16.6% within 12 months and malignancy, including PTLD 
(24.4%) thereafter [8]. Whether the high incidence of infections and malignancies is 
the consequence of immunosuppressive agents 01' also of an intrinsically disturbed 
immune system has to be elucidated. Cytokines play an impOliant pali in the regulation 
of the host defense and immune responses. For example, TNF-(l is a primary mediator 
of immune regulation, produced by immune competent cells, such as monocytes and 
lymphocytes. It is a central cyiokine in the Antigen Presenting Cell (APC) system, 
which is required for T cell activation. IL-2 in turn, is an impoliant cytokine for T-cell 
proliferation and differentiation. Disturbances in either cytokine system, TNF -(lor IL-
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2, result in ineffective defense mechanisms against infections or malignant diseases, In 
a previous study in peripheral blood ofHTx patients we found high levels of biological 
active, soluble TNF receptors, sTNF-RI and sTNF-R2 [15]. In the present study we 
have analyzed the expression of the TNF-a receptor2 (CDI20b) on T-cells and 
monocytes and the IL-2 receptors (CD25 and CD122) on T-cells to evaluate the degree 
of activation of the TNF-a and IL-2 system. Moreover, we measured a general 
activation marker, HLA-DR on T-cells. Measurements were performed using 
quantitative flow cytometry. 
Patients and methods 
In peripheral blood of 11 cardiac allograft recipients (9 men, 2 women; median age: 
55.1 years [range 43-67J, median time after transplantation: 576 days [range 231-
3975)) we measured receptor expression of the TNF-a and IL-2 systems. All patients 
were in good clinical condition, without overt signs of heart failure, infections or 
malignancy and received cyclosporine and prednisolon as maintenance 
immunosuppression. Blood samples were simultaneously taken at the time of 
endomyocardial biopsy. Histological analysis of these biopsies showed no rejection, 
according to ISHLT criteria [3J. Twelve healthy subjects served as controls (4 men, 8 
women, mean age: 30 years [range 24-52)). 
Flow cytometry analysis 
Peripheral blood samples were collected in EDT A containing tubes and monitored for 
the presence of monocytes and lymphocytes. Surface markers were analyzed by two-
colour flow cytometry after staining with monoclonal antibodies directed against CD 14 
(monocytes), WT31 as a marker for the alp chain of the T-cell receptor (TCR), and 
CD25 (IL-2Ra), CDl22 (lL-2RP), (Becton Dickinson, San Jose, CA, USA), HLA-DR 
(IllIlllunotech, Marseille, France) and CDI20b (TNF-R2, Serotec, Oxford, UK). 
Antibodies, except CD120b, were directly conjugated to fluorescein isothiocyanate 
(FITC) or phycoerythrin (PE). For CDI20b we used a two-step staining. After the 
primary step with CD120b, cells were incubated with F(abh Goat-anti-Rat IgG PE. 
The staining procedure was performed by incubating 15 III 1/100 diluted CDI20b 
antibody with 100 III blood (30 min, at 4°C). After washing in Hanks' Balanced Salt 
Solution (HBSS, Gibco BRL, Paisly, UK) with 0.1 % Bovine Selum Albumin (BSA, 
Sigma, St Louis, MO, USA) and 0.01 % sodium azide (Merck, Darmstadt, Germany), 
the red blood cells were lysed by FACS Lysing Solution (Becton Dickinson). Samples 
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were centrifugated and washed in Cell Pack (TOA, Hamburg, Germany). Flow 
cytometric analysis was performed on FACscan flow cytometer using Cell Quest 
software (Becton Dickinson). From each tube 1000 events were measured. To compare 
various measurements in time the flow cytometer was calibrated using specific 
calibration beads (Calibration Beads Quantum 1000, Flowcytometry Standards Corp. 
San Jose, PR, USA). Each bead contains a known amount of fluorochrome. The 
intensity of the fluorescence is converted using Quick Cal program for quantum beads 
software to a standard curve. The intensity is denoted as molecular equivalents of 
fluorochrome, MESF. (Figure 1) . 
136 
Chapter 8 
FITe PE 
" 
0 ~ i Calibration Plot· i! ~ 0 .. -
J ~ 
.... ", .. 
il g .... 
• ~ ,
./ tiro., , 
<If 0 
./ ~ 2 .,_ ....... 
:s if ~=~~ i ... g 
~ 
'40 .. , 720 OOQ 
HI$~r;lm Ch4nnal 
Figure 1: 
Upper panel: Flow cytometric analysis of calibration beads, each of which 
contains a specific amount of fluorescine. 
Lower panel: Standard curve of fluorescence intensity constructed after 
flowcylometric analysis of calibration beads, using Quick Cal program for 
quantum beads software, The intensity of the fluorescence is depicted as 
molecular equivalents of soluble fluorochrome (MESF) 
Statiscial analysis 
Data are presented as mean ± SD or median with range, The unpaired Student's t test 
was used to analyse the receptor expression data, P-vaIues less than 0,05 were 
considered significant. 
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Results 
Petipheral blood samples from patients and controls contained comparable absolute 
numbers of a/~ TCR positive lymphocytes: patients: median 1094 cells/l.ll [range: 334-
3104 cells/l.ll] versus controls: 979 cells/l.ll [range: 517-1773 cells/l.ll]. The absolute 
number of CD14 positive monocytes in peripheral blood was significantly higher in 
patients: median 468 cells/l.ll [234-735ce11s/l.lll versus controls 314 cells/l.ll [rangeI30-
503 cells/l.li], p=O.013. Quantitative flow cytometric analysis of the expression level of 
the T-cell activation markers, CD25 and CD 122 showed no difference between patients 
and controls. CD25: MESF: 355 ± 4.4 versus 358 ± 4.2, p=0.59; CD 122: MESF: 288 ± 
4.9 versus 283 ± 3.6, p=0.43. In addition, the expression of the general activation 
marker HLA-DR on T-ce11s was comparable: MESF: 315 ± 6.5 versus 336 ± 7.5, 
respectively (p=0.13). In contrast, expression of the activation marker of the TNF-a 
system, TNF-R2 (CD120b) was significantly higher on both TCR a/~ positive T-cells 
and monocytes from patients. On lymphocytes: mean MESF: 5733 ± 3409 versus 3078 
± 1935, p=0.032, and on monocytes: MESF: 6220 ± 2091 versus 2563 ± 808 (p=0.023, 
Figure 2). 
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Figure 2: 
Expression of the TNF receptor 2 (TNF-R2 = CD120b) on lymphocytes (left) 
and monocytes (right) in patients after heart transplantation (HTx) compared 
to controls, using qauntitative flow cytometry. The fluorescence is denoted as 
Molecular Equivalents of Soluble Fluorochrome (ME SF) 
Discussion 
After heart transplantation high levels of cytokine activity can be detected in 
endomyocardial biopsies as well as in peripheral blood [5,6,10]. However, no clear 
relation between peripheral cytokine patterns and intragraft cytokine expression was 
found [7,10]. Within the transplanted heart the TNF-a system seemed to be 
continuously activated, while IL-2 mRNA expression was clearly related to rejection 
[1]. In peripheral blood of cardiac allograft recipients high levels of sTNF-receptors 
and sIL-2 receptor were reported, but these elevated levels were not consistently 
related to rejection [11,13]. In contrast, a conelation between cytokine activation and 
cardiac hemodynamic parameters is described [8,14], as well as between TNF-R and 
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clinical outcome after heart transplantation [5]. In the present study we measured the 
degree of activation of the TNF-« and IL-2 systems in peripheral blood by flow 
cytometric analysis. Increased expression of the TNF-R2, on both monocytes and 
lymphocytes, indicates an activated peripheral TNF-a system. In our previous study we 
found no upregulation of TNF-« mRNA in peripheral blood mononuclear cells, which 
is in contradiction with peripheral TNF-« activation. On the other hand, the high levels 
of sTNF-R, again, support the idea that the TNF-a system is activated after heart 
transplantation. Indeed, we described a constitutively TNF-« mRNA expression in 
endomyocardial biopsies after transplantation [1]. These data and our current results 
suppOli our hypothesis that TNF-receptor expression on PBMC is induced by intragraft 
TNF-u production. In contrast to our TNF-R2 findings, we did not find an increased 
expression of the activation markers of the IL-2 system on peripheral blood cells 
suggesting that the IL-2 system is not activated. Free plasma TNF-u or IL-2 could not 
be detected, probably due to the high levels of soluble receptors of these cytokines. 
Previously, we showed that high sTNF-R levels impair the bioavaiJabiJity of TNF-« 
[15]. This, consequently, may influence T-cell activation and result in an decreased 
defense mechanism against infections and malignancy. We postulate, that the 
transplanted heart, as source of continuous TNF-u production, might very well function 
as a central cause of the disturbed cytokine system and forms, together with the use of 
inmml10suppressive agents, a continuous source of flUther immune suppresssion after 
heart transplantation. 
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CHAPTER 9 
Summary alld COllclusions 
Summary 
In this thesis we have tried to clarify the role of the TNF-u system in the immune 
incompetence of patients with organ failure and after transplantation. 
In chapter 2 a unbalanced TNF -u system is found in patients with progressive renal 
failure. At first no free TNF-u was detected. When a more sensitive ELISA kit is used, 
significantly increased circulating TNF-u levels in HD patients are found compared to 
ESRF and CAPO. This indicates an activated TNF-u system, especially in HD patients. 
In contrast, no ovett activation of TNF-u is found in patients on CAPD or with pre-
dialysis ESRF. The dialysis procedure, itself, rather than the uremia, seems to activate 
the TNF-u in HD. Activation of TNF-u results in the production of sTNF-RI and 
sTNF-R2. Due to decreased renal clearance high levels of these soluble receptors are 
found. Recovery studies reveal biological activity of these soluble receptors, which are 
capable of binding up to 75% of the added free TNF-u and thereby inhibiting the 
bioactivity and bioavailability of produced TNF-u. This unbalanced TNF-u system 
plays a role in the immune incompetence of patients on HD and their high 
susceptibility for infections and malignancy. 
In chapter 3 activation of the TNF-u system at the single cell level in HD patients is 
demonstrated. The reproducable quantitative flow cytometry technique was used to 
quantitate the amount of cell surface expression of the TNF-u receptor, TNF-R2 
(=CD120b) on immune competent cells, monocytes and lymphocytes. The higher 
expression levels of the TNF-R2 ret1ect the activated state of the cells involved. 
Cytokines secreted by activated monocytes mediate the activation of T-cells. However, 
in spite of the activation of the TNF-u system the IL-2 system is not activated. This is 
shown by comparable expression of the IL-2R, IL-2Ra (CD25) and IL-2R~ (CDI22), 
on lymphocytes from HD patients and healthy controls. This strongly suggests that the 
T-cells are not activated and that the interaction between APC (TNF-u) and T-cells (IL-
2) is disturbed. In contrast to the levels of soluble TNF-R, the expression of the 
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membrane-bound TNF-R2 did not cOlTelate with renal function, snpporting the 
hypothesis that renal failure itself does not induce cytokine membrane receptor 
expression. 
In chapter 4 ill vitro stimulation of T -cells is described in order to find a possible 
inttinsic T-cell defect in lID patients. Again, an activation of the APC is found, without 
signs of activated T-cells. TNF-a is increased on the mRNA level as well as on the 
protein level, membrane-receptor expression and soluble receptor level. IL-2 is not 
increased on mRNA level 01' plasma level. The sIL-2R levels are also significantly 
increased in lID patients, due to decreased renal clearance. These sIL-2R are biological 
active, as are the sTNF-R. The proliferation capacity of T-cells from lID patients is 
lower compared to controls. However, when the data are conected for the lID-indnced 
lymphopenia no differences are present in proliferation capacity of T-cells. The 
inl1uence of uremic plasma on proliferation capacity of PBMC obtained from healthy 
controls shows inhibition on the proliferation capacity, however not significant. 
Significantly less TNF-a production is found upon PHA stimulation in HD patients, in 
spite of high mRNA expression for TNF-a and high TNF-R expression on T-cells. We 
conclude that continuous stimulation of T-cel1s leads to tachyphylaxis for TNF-a 
production and that no intrinsic T-cell defect is present. 
In chapter 5 the proliferation capacity of T-cells obtained from lID patients on PHA, 
TNF-a, lL-2 and lL-IS stimulation is evaluated. It appeares that these cytokines are 
able to induce T-cell proliferation. When TNF-a concomitantly was given with IL-2 or 
the macrophage-derived T-cell growth factor IL-1S, T-cell proliferation is augmented 
compared to stimulation of one cytokine alone. Proliferation capacity of T-cells 
obtained from HD patients is comparable to the proliferation capacity of T-cells from 
healthy controls. These data show that T-cells from lID patients have no intrinsic 
defect. 
In chapter 6 the course of TNF-a production and its soluble receptors, sTNF-RI and 
sTNF-R2, is followed after successful renal transplantation. TNF-a is not detectable 
before and after transplantation. The levels of sTNF-Rl and sTNF-R2 are Significantly 
increased before transplantation, and decrease dramatically after the transplantation, in 
concordance with increasing renal function. But despite recovery of the renal function 
the levels of the soluble receptors remained significantly increased compared to healthy 
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controls. After one year, the levels of soluble receptors, sTNF-RI and sTNF-R2, are 
still significantly increased compared to controls, irrespective whether the patients are 
on cyclosporine or azathioprine as maintenance immunosuppressive therapy. After one 
year the creatinine clearance of patients on cyclosporine therapy is 59 mllmin, in 
contrast to patients on azathioprine: 84 mllmin. The fractional clearance of sTNF-R I is 
9% and of sTNF-R2 5%, in the first week after transplantation. The fractional 
clearance of both soluble receptors decreases to approximately 2% after one year. 
Messenger-RNA expression for TNF-o. is comparable in patients before and dUl'ing 6 
days after transplantation. This shows an ongoing unbalanced TNF -a system, despite 
of recovery of renal function. 
In chapter 7 the actual activity of the TNF -a system in patients suffering from severe 
healt failure (HF) and in patients after heart transplantation (HTx) is studied. 
Messenger-RNA expression levels for TNF-o. are comparable in PBMC derived from 
patients with HF, after HTx and fi'om controls. The peripheral TNF-o. system in HF and 
after HTx is not activated, shown by this normalmRNA expression. Detectable TNF-o. 
protein levels are present in HF, when a sensitive ELISA kit is used, while after HTx 
and in controls no detectable TNF-o. protein levels are present. In contrast, the soluble 
TNF-receptors, sTNF-RI and sTNF-R2, are significantly increased in both HF and 
after HTx and thereby reflecting TNF -a activation. These high levels of sTNF -R are 
biological active and bind 21% (HF) and 25% (HTx) of free added TNF-o., reSUlting in 
a decreased bioavailability of produced TNF-o.. In HF and HTx patients the TNF-o. 
activation takes place in the failing or transplanted heart. Infiltrating immune 
competent cells i.e. lymphocytes, monocytes, but also activated myocytes 01' 
endothelial cells may produce and secrete TNF-o.. The everpresent mRNA expression 
for TNF-o. in endomyocardial biopsies supports these findings. 
In chapter 8 the activation of the TNF -a and IL-2 system, using the quantitative flow 
cytometry is measured. In peripheral blood of patients after HTx comparable numbers 
of T-cells are present, in contrast to absolute numbers of monocytes, which are 
significantly higher in these patients. Activation markers of the IL-2 system, the IL-
2Ro. (CD25) and IL-2R~ (CDI22) on T-cells are comparable between patients and 
controls, suggestive for non-activated T -cells. In contrast, the expression of the 
activation marker for TNF-o., TNF-R2 (CDI20b), on monocytes as well as on 
lymphocytes is significantly increased in patients after HTx. In addition to chapter 7, 
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we conclude that the TNF-a system patients after heart transplantation is activated, and 
that most likely, this activation takes place in the graft. The transplanted heart functions 
as a central source of continuous TNF production, resulting in high levels of TNF-R, 
and in biological active soluble receptors, which prevent systemic TNF-a effects and 
thereby consequently contribute to further immune suppression in those patients. 
Conclusions 
From this study we conclude that the immune incompetence of patients on chronic 
hemodialysis is the result of impaired bioavailability of TNF-a in combination with a 
HD-related lymphopenia. 
We found a chronic activated TNF-a system, shown by high expression of TNF-a 
mRNA, increased levels of TNF-a protein, high expression of TNF-R on the 
membranes of immune competent cells, i.e. lymphocytes and monocytes, and high 
levels of biological active sTNF-R. This in combination with a reduced TNF-a 
production capacity by T-cells leads to a decreased bioavailability ofTNF-a. 
We did not find an intrinsic T-cell defect, but there is a marked lymphopenia in 
patients on HD, which consequently leads to an impaired T-cell function. 
So, the coincidence of low TNF-a bioavailability and a reduced number of T-cells 
result in an inadequate immune response in HD patients. 
Patients with end-stage renal failure have no activation of the TN F -a system, 
suggesting that uremia alone is not responsible for the activation of the TNF-u system. 
Patients on CAPD are comparable to patients on HD in respect to their renal function, 
but no increased mRNA expression for TNF-a is present in peripheral blood 
mononuclear cells. The high expression of the membrane-bound TNF-R on both 
lymphocytes and monocytes are nevertheless suggestive for an activated TNF-u 
system, and again due to impaired clearance of sTNF-R in CAPO patients the bio-
availability ofTNF-u is reduced. 
The continuous activation of the TNF-u system is the result of the blood-membrane 
contact in HD patients, while in patients on CAPD it is caused by low-grade peritoneal 
infections of inflammation. 
Nevertheless, the activated TNF -u does not result in activation of T-cells, in any of the 
patient groups. From these results we conclude that the interaction between APC 
(TNF -u system), and the T-cells (IL-2 system), is disturbed as result of the impaired 
TNF-u bioavailability. 
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In patients suffering from heali failure, the TNF-C( system is also activated, but the ratio 
between TNF-C( and the sTNF-R is less disturbed compared to the ratio TNF-C( I sTNF-
R in renal failure, because of normal renal clearance of the sTNF-R. The high levels of 
TNF-a, probably due to frequent bacterial infections from the gut, may lead to further 
deterioration of the heati function. 
After organ transplantation, heart or kidney, the TNF -C( system, appears to be 
constantly activated, reflected by increased expression of TNF-R on the membranes of 
immunecompetent cells. Due to immunosuppressive therapy the T-cell function is 
compromised. The combination of inhibition of T-cell function and a constantly 
activated TNF-a system leading to high levels of biological active sTNF-R results in a 
fmiher immunosuppressive status of patients after organ transplantation. 
We conclude that: 
I. the TNF-a system in patients with renal and/or heart failure, and in patients after 
kidney or heati transplantation is activated 
2. as the result of elevated levels of biological active sTNF-R the bioavailability of 
TNF-a is impaired, further contributing to the immunosuppressive status of these 
patients 
3. HD patients have no intrinsic T-cell defect 
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Samenvatting 
Patienten met een eindstadium orgaanfalen, zoals bijvoorbeeld niedalen, hebben een 
verminderde afweer. Hierdoor zijn zij gevoeliger voor infecties, hebben een slechte 
response op vaccinaties, zoals tegen hepatitis B of influenza en hebben een hogere kans 
op het krijgen van kwaadaardige ziekten i . Oit lijkt in tegenspraak met de geactiveerde 
staat, waarin een gedeelte van hun afweercellen zich bevindt2. Ons immuunsysteem is 
ontwikkeld om ons te beschermen tegen ziekmakende factoren (antigenen). De cellen 
die de immuniteit onderhouden zijn de witte bloedcellen, zoals Iymfocyten en 
monocyten, macrofagen en natural killer cells'. De immuunreactie bestaat uit drie 
verschillende fasen (signalen) met als doel de ziekmakende factor te elimineren. De 
eerste fase is de antigeen presentatie, hierin wordt het antigeen door zogenaamde 
antigeen presenterende cellen, APC, aangeboden aan Iymfocyten. Het antigeen bevindt 
zich in een membraan gebonden molecuul, MHC klasse II op de APC. Op de T-
Iymfocyt zit de receptor, die het antigeen herkent. Het tweede signaal heet de co-
stimulatie. Dit signaal is nodig om de T-cel te activeren. Na activatie zullen bepaalde 
stoffen, cytokinen, geproduceerd worden, die het verdere beloop van de immuunreactie 
verzorgen4 (signaal 3). De belangrijkste cytokinen in deze reactie zijn IL-2 en TNF-a. 
Cytokinen werken via specifieke receptoren, die op de membraan van hun 
doelwitcellen zitten. Voor IL-2 is dat de IL-2R op Iymfocyten en NK-cellen. Deze IL-
2R bestaat uit drie ketens, de a-, ~- en y-keten. Deze ketens worden ook weI de CD25 
(a-keten), CDI22 (~-keten) en de CDI32 (y-keten) genoemd. Na binding van IL-2 op 
zijn receptor gaat de T-cel prolifereren en differentieren. Daamaast heeft IL-2 invloed 
op de cytolytische activiteit van NK-cellen en is IL-2 betrokken bij apoptose, 
geprogrammeerde celdood. Voor TNF-a zijn twee receptoren bekend, de Rl (ook weI 
p55 ofCDl20a) en de R2 (ook weI p75 ofCDI20b). Deze receptoren bevinden zich op 
aile lichaamscellen, behalve erytrocyten en rustende T-cellen. Na binding van TNF-a 
ontstaat productie van enzymen en adhesiemoleculen, terwijl binding via R2 (op 
Iymfocyten) reslllteeit in T-cel proliferatie. Na binding van het cytokine op zijn 
receptor wordt het complex gedeeltelijk geintemaliseerd. Het extracellulaire gedeelte 
van de receptor wordt door proteolyse afgesplitst van de membraan en kan in het 
perifere bloed als oplosbare (soluble) receptor (sIL-2R, sTNF-Rl en sTNF-R2) 
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aangetoond worden. Wanneer er sprake is van een verminderde afweer in een patient, 
dan kan de afweeneaktie, of wei immuunresponse op verschillende niveaus verstoord 
zijn. 
In dit proefscruift hebben we getracht een inzicht te krijgen op welk niveau de 
immuunresponse in patienten met orgaanfalen en na orgaantransplantatie verstoord is. 
We hebben ons voornamelijk gericht op de interaktie van de inmmuncompetente 
cellen, de lymfocyten en monocyten, en de centrale cytokinen, TNF-C( en IL-2, in 
patienten met nierfalen (ESRF), patienten op hemodialyse (HD) en peritoneale dialyse 
(CAPD), na niertransplantatie (NT) en bij patienten met hartfalen (HF) en na 
hm1transplanlatie (HTx). 
Hoofdstnk 2 beschrijft een verstoorde balans in het TNF-C( systeem in patienten met 
progressief nietfalen. Dit is het gevolg van slerk verhoogde spiegels sTNF-receploren. 
HD patienlen hebben tevens een significant hogere expressie van hel mRNA voor 
TNF-C( in tegenstelling tot patienten op CAPD of met ESRF. De sTNF-R zijn 
biologisch actief en blijken in staat om 75% van toegevoegd rhTNF-C( binden, 
waardoor de beschikbaarheid van lokaal geproduceerd TNF-C( gerellld wordt. Hierin 
ligl mogelijk een verklating voor de verstoorde immuniteit van HD patienten 
In hoofdstnk 3 wordt de activatie van het TNF-C( systeem op celniveau in HD 
patienten aangetoond. Met behulp van de reproduceerbare kwantitatieve flowcyto-
melrische analyse methode hebben we de aanwezigheid van TNF-R2 op lymfocyten en 
monoeyten bepaald. Er is een slerk verhoogde expressie aanwezig van de TNF-R2 op 
beide celtypen, suggestief voor activatie van het TNF-C(. Dit resulteert niet in activatie 
van het IL-2 systeem, want de expressie van IL-2R C(- en p-ketens op de lYlllfoeyt zijn 
vergelijkbaar met de expressie die gezien wordt op lymfoeyten van gezonde controles. 
Hieruit concluderen we dat de interaclie tussen de APC (monoeyt) en de lyrnfoeyt 
verstoord is, daar een duidelijk geaetiveerde monoeyt, met verhoogde TNF -C( lllRNA 
en receptorexpressie, geen aelivatie van de lymfoeyl geeft. Het niveau van TNF-R2 
expressie is niet gecorreleerd aan nierfunktie, zodat uremie op zichzelf niet leidt tot de 
verhoogde cytokinen membraanreceptor expressie. 
In hoofdstnk 4 worden ill vitro stimulatie testen beschreven van uremische T-cellen, 
verkregen van HD patienten teneinde een mogelijk T-cel defect op te sporen. IL-2 
mRNA expressie van deze cellen en plasma eiwit spiegels zijn niet verhoogd, maar ook 
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hier is er sprake van sterk verhoogde concentraties, biologisch actieve sIL-ZR. Dit 
laatste is het gevolg van verminderde rena Ie klaring, welke tot gevolg heeft dat lokaal 
geproduceerd IL-Z minder beschikbaar is. De mitogeen-geYnduceerde T-cel proliferatie 
is vergelijkbaar in patienten en controles, echter aileen als er gecoo'igeerd wordt voor 
de aanwezige hemodialyse-gerelateerde Iymfopenie. Uremisch plasma toont een 
remmend effect op "gezonde" T-cel proliferatie. Tevens is een significant lagere, 
mitogeen-gei'nduceerde TNF-a prodllctie gevonden door T-cellen van HD-patienten. 
De conclusie uit deze studie is dat door de continue stimulatie er een uitputting voor 
TNF-a productie is opgetreden in patienten op chronische hemodialyse, zonder 
duidelijk T-cel defect. 
In hoofdstuk 5 wordt de cytokinen afhankelijke T-cel proliferatie verder uitgewerkt. 
T-cellen van HD patienten zijn ill vitro gestimlileerd met TNF-a, IL-Z of IL-15. Dat 
laatste is een bekende T-cel groeifactor, die geproduceerd wordt door geactiveerde 
macrophagen. Er is geen verschil in proliferatie capaciteit van T-cellen van HD 
patienten en gezonde controles. Stimulatie met combinaties van cytokines, zoals TNF-
a met IL2 of TNF-a met IL-15 geef! een verdere toename van de proliferatie capaciteit 
in beide groepen. Hiel1lit concluderen \Vij dat patienten op HD een goede T -cel functie 
hebben. 
Hoofdstuk 6 toont het beloop van TNF-a en zijn receptorenna een geslaagde Iiving-
niertransplantatie. Dagelijks na de niertransplantatie zijn TNF-a mRNA, sTNF-R in 
bloed en urine gemeten. Bij herstel van de nierfunktie vindt slechts een gedeeltelijk 
herstel van de TNF-balans plaats. De sTNF-R in het bloed dalen sterk en verschijnen in 
de urine, echter de plasmaconcentratie van de sTNF-R blijft verhoogd in vergelijking 
met gezonde controles. Ook na 1 jaar, ongeacht de immuunsuppressieve therapie, 
cyclosporine of azathioprine, blijven de plasmaconcentraties van sTNF-R verhoogd, 
resulterend in het blijvend niet in balans zijn van het TNF-a systeem. 
In hoofdstuk 7 is het TNF-a systeem onderzocht in patienten met ernstig hartfalen 
(HF) en na halttransplantatie (HTx). TNF-a is behalve om zijn pro-inflammatoire, ook 
bemcht om zijn cardiodepressieve eigenschappen. Er is geen verschil in mRNA 
expressie voor TNF-a in perifere bloedcellen, echter in patienten met hartfalen zijn 
significant hogere TNF-a concentraties in vergelijking met HTx patienten en gezonde 
controles gevonden. De sTNF-R zijn in de patientengroepen significant hoger dan in de 
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controlegroep, en ook hier blijken de sTNF-R biologisch actief en zijn in staat om 21 % 
(in HF) en 25% (in HTx) van het toegevoegde TNF-o. te binden. In verband met de 
nonnale nierfunktie is geen sprake van hoge receptor concentraties door venninderde 
klaring, maar door overmatige productie. Als de sTNF-R een uiting zUn van een actief 
TNF-o. systeem, dan vindt de activatie niet plaats in de periferie, maar eerder in het 
falend of in het getransplanteerde hart. 
Hoofdstuk 8 beschrijft de activatie van het TNF-o. en lL-2 systeem na 
hmttransplantatie op celniveau, gemeten met de kwantitatieve flowcytometde. Het 
blijkt dat het TNF-o. systeem geactiveerd is, gezien de significant toegenolllen TNF-R2 
expressie in monocyten en Iymfocyten. In tegenstelling tot het TNF-o. systeelll lijkt het 
IL-2 systeem juist niet geactiveerd. De expressie van de IL-2R op lymfocyten, zowel 
de IL-2Ro. als de IL-2R~ keten, is vergelijkbaar in HTx patienten en gezonde controles. 
Dit steunt de hypothese dat het geactiveerde TNF-u systeelll niet in staat is om de de T-
cellen te activeren. In het getransplunteerde hart is een vrijwel continue IllRNA 
expressie voor TNF-a aanwezig. Deze continue TNF-u productie resulteert in 
op-regulatie van de TNF-R, die l1a binding met TNF-o. leiden tot productie van 
biologisch actieve sTNF-R. Hierdoor is er ook na HTx sprake van dat het TNF-o. 
systeem niet in balans is, hetgeen resulteert in verclere imrnuunsuppressie in deze 
patienten. 
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Dankwoord 
Het proefschrift is klaar! Yoor mezelf heb ik een mijlpaal bereikt. Mede dankzij de 
hulp van velen is dit werk voltooid. Dit dankwoord is derhalve voor hen geschreven. 
Naar Nico gaat mijn grootste dank uit. Jouw vertrouwen in mij en je steun waren 
onontbeerlijk. De meeste zondagen waren de laatste jaren gevuld volgens een vast 
patroon: werken aan het proefschtift. We zullen voor de komende zondagen andere 
plannen maken. De eerste tijd zal zeker in het licht van inpakken, op11limen en 
verhuizen staan. Maar de komende zomer kunnen we dan oak genieten van ons paleisje 
op de 14' verdieping van de Hoge Erasmus. 
De volgende, zonder wie dit proefschrift nooit het daglicht had kunnen aanschouwen, 
is mijn promotor. Beste Willem, ik wil je bijzonder danken voor je nooit aflatende 
enthousiasme voor de wetenschap, het veltrouwen in mij, je enorme steun en je 
verhelderend realisme, hetgeen mij geholpen heeft om door te gaan. Je hebt me geleerd 
hoe je een onderwerp tot iets eigens maakt. Heel veel dank hiervoor. 
Carla, mijn copromotor, ik wil je hartelijk danken voor je enorme hulp. Nooit klopte ik 
tevergeefs bij je aan. Je stond altijd klaar met adviezen, steun en waardering. Je snelle 
revisies van aUe artikelen, je goede ideeen maakten dat het onderzoek steeds weer iets 
extra's kreeg. Je kritische vragen dwongen mij mijn doe I en resultaten duidelijk, 
begrijpelijk en helder te omschrijven. Ik hoop dat we in de toekomst nag veel zuUen 
samenwerken. Ik ben er trots op dat ikje eerste promovendus ben. 
De leden van de commissie wil ik hartelijk danken voor hun snelle beoordeling van het 
manuscript. 
Professor Pols, beste Huib, de inleiding is tach wat langer geworden dan gepland. Ik 
ben je veel dank verschuldigd voor het feit dat ondanks aile ontwikkelingen rondom 
onze nieuwe afdeling lnwendige Geneeskunde, je tijd hebt vrijgemaakt voor deze 
commissie. 
Professor ten Berge, beste lneke, jij hebt me vanaf het allereerste begin gestimuleerd 
am door te gaan met onderzoek met als doel een proefschrift. Je bent een stimulans 
voor velen, maar zeker voor mij. Ik dank je voor de tijd en de steun die je me gegeven 
hebt. Ik ben heel blij dat je in de commissie plaats hebt willen nemen. 
Doctor Buunnan, beste Wim, het is een eer om je in de commissie te hebben. TNF-a is 
jouw onderwerp en ik prijs mij zeer gelukkig dat je dit proefschtift hebt willen 
beoordelen. Hartelijk dank hiervoor. 
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Herr Doctor Matthias Gimdt, herzlichen Dank fUr Thnen Bereitheit in diesem 
Kommission Platz zu nehmen. Auf dem Kongresse des Amerikanischer Gesellschaft 
fUr Nephrologie haben wir oft gesprochen libel' unserem gesamtlichen Interesse fill' die 
Cytokinen. Es ist ein Ehr das Sie heute anwesend sind und ich danke Sie herzlich 
dafUr. 
Aggie Balk en Bob Zietse wil ik bedanken Vaal' het zitting nemen in de commissie. 
Daamaast wil ik Aggie bedanken vaal' haar steun en goede raad tijdens de voorberei-
dingen van dit proefschrift en vaal' de adviezen over de hoofdstukken 7 en 8. 
Tevens wil ik nag vele anderen bedanken. Allereerst de patienten die zander aarzelen 
hun bloed af wilden staan voor aile in dit proefschrift beschreven testen. Ik wil hen 
bedanken voor hun medewerking en de belangstelling die zij getoond hebben. Oak de 
'gezonde' controles wil ik niet vergeten in dit dankwoord. Zonder hen was er geen 
onderzoek mogelijk geweest. Dank in het kwadraat! 
De verpleging van de afdeling hemodialyse, maar oak van de CAPD, de nieltrans-
plantatie en 3 Noord wil ik bedanken voor hun medewerking, de belangstelling en 
enthousiasme voor dit proefschrift. 
Aile medewerkers van ons laboratorium wil ik danken voor hun medeleven, steun, 
belangstelling en zeker ook voor de gezelligheid bij de koffie, labborrels en 
labweekenden. Zonder iemand tekort te doen wil ik Lisette, Cees en Chris bedanken 
voor aile bepalingen die zij voor dit onderzoek verricht hebben. 
Mijn dank gaat ook nit naar de afdeling Virologie, wam onder leiding van Bert Nieste!'s 
de mRNA bepalingen verricht mochten worden. 
Daarnaast wil ik mijn collega's, de secretaressen en polikliniekassistenten van de 
secties Transplantatie en NefrologielHypertensie bedanken voor de steun bij en de 
belangstelling voor dit proefschrift. 
Mijn broer Jan wit ik hartelijk danken VOOI' het ontwerpen Van de voor- en achterkant 
van mijn proefschrift. Je hebt op zeer artistieke en kundige wijze de titel en de 
strekking weten te verwoorden in een afbeelding. En de vliegenmeppers vind ik oak 
heelleuk. 
Peter en Marjolein, wat had ik zonder jullie moeten doen? Ontzettend bedankt dat jullie 
dit proefschrift tot een juweel hebben omgetoverd! 
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Dankwoord 
En tot slot mijn paranimfen. Lieve Joke, heel vee! dank dat je mijn paranimf wilt zijn. 
Je bemoedigende woorden en de waaI'dering die je me geeft zijn een weldaad. Ik hoop 
in de nabije toekomst voo!' jou hetzelfde te kunnen betekenen. 
Lieve, lieve Cornelie, mijn steun en toevedaat in roerige dagen. Wie andel's dan jij kan 
naast me staan op deze dag. 
Lieve Nico, voor jou waren de eerste maar zijn ook de laatste wOOl'den van dank. Ik 
weet aileen niet hoe ik het moet zeggen, maar je bent en blijft 'my one and only 
Valentine' . 
Palm Springs, oktober 2000 
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